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ABSTRACT 
 
THE MOLECULAR BASIS FOR POST AND CO-TRANSLATIONAL N-TERMINAL 
ACETYLATION 
Robert S. Magin 
Ronen Marmorstein 
 
 N-terminal acetylation is among the most common protein modifications in eukaryotic 
cells, where up to 90% of proteins carry this mark. Over the last decade, significant progress has 
been made in elucidating the function of N-terminal acetylation for a number of diverse systems. 
The enzymes responsible for this modification are the N-terminal acetyltransferases (NATs). The 
NATs are a group of conserved enzymes in eukaryotes, which can be broadly classified into two 
groups. The major NATs, NatA-NatC, are promiscuous and responsible for acetylating the 
majority of N-termini in the cell, and have hundreds to thousands of protein substrates. Recently, 
it has been suggested that they also may target lysine residues. These NATs largely act co-
translationally. They interact with the ribosome near the exit tunnel and acetylate the nascent 
protein chain as it is being translated. The other NATs, NatD-NatF, are more specialized in their 
substrate specificity and localization patterns.  
 There is a large amount of structural information on the molecular basis of NAT activity. 
These studies have revealed how the NATs are specific for N-termini, and how binding partners 
affect their activity. However, the structural characteristics of the specialized NATs remain 
unknown, the full substrate scope of NATs remains to be determined, and how the NATs interact 
with the ribosome is largely unexplored, despite the importance of this modification in a co-
translational context. Therefore, to address these gaps in knowledge, we determined the crystal 
structures of NatD and NatF with their substrate peptides bound, and by carrying out biochemical 
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and enzymological assays, we revealed the molecular basis for their unique specificity and 
localization. We also showed that there is no difference in lysine acetylation of substrate proteins 
with or without NatA, suggesting that reported substrates are acetylated chemically rather than 
enzymatically. Finally, we determined regions on the NatA complex that promote interaction with 
the ribosome. This dissertation provides a framework for understanding the molecular basis of the 
specialized NATs, and how NATs interact with the ribosome for co-translational protein 
acetylation. These studies have implications in developing inhibitors for the specialized NATs, 
and in understanding co-translational events in general.  
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CHAPTER 1: In the beginning: N-terminal Acetylation 
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1.1 Protein modifications 
 
Determining the genetic code was a triumph of 20th century science, and marked the 
beginning of modern molecular biology. However, it is clear that the proteinogenic amino acids 
do not account for all of the diversity of protein structure and function. There are a number of 
ways in which proteins can escape from the chemical space imposed on them by the genetic code. 
Non-canonical amino acids, such as selenocysteine and pyrrolysine, known as the 21st and 22nd 
amino acid, can be incorporated into directly into proteins during translation in the context of 
repurposed stop codons in the mRNA (Yuan et al. 2010). Many proteins employ organic and 
inorganic cofactors to substantially increase the diversity of the chemistry they perform 
(Denessiouk, Rantanen, and Johnson 2001). However, modifications to the side chains 
themselves are among the most powerful means to affect protein structure and function 
(Prabakaran et al. 2012). 
 Modifications to protein side chains have been studied for decades and are widespread 
and diverse in their chemistries and functions (Figure 1.1) (Verdin and Ott 2015; Fischer et al. 
1959). Acetylation, phosphorylation, methylation are among the most commonly studied 
modifications, although hundreds have been described (Shortreed et al. 2015). These three 
modifications often act as binary switches, which toggle a protein between two different states. 
These switches may affect enzyme inactivation/activation, modulation of protein interactions, 
multimeric states of a protein, or localization (Prabakaran et al. 2012; Cain, Solis, and Cordwell 
2014; Seet et al. 2006). Other modifications will change the chemical reactivity of a side chain, 
such as generating formylglycine from cysteine or serine (Appel and Bertozzi 2015), and 
carbamylation of lysines (Hsieh et al. 2013). Other modifications that attach large side-chains like 
ubiquitin and complex sugar moieties give rise to new signaling pathways and recognition sites 
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for other proteins (Yau and Rape 2016; Spiro 2002). Utilizing protein modifications allows for 
rapid control of cellular processes, expanded chemistry beyond the canonical amino acids, and 
dynamic regulatory power. 
 
Figure 1.1 Chemical diversity of protein modifications  
Figure taken from (Ribet and Cossart 2010) 
1.2 Acetylation 
	
 Acetylation is among the most common protein modifications. This occurs when acetyl-
CoA transfers an acetyl group to a lysine side chain (Figure 1.2A), or N-terminus of a protein 
(Figure 1.2B) (Verdin and Ott 2015). Acetylation changes the physicochemical properties of the 
side chain or N-terminus of the protein. It does this by increasing the hydrophobicity of the side-
chain, neutralizing the positive charge, and adding a carbonyl group capable of serving as a 
hydrogen bond acceptor.  
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Figure 1.2 Protein acetylation 
(A) Schematic of lysine acetylation (B) Schematic of N-terminal acetylation (C) Structure of 
acetyl-CoA with component parts indicated 
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In the language of protein modifications, the nomenclature of “writers,” “readers,” and 
“erasers” is often used to describe the enzymes which attach the modification, the domains 
responsible for binding to the modified side-chain and affecting function, and the enzymes which 
remove the modification, respectively (Pande 2016). All of these proteins have been described for 
the process of lysine acetylation (Figure 1.3). There is a large family of acetyltransferases found 
in all domains of life. These enzymes utilize acetyl-CoA as an acetyl donor to acetylate their 
cognate protein substrates (Figure 1.2C). These include the GCN5 family, the MYST family, and 
the HAT1 family. These enzymes all share a common acetyl-CoA binding core, and differ in their 
substrate binding and regulatory regions (Marmorstein 2001). The readers of acetylation include 
bromodomains and YEATS domains (Marmorstein and Zhou 2014). Finally there is a large 
families of enzymes which deacetylate acetyl-lysines, the HDACs, which have been extensively 
characterized (Haberland, Montgomery, and Olson 2009). Importantly, all of these proteins are 
often found in large complexes with binding partners that can regulate their localization, stability, 
and substrate specificity (McCullough and Marmorstein 2016).  
Most famously, acetylation affects histone tails and prevents them from forming 
electrostatic interaction with DNA, thus serving to decompact chromatin (Figure 1.3) (Verdin and 
Ott 2015). Indeed, much of the literature regarding acetylation focuses on histone modifications 
and the effect this has on gene expression. However, despite this focus, acetylation is a 
widespread and ancient protein modification, which is now appreciated to affect thousands of 
substrate proteins throughout the cell (Choudhary et al. 2014).  
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Figure 1.3 Effectors of acetylation 
Protein acetylation is most widely studied in the context of chromatin compaction and gene 
expression through the acetylation of histone tails. Writers are acetyltransferases which make the 
mark, readers are effector domains that relay signals about the state of the tail, and erasers are 
deacetylases that remove the mark. Note that this paradigm has been expanded far beyond 
histones and is now recognized as a major PTM in the entire proteome. This figure was adapted 
from (Verdin and Ott 2015) 
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1.3 N-terminal acetylation 
	
 Although less studied than lysine acetylation, N-terminal acetylation was observed as 
early in 1958, when Kozo Narita noted an N-terminal serine in a digested protein sample from 
tobacco mosaic virus (Narita 1958). It was subsequently found in many other diverse proteins 
(Strous, Westreenen, and Bloemendal 1973; Pestana and Pitot 1974; Strous, Berns, and 
Bloemendal 1974; Kasten-Jolly and Taketa 1982), and as researchers looked, it was noted to be 
very common (Brown and Roberts 1976; Polevoda, Norbeck, and Takakura 1999). With the 
power of proteomics, it became clear that N-terminal acetylation is a widespread modification in 
eukaryotic cells, and is the exception rather than the rule. Depending on the organism 50-90% of 
soluble proteins are N-terminally acetylated (Van Damme, Evjenth, et al. 2011; Van Damme et 
al. 2012). Thus, within eukaryotes, N-terminal acetylation is one of the most common 
modifications that occur on proteins.  
 The reason for this widespread modification is still unclear. Initially it was thought that 
such a common modification likely leads to a common functional outcome for all proteins which 
are affected, and it was hypothesized that the modification generally acted to protect proteins 
from degradation (Jornvall 1975). However, this was disproven when it was found that the 
presence of an acetyl group did not change the stability of a large sample of proteins in cellulo 
(Brown 1979). In fact, Varshavsky and colleagues have shown that acetylated N-termini act as N-
degrons, and can promote protein degradation through the ubiquitin system (Figure 1.4) (Hwang, 
Shemorry, and Varshavsky 2010). In this way, they argue that N-terminal acetylation acts as 
quality control in subunit stoichiometry, as in the case of the APC/C subunits Hcn1 and Cut9 
(Shemorry, Hwang, and Varshavsky 2013), and that the general function is largely in the 
degradation of proteins in the cell (Park et al. 2015). As N-terminal acetylation is irreversible 
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(Aksnes et al. 2016), this suggests that proteins are immediately marked for degradation when 
they are translated. However, this claim has only been definitely shown for a handful of proteins, 
and whether it indeed is a general function of N-terminal acetylation remains to be seen.  
 There are many other functional consequences of N-terminal acetylation that are limited 
to specific systems (Figure 1.4). N-terminal acetylation can mediate protein-protein interactions. 
It promotes the interaction of the E2 ligase Ubc12 with Dcn1 to promote neddylation of cullins 
(Scott et al. 2011; Scott et al. 2014), and enhances the interaction of the chromatin regulatory 
protein Sir3 with the nucleosome (Arnaudo, Fernández, and McLaughlin 2013). N-terminal 
acetylation can affect protein localization, as it ensures Golgi localization for the GTPase Arl3p 
(Behnia et al. 2004), and membrane localization for alpha-synuclein (Dikiy and Eliezer 2014). It 
also has been shown to have an influence on whether proteins enter the secretory pathway. 
Cytosolic proteins are enriched for N-acetyl groups, and whether or not an N-terminus is 
acetylated can affect whether is enters the secretory pathway or not (Forte, Pool, and Stirling 
2011). Finally, N-terminal acetylation is implicated in protein folding and aggregation. A 
knockout of NatA in yeast cells showed a global increase in misfolded proteins and chaperone 
levels (Holmes et al. 2014). In human cells, both the chaperone HYPK, which stably associates 
with the NatA complex, and the NatA complex itself help prevent aggregation of hutingtin 
(Arnesen et al. 2010).  
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Figure 1.4 Functional consequences of N-terminal acetylation  
An overview of some effects of N-terminal acetylation. (1) Acetylation creates degradation 
signals for some proteins through the Ac/N-end rule pathway. (2) Protein-protein interactions 
may be enhanced depending on the presence of an acetyl group. (3) Protein localization can 
depend on an N-terminal acetyl group through protein-protein interaction or protein-membrane 
interactions. (4) Proteins that are N-terminally acetylated are less likely to go through the 
secretory pathway. (5) Protein folding and aggregation is affected by N-terminal acetylation. This 
figure was adapted from (Aksnes et al. 2016) 
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Although it is the most widespread, N-terminal acetylation is only one of many 
modifications that occur on the N-termini of proteins. Another quite common modification is 
initial methionine excision by methionine aminopeptidases, a process that is conserved 
throughout all domains of life (Lowther and Matthews 2000). This occurs when the second 
residue in a peptide has a small side-chain (Ala, Cys, Gly, Pro, Thr, or Val). More specialized N-
terminal modifications include N-terminal myristoylation (Xu et al. 2015), N-terminal 
methylation (Dong et al. 2015), and N-terminal arginylation (Kashina 2014). These processes 
occur on a smaller subset of proteins than N-terminal acetylation, and have different functional 
consequences. N-terminal myristoylation is essential for proper protein localization to 
membranes, and can also be important for the structural integrity of some proteins. N-terminal 
arginylation creates a degradation signal on a protein, as an arginine at the N-terminus of a 
protein is destabilizing via the N-end rule (Tasaki et al. 2012). It has also been studied in other 
contexts, and has other cellular and functional consequences. N-terminal methylation is less 
studied, and its role remains unclear.  
 
1.4 N-terminal acetyltransferases (NATs) 
	
N-terminal acetylation is carried out by a family of enzymes called N-terminal 
acetyltransferases (Aksnes et al. 2016). There are six NAT complexes which are universally 
present in eukaryotes, and all of them were likely present in the last common eukaryotic ancestor 
(Rathore, Faustino, and Prudêncio 2016). They also have homologs in bacteria and archaea, but 
N-terminal acetylation is not as widespread in these domains of life (Vetting et al. 2008; Liszczak 
and Marmorstein 2013). These enzymes are designated NatA-NatF (Figure 1.5). The 
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nomenclature of the NATs and their subunits are presented in Table 1.1. The NATs differ in their 
N-terminal substrate specificity, and can be separated into the major NATs and the minor NATs. 
 
 
 
 
 
Table 1.1 Nomenclature of NAT subunits 
NAT Catalytic Subunit Auxiliary Subunit Additional subunits 
NatA Naa10 Naa15 Naa50, HYPK 
NatB Naa20 Naa25  
NatC Naa30 Naa35 Naa38 
NatD Naa40   
NatE Naa50   
NatF Naa60   
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Figure 1.5 The N-terminal acetyltransferase (NAT) Family 
Subunit composition, substrate specificity, and localization of the NATs. (A) The major NATs, 
which are responsible for acetylating the majority of the proteome. (B) The other NATs have 
more limited substrate profiles, or specialized localization. NatA-E are shown associated with the 
ribosome (discussed below). This figure was adapted from (Aksnes et al. 2016) 
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The three major NATs are NatA, B, and C, which are responsible for acetylating the vast 
majority of N-termini in the cell (Figure 1.5A). The major NATs are comprised of a catalytic 
subunit, and a larger auxiliary subunit that is necessary for catalysis. Some have additional 
binding partners. These can be other NATs, like Naa50, or regulatory proteins like HYPK, both 
of which bind to NatA. NatA, B, and C all bind to the ribosome and act to co-translationally 
modify nascent N-termini as they emerge from the ribosome exit tunnel (discussed more in 
section 1.5). Each has hundred of substrates and recognizes N-termini based on the first two 
residues. NatA recognizes N-termini with small residues (Ala, Cys, Gly, Ser, Thr, Val) at their N-
terminus after the initial methionine (iMet) has been cleaved by methionine aminopeptidase. 
NatB acetylates substrates with an iMet followed by an acidic residue or their corresponding 
amides, and NatC acetylates N-termini with an iMet followed by large hydrophobic residues. It 
has been reported that in addition to their promiscuity in the number of N-terminal substrates they 
have, that the catalytic subunits of some NATs target lysine residues as well, without interacting 
with their auxiliary binding partners (Dorfel and Lyon 2015). If true, this would significantly 
expand the substrate scope of the NATs. This is a controversial claim in the field, and has been 
challenged by many groups (Arnesen et al. 2005; Murray-Rust et al. 2006).  
The other NATs are more specialized in their substrates specificities and localization 
(Figure 1.5B). These NATs do not require an auxiliary subunit in order to be catalytically active 
(Aksnes et al. 2016). NatD stands out from all of the other NATs with its stringent specificity; it 
only has two known substrates, histones H2A and H4, which both start with the sequence 
SGRGK (Polevoda, Hoskins, and Sherman 2009). How NatD is so specific while the other NATs 
are promiscuous is an open question. Naa50 associates with the NatA complex, and is require for 
chromosome segregation, potentially through acetylating Scc1, a subunit of the cohesin complex 
(Ribeiro et al. 2016). Naa60 is also unique in that it localizes to the Golgi and primarily acetylates 
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the N-termini of membrane proteins (Aksnes, Van Damme, Goris, Starheim, Marie, Støve, et al. 
2015). Both Naa50 and Naa60 recognize the iMet of a peptide but have a broader flexibility in the 
residue in the second position, and the full scope of their in vivo substrates is yet to be 
determined.   
Over the last five years, a large amount of work has been done to establish the structural 
basis for the activity of the NATs (Liszczak et al. 2013; Liszczak and Marmorstein 2013; Magin, 
Liszczak, and Marmorstein 2015b; Støve et al. 2016; Hong et al. 2017; Weyer et al. 2017). The 
NATs belong to the GNAT superfamily of acetyltransferases. The superfamily fold is 
characterized by a mixed alpha-beta arrangement, in which alpha helical regions surround a 
central beta sheet made up of seven beta strands (Figure 1.6). There is a conserved acetyl-CoA 
binding site in the core of the enzyme comprised of two beta strands and an alpha helix. The 
substrate-binding site varies between different acetyltransferases. It is comprised of two alpha 
helical/loop regions that flank the core of the enzyme. These regions mediate the substrate 
specificity of the acetyltransferase. In classical histone acetyltransferases, the peptide-binding site 
is wide and can accommodate an extended peptide that inserts a lysine close to the acetyl group in 
the acetyl-CoA to be acetylated (Figure1.6A and 1.6C) (Rojas et al. 1999). In all NAT structures 
solved to date, however, the binding site is occluded by the β6-β7 loop, which sterically blocks 
peptides from lying across the active site (Figure 1.6B and 1.6D, Figure 1.7). N-termini, however, 
can easily access the active site, as they are at the end of the polypeptide chain. In this way, the 
NATs show high preference to N-termini rather than lysines, which conflicts with reports that 
they possess lysine acetyltransferase activity. In addition to the steric blockage of the active site, 
there is a conserved motif of two tyrosines in the β6-β7 loop which hydrogen bond to the 
backbone amides of the N-terminus in the NAT, further stabilizing the interaction of the N-
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terminus with the enzyme. All of the NAT structures solved to date orient the peptide in the same 
manner from the active site (Figure 1.8).  
 
Figure 1.6 The NATs have a sterically hindered peptide binding site 
(A) Structure of a classical histone acetyltransferase, GCN5 (PDB: 1QSN) as a blue cartoon, and 
H3 peptide in cyan sticks. (B) Structure of Naa10 (PDB: 4KVM) as an orange cartoon, and SASE 
peptide as wheat sticks. Note the indicated β6-β7 loop in Naa10.  
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Figure 1.6 (continued from previous page): (C) Surface view of GCN5 with H3 peptide. (D) 
Surface view of Naa10 with SASE peptide.  
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Figure 1.7 Superposition of NAT structures  
Superposition of solved NAT crystal structures. All are shown as cartoon. Naa10 (PDB: 4KVM) 
is in orange, Naa50 (PDB: 3TFY) is in cyan, ssNAT (PDB: 4LX9) is in purple, and the bacertial 
NAT RimI (PDB: 2CNM) is in blue.   
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 The NATs use an ordered, sequential mechanism, which is typical for the GNAT family 
of acetyltransferases (Evjenth et al. 2009). Unlike the MYST family, which utilize a catalytic 
cysteine in a ping-pong mechanism (Yuan et al. 2012), the NATs all form ternary complexes with 
both acetyl-CoA and the substrate peptides. Interestingly, the position and residue identity of the 
general base in NATs is quite variable (Figure 1.8). In the structure of a bacterial NAT, RimI, the 
general base is E103 in β5 (Figure 1.8A) (Vetting et al. 2008). In Naa50, a water molecule 
oriented by Y73 in β4 and H112 in β5 acts as a general base (Figure 1.8B) (Liszczak, Arnesen, 
and Marmorstein 2011). In Naa10, the situation is more ambiguous (Liszczak et al. 2013). E24 in 
the α1-α2 loop was found to be essential for catalysis (Figure 1.8C). However, this residue is not 
in a position to directly deprotonate the N-terminus, making its status as a general base come into 
question. For Naa10, it may instead be acting to orient the N-terminus, or polarize it to be more 
nucleophilic. Since the N-termini of proteins tend to have a lower pKa than lysine side chains on 
average, utilizing a residue as a general base is potentially not as critical for the NATs as lysine 
acetyltransferases. Interestingly, in the structure of a NAT from the archaea Sulfolobus 
solfataricus (ssNAT), there are three catalytic residues: E84 in the α1-α2 loop, H137 in β4, and 
E176 in β5 that allow the enzyme to act on both serine-initiating peptide, and methionine-
initiating peptides (Figure 1.8D) (Liszczak and Marmorstein 2013). Thus, ssNAT uses a 
combination of catalytic residues seen in the other NATS to acetylate a broad substrate profile. 
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Figure 1.8 The position and identity of the catalytic residue(s) differs between NATs 
All structures in this figure are shown as cartoons, with their substrate peptide as white sticks. 
The tyrosines in the β6-β7 loop are shown as sticks, as is the tyrosine in the α1-α2 loop 
(tryptophan in RimI) (A) Structure of the bacterial NAT RimI in blue, with general base E103 
labeled and shown as sticks (B) Structure of Naa50 in cyan, with general bases Y73 and H112 
labeled and shown as sticks (C) Structure of Naa10 in orange, with catalytic residue E24 labeled 
and shown as sticks (D) Structure of ssNAT in purple, with general bases E84, H137, and E176 
labeled and shown as sticks.  
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 Finally, while there is less information about the NATs in complex with their auxiliary 
subunits, the structure of the heterodimeric NatA complex is available (Liszczak et al. 2013). The 
structure reveals an intimate interaction between Naa10 and Naa15, with Naa15 wrapping around 
Naa10 in a molecular “nest,” that modulates the activity of the enzyme (Figure 1.9). This 
complex will be discussed more thoroughly in chapter 5.  
 
1.5 Co-translational modifications  
	
It has long been known that N-terminal acetylation is largely a co-translational process 
(Gautschi et al. 2003). Experiments conducted over 30 years ago showed that nascent N-termini 
isolated from ribosomes were acetylated with as few as 25 residues translated (Strous, 
Westreenen, and Bloemendal 1973; Pestana and Pitot 1974; Strous, Berns, and Bloemendal 
1974). More recently, NatA, B and C have all been shown to interact with the ribosome through 
their auxiliary subunits in both yeast and human cells (Figure 1.5A) (Polevoda et al. 2008). For 
NatA, this interaction is salt dependent, and a pull down from a yeast system indicated ribosomal 
proteins L23 (Rpl25p) and L29 (Rpl35p) in the NatA interaction (Polevoda et al. 2008). Both of 
these proteins are found near the peptide exit tunnel in the 60S subunit of the ribosome. 
Moreover, N-terminal acetylation has also been shown to compete with signal recognition 
particle (SRP) targeting, further suggesting a dynamic interplay of various ribosomal binding 
proteins which are in involved in N-terminal processing (Forte, Pool, and Stirling 2011).  
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Figure 1.9 Structure of the NatA complex  
Naa15 is shown in green, Naa10 is shown in cyan, and the substrate peptide is shown in magenta 
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In addition to N-terminal acetylation, there are a number of other well known co-
translational processes and modifications (Figure 1.10) (Giglione, Fieulaine, and Meinnel 2015). 
These include translational stalling and localization to the endoplasmic reticulum by the SRP for 
transmembrane proteins, or those destined for the secretory pathway (Akopian et al. 2013). Other 
co-translational modifications include iMet removal by methionine aminopeptidases (MAP), 
methionine deformylation in bacteria by peptide deformylases (PDF), and N-terminal 
myristoylation by N-terminal myristoylases (Giglione, Fieulaine, and Meinnel 2015). The two 
enzymatic processes that are most analogous to N-terminal acetylation are MAP activity and PDF 
activity. Both are very widespread, and occur on a high percentage of all proteins that are 
translated (Kramer et al. 2009). These two proteins both directly interact with the ribosome and 
are also both highly dynamic with a high on/off rate for association with the ribosome (Sandikci 
et al. 2013; Bingel-Erlenmeyer et al. 2008).  
In addition to these enzymatic events, there are a number of protein chaperones which 
bind to the emerging polypeptide at the ribosome exit tunnel to assist in co-translational folding 
(Kramer et al. 2009). These include trigger factor in bacteria (Kramer et al. 2002; Maier et al. 
2003), NAC and the Ssb/Ssz/Zuotin triad in eukaryotes (Wiedmann et al. 1994; Gautschi et al. 
2002). Thus, the nascent N-terminus immediately encounters a number of factors involved in its 
processing as soon as it reaches the end of the exit tunnel. Importantly, all of these proteins are 
believed to directly interact with the ribosome. Although the detailed molecular basis for these 
interactions are not known for all of the factors, there do seem to be commonalities. The 
ribosomal protein L23 acts as an important docking site for SRP, trigger factor, NAC, and NatA, 
and many proteins use electrostatic interactions to interact with the ribosome, with both the rRNA 
and a conserved negatively charged patch found on a surface exposed region of L23 (Schaffitzel 
et al. 2006; Wegrzyn et al. 2006; Kramer et al. 2002; Becker et al. 2009; Ataide et al. 2011).  
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Figure 1.10 Co-translational modifications 
Overview of co-translational modifications in bacteria and eukaryotes. Abbreviations are as 
follows: PDF- peptide deformylase, MetAP- methionine aminopeptidase, Nat- N-terminal 
acetyltransferase, NMT- N-myristoyltransferase. This figure was adapted from (Giglione, 
Fieulaine, and Meinnel 2015) 
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1.6 NATs in development and disease 
	
As NATs have so many substrates and affect a wide variety of cellular processes, it is 
perhaps not surprising that the misregulation of NAT activity is implicated in a wide variety of 
developmental defects and diseases. Many genetic disorders have been described which affect the 
Naa10 subunit of the NatA complex. One such mutation, S37P, causes Ogden Syndrome, an X-
linked syndrome which causes cardiac arrhythmias, an aged appearance, developmental delays, 
and is ultimately fatal by the third year of life (Rope et al. 2011). Other disorders with different 
mutations have been described, but share common phenotypes of intellectual disability, cardiac 
abnormalities, and developmental delay (Casey et al. 2015; Popp et al. 2015; Saunier et al. 2016). 
These disorders affect the client population of proteins which are acetylated in the cell 
(Myklebust et al. 2015). The fact that there is such a wide variety of substrates in the cell which 
are affected by N-terminal acetylation means that it is likely that the causes of these disorders 
arise from a complex combination of aberrant protein processing.  
In addition to genetic disorders, N-terminal acetylation has also been implicated in a 
number of cancers (Dorfel and Lyon 2015). These studies have yielded varying results about the 
effects of knocking out N-terminal acetylation. Overall, the effects can promote apoptosis, or 
prevent it, and the various tissues, cellular and proteomic context in which these changes occur 
likely affect the outcome of aberrant N-terminal acetylation (Pavlou and Kirmizis 2016; Wang et 
al. 2012; Yang et al. 2016; Zeng et al. 2014). More research will be required to define the role 
that this process plays in cancer formation and apoptosis.  
These factors have made N-terminal acetylation an attractive target for disease treatment. 
Bisubstrate inhibitors have been developed, which covalently link an N-terminal like peptide to a 
non-hydrolyzable CoA moiety (Foyn et al. 2013). These bisubstrate inhibitors have proved 
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extremely valuable in research applications and will hopefully set the stage for therapeutic uses in 
the treatment of disease.   
 
1.7 Dissertation objectives 
 
 Although a great deal of work has been done elucidating the molecular basis of N-
terminal acetylation, there are still many unanswered questions in the field. These concern both 
the specialized NATs, and the major, promiscuous NATs. The structural features of the more 
specialized NATs are unknown, and the molecular basis underlying their specificity and 
localization remains to be explored. What confers the stringent specificity to Naa40 compared to 
the other more promiscuous NATs? Are there unique special features of Naa60 which allow it to 
act differently at the Golgi versus the cytosolic NATs. Why are these proteins able to catalyze 
reactions without auxiliary subunits? 
 Similar questions arise for the more promiscuous NATs. If they are actually able to 
acetylate lysine residues, how does this occur? Are there structural changes that accompany a 
lysine position in the active site, and if so, are there specific sequence determinants that guide the 
lysine substrate profile? Finally, how do the NATs associate with the ribosome? Do they compete 
for the same binding spot or occupy different positions around the exit tunnel simultaneously? 
What are the molecular determinants on the NATs that allow them to interact with the ribosome, 
and what is the nature of the interaction? Answering these questions will allow for a broader 
understanding of the NATs from a structural standpoint that will help understand the function of 
the specialized NATs, and increase our understanding of co-translational events in the cell. These 
studies will potentially aid in the development of new research tools and therapeutics that can be 
applied to not only the NATs, but other systems as well.  
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 The focus of my dissertations is to probe the mechanism of action and substrate 
recognition of the NATs, in both a post and co-translational context. To this end, I determined the 
crystal structure of Naa60 and Naa40 in complex with their substrate peptides, and carried out 
mutational and enzymological analysis of the enzymes. I assayed the ability of the Naa10 to 
acetylate lysine residues, using enzymatic and biochemical means. Finally, I probed the 
interaction of NatA with the ribosome using purified proteins. Through these studies I was able 
to: 
(1) Characterize the unique features of Naa60 that may influence its localization and 
substrate specificity 
(2) Show how Naa40 is able to maintain exquisitely substrates selectivity by varying the 
NAT fold with novel features 
(3) Demonstrate that Naa10 is not able to acetylate its reported lysine substrates, which 
instead represent a group of proteins that are chemically acetylated 
(4) Find two regions in the NatA complex that are essential for ribosome binding and 
have implications for the mechanism the other NATs may bind to the ribosome 
The last chapter of my dissertation is more speculative. There, I discuss a hypothesis on the 
evolution of the NATs based on an emerging model of eukaryogenesis and the implications this 
has for how we think about N-terminal acetylation. 
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CHAPTER 2: Crystal Structure of the Golgi-Associated Human Naa60 Reveals the 
Molecular Determinants for Substrate-Specific Acetylation 
	
 
 
 
 
 
 
 
 
	
	
	
This research was performed in collaboration with Dr. Svein Støve from the University of 
Bergen. Dr. Støve solely performed all of the enzymatic and DSF assays. This work was 
originally published in Structure (Støve et al. 2016) © Cell Press 
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2.1 Introduction 
 Naa60 is the most recently identified and least studied NAT. Naa60 is distinct in its 
subcellular localization pattern; while Naa10–Naa50 are located throughout the cytoplasm and in 
some cases also in the nucleus, Naa60 displays an organellar localization pattern associating with 
Golgi membranes (Aksnes, Van Damme, Goris, Starheim, Marie, Stove, et al. 2015). Depletion 
of NAA60 results in Golgi fragmentation in HeLa cells (Aksnes, Van Damme, Goris, Starheim, 
Marie, Stove, et al. 2015) and abnormal chromosome segregation in drosophila DmeI2 cells (Van 
Damme, Hole, et al. 2011a), resembling the observed phenotypes of NAA50 depleted drosophila 
cells. Interestingly, although Naa60 is present in most eukaryotes, it has been lost in the fungi 
lineage. This is why it was initially believed to only be present in multicellular eukaryotes, as it 
was absent in the model organism Saccharomyces cerevisiae. (Van Damme, Hole, et al. 2011b; 
Rathore, Faustino, and Prudêncio 2016). 
Initial studies of human Naa60 suggested that although there was extensive redundancy 
in the substrate specificity profile of Naa30, Naa50 and Naa60 in vitro, there is a large over-
representation of transmembrane proteins in the Naa60 acetylome, suggesting that Naa60 has 
evolved to specifically acetylate the cytosolic N-termini of membrane proteins from its 
membrane-associated localization (Aksnes, Van Damme, Goris, Starheim, Marie, Stove, et al. 
2015). Additionally, unlike the other NATs, Naa60 can efficiently acetylate MK starting peptides, 
a class of substrates that are not acetylated in yeast, but are in animal cells (Van Damme, Hole, et 
al. 2011b). 
In this study, we set out to investigate the structure and biochemical properties of human 
Naa60. To this end, we cloned, purified and crystallized Naa60 both in complex with CoA and in 
complex with a bisubstrate analogue closely resembling CoA and an acetylated substrate 
polypeptide. We also carried out structure-based mutagenesis and biochemical and enzymatic 
studies in order to make structure-function correlations underlying Naa60-specific activities. The 
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Naa60 structure adopts a Gcn5-related N-acetyltransferases fold, but contains extended β3-β4 and 
β6-β7 loops that we demonstrate are important for Naa60 function. By the use of site directed 
mutagenesis and kinetic analysis we show that Naa60 employ a catalytic mechanism similar to 
Naa50, while the β3-β4 and β6-β7 loops play important roles in substrate-specific binding, and 
that the latter loop also mediates a dimer to monomer transition. Collectively, the data presented 
here reveal the molecular basis for Naa60-specific acetyltransferase activity with implications for 
Golgi-specific functions for this multicellular-specific NAT.  
 
2.2 Results 
2.2.1 Structure of Naa60/CoA-Ac-MKAV7 reveals Naa60-specific regions 
Sequence alignment of human Naa60 with other NAT homologues reveals sequence 
homology within the N-terminal 180 amino acids (Figure 2.1), but sequence divergence of C-
terminal residues 181-242 that have been shown to be responsible for the Golgi subcellular 
localization of Naa60 (Aksnes, Van Damme, Goris, Starheim, Marie, Stove, et al. 2015; Aksnes 
et al. 2017). Within the conserved NAT region, Naa60 shows the greatest regions of sequence 
divergence in the β3-β4 (residues 73-94) and β6-β7 (residues 165-173) loops, which are also 
longer in Naa60 than other eukaryotic NATs. Interestingly, the β3-β4 loop of the NAT 
homologue from Sulfolobus solfataricus (ssNAT) is also extended compared to β3-β4 loops of 
other NATs, and was previously shown to be important for ssNAT function (Liszczak and 
Marmorstein 2013).   
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Figure 11 Sequence alignment of selected NATs  
(A) Sequence alignment of Naa60 (1–184) and NAT homologs. Sequence identity is shown with 
white letters in red boxes and sequence similarity with red letters in blue frames. The secondary 
structure elements of Naa60 are shown on top of the alignment. The β3-β4 loop is marked in pink 
and the β6-β7 loop in light blue. (B) IC50 values of the two bisubstrate analogs CoA-Ac-
MAPL7 and CoA-Ac-MKAV7 in addition to the control compound desulfoCoA. (C) Overall 
structure of the binary Naa60/CoA-Ac-MKAV7 complex. Naa60 is shown in yellow, the β3-β4 
loop is shown in pink (on the back side of the structure), the β6-β7 loop in light blue, and the 
CoA-Ac-MKAV7 inhibitor is shown as green sticks with oxygen, nitrogen, and phosphate shown 
in red, blue, and orange, respectively. 
  
 
 
 
31 
	
 In order to structurally and biochemically examine human Naa60, we cloned, expressed 
and purified different N-terminal Naa60 variants and were able to prepare a construct containing 
residues 1-184, which was amenable to biochemical and structural analysis. We also prepared 
two bisubstrate analogues, CoA-Ac-MAPLDLD (CoA-Ac-MAPL7) and CoA-Ac-MKAVQAD 
(CoA-Ac-MKAV7) derived from previously identified N-terminal Naa60 in vivo substrates (Van 
Damme, Hole, et al. 2011a; Aksnes, Van Damme, Goris, Starheim, Marie, Stove, et al. 2015). 
Both bisubstrate analogues were very potent inhibitors, with a half maximum inhibitor 
concentration (IC50) of 1.0 ± 0.1 µM and 2.44 ± 0.6 µM, respectively, whereas the IC50 of 
desulfoCoA was 394.7 ± 43.3 µM (Figure 2.2A). 
 We obtained crystals of Naa60 (5-184) in binary complex with CoA-Ac-MKAVQAD 
and to determine its structure to a resolution of 1.53 Å, using molecular replacement with ssNAT 
(PDB ID: 4LX9) as a search model. The crystals formed in spacegroup P41 and contained two 
Naa60/CoA-Ac-MKAV7 complexes per asymmetric unit. The resulting electron density allowed 
for the tracing of residues 5-184 of Naa60, and the CoA-Ac portion and residues 1 to 4 of the 
bisubstrate inhibitor (herein called CoA-Ac-MKAV7). Both complexes in the asymmetric unit 
overlay almost perfectly except for a slight adjustment of the side chain positions of M1p and K2p 
of the bisubstrate inhibitor. The final model was refined to an Rwork/Rfree of 0.1905/0.2084 with 
good geometry (Table 2.1). We also obtained crystals and determined the structure of Naa60 in 
complex with CoA (more thoroughly described below). Naa60 adopts the characteristic GNAT 
(Gcn5-related N-acetyltransferase) fold found in all NATs, consisting of a mixed α/β fold with a 
conserved AcCoA binding site (Figure 2.2B). In contrast, the β3-β4 and β6-β7 loops adopt 
Naa60-specific structures. The β3-β4 loop folds back towards the peptide and core domain, and 
the β6-β7 loop, contains a β-hairpin structure with two shorts strands that we call β6’ and β7’ that 
hangs over the peptide binding site in a manner that is highly characteristic for all NATs (Figure 
2.2B).  
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Figure 12 Overall Structure of the Binary Naa60/CoA-Ac-MKAV7 Complex  
(A) IC50 values of the two bisubstrate analogs CoA-Ac-MAPL7 and CoA-Ac-MKAV7 in addition 
to the control compound desulfoCoA. (B) Overall structure of the binary Naa60/CoA-Ac-
MKAV7 complex. Naa60 is shown in yellow, the β3-β4 loop is shown in pink (on the back side 
of the structure), the β6-β7 loop in light blue, and the CoA-Ac-MKAV7 inhibitor is shown as 
green sticks with oxygen, nitrogen, and phosphate shown in red, blue, and orange, respectively. 
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Table 2.1 Data Collection and Refinement Statistics 
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2.2.2 Naa60 shows the greatest structural and functional similarity to Naa50 
A superposition of the Naa60/CoA-Ac-MKAV7 structure with other NAT structures 
shows the highest degree of structural similarity to Naa50 (PDB: 3TFY) with an RMSD of 1.59 Å 
for backbone atoms, although there is still significant structural superposition with Naa10 (PDB: 
4KVM) (RMSD = 1.96 Å) and ssNAT (PDB: 4LX9) (RMSD = 1.70 Å) (Figure 2.3A). Consistent 
with the sequence divergence between these proteins, Naa60 shows the greatest structural 
divergence with these proteins in the β3-β4 and β6-β7 loops (Figures 2.3B and 2.3C). 
Interestingly, the β3-β4 loop of ssNAT is most similar to the corresponding loop of Naa60 and 
has previously was shown to be important for ssNAT function by hanging over and contacting the 
β5, β6, β7 strands to position residues in these strands to make peptide substrate interactions 
(Liszczak and Marmorstein 2013). As discussed below, this loop plays a similar role in Naa60. 
As expected, two tyrosine residues in the β6-β7 loop of Naa60 (Y164 and Y165) are conserved 
and play a role in peptide anchoring (Figure 2.3C). 
A superposition of the Naa60/CoA-Ac-MKAV7 structure with other NAT structures also 
reveals that the active site of Naa60 most closely resembles the active site of Naa50, in which two 
residues contribute to general base catalysis. In Naa50, these residues are Y73 and H112 and the 
corresponding residues in Naa60 are Y97 and H138 (Figure 2.4A). Both structures also show an 
ordered water molecule in a similar position to facilitate proton extraction from the target amine. 
The water molecule is coordinated by the side chain of Y97, backbone carbonyl of L98, backbone 
nitrogen of H138, and M1p N-terminus (Figure 2.4A). 
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Figure 13 Structural Alignment Highlighting Specific Features of Naa60  
(A) Superimpositon of Naa60 (yellow) with Naa50 (cyan), SpNaa10 (orange), and ssNAT 
(white). CoA-Ac-MKAV7 bound to Naa60 is shown as green sticks. (B) Superimposition of 
Naa60 (yellow), Naa50 (cyan), SpNaa10 (orange), and ssNAT (white) β3-β4 loop. (C) 
Superimposition of Naa60 (yellow), Naa50 (cyan), SpNaa10 (orange), and ssNAT (white) β6-β7 
loop containing a hairpin structure with two short strands (β6′ and β7′). 
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Figure 14 Catalytic Mechanism and Peptide Binding Site of Naa60 (from previous page) 
(A) Superimposition of the Naa60 and Naa50 active site (shown in yellow and cyan, 
respectively). Residues associated with catalysis (Y97, H138 of Naa60 and Y73, H112 of Naa50) 
are shown as yellow and cyan sticks. An ordered water molecule involved in catalysis is shown in 
yellow and cyan for the Naa60 and Naa50 structure, respectively. The bisubstrate analog CoA-
Ac-MKAV7 is shown as green sticks in all figures. (B) Residues F34, P35, I36, L140, Y165, and 
I167 (yellow sticks) form a hydrophobic pocket surrounding the substrate peptide M1p side chain. 
(C) Structural alignment of Naa60 and Naa50 active sites. Residues L99, Y38, and Y165 of 
Naa60 that play important roles in peptide anchoring and are structurally conserved between 
Naa60 and Naa50 are shown as yellow sticks. Hydrogen bonds are illustrated as dashed lines. (D) 
Superimposition of the cavity surrounding the Naa60 and Naa50 peptide binding site. (E) Active 
site surface representation of Naa60. (F) Active site surface representation of Naa50. 
  
 
 
 
 
 
 
 
 
 
38 
	
In addition to similarities in the active site, Naa60 and Naa50 both contain a conserved 
hydrophobic core that recognize Met1 of the cognate N-terminal substrate. Specifically, F34, P35, 
I36, L140, Y165 and I167 of Naa60, which are conserved in Naa50, surround the side chain of 
M1p (Figure 2.4B). The peptide is anchored in the active site of the enzyme through several 
hydrogen bonds. Y38 and Y165, both of which are conserved between Naa50 and Naa60, form 
hydrogen bonds to the carbonyl groups of M1p and K2p respectively, while the backbone carbonyl 
of L99 forms a hydrogen bond to the backbone amide of M1p (Figure 2.4C). 
 There   are   also   major   differences   between   these   enzymes. While   the   Naa50   
structure   reveals   a   second   hydrophobic pocket for residue 2p, the corresponding region of 
Naa60 is more solvent exposed and thus can accommodate more variability in position 2p 
(Figures 2.4D–2.4F). Indeed, K2p of the MKAV7 peptide region of the CoA-Ac-MKAV7 
bisubstrate inhibitor, as well as A3p and V4p side chains, do not make significant interactions to 
the protein. The larger and more solvent-exposed cavity of Naa60 suggest that this enzyme is able 
to accommodate larger and more polar residues at positions 2p and 3p compared with Naa50, 
which previously has been shown to prefer methionine-starting substrates with hydrophobic 
amino acids such as leucine or valine in position 2p. An interesting feature of the binding pocket 
is the presence of E70 in β3 (Figure 2.4D). This replaces a bulkier basic residue that is found in 
all of the other NATS at this position (Figure 2.4D and Figure 2.1), and it likely contributes to the 
ability of Naa60 to more efficiently acetylate peptides with lysine in the second position than the 
other NATs.  
 
2.2.3 Mutational analysis of Naa60 shows good correlation with the structure 
In order to examine the importance of specific residues on the catalytic and substrate 
binding function of Naa60, several Naa60 point mutants were created and tested for activity using 
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the substrate peptide MKAV24 peptide substrates, representing a substrate that previously was 
shown to be acetylated by Naa60 in vivo (Van Damme, Hole, et al. 2011a; Aksnes, Van Damme, 
Goris, Starheim, Marie, Stove, et al. 2015). Mutation of residues directly involved in the catalysis 
of Naa60 resulted in severe impairments. An Y97F point mutant showed complete loss of 
catalytic activity (Figure 2.5) confirming that this residue is important for Naa60 catalysis. 
Interestingly, H138F and H138A mutants turned out to be very unstable and difficult to purify, 
suggesting that this residue not only is involved in catalysis, but that it also is important for 
maintaining the overall structure of Naa60.  
We also prepared several point mutants of residues that form the hydrophobic pocket 
surrounding the M1p side chain. P35A, I36A, and I167A all showed an approximate 2.5- to 4-fold 
reduction in kcat and a small increase in KM when tested toward the substrate polypeptide   
MKAV24 (Figure 2.5A). Surprisingly, the Naa60 L140A mutant had a 4- to 5-fold increase in kcat 
but at the same time a 5- to 10-fold increase in KM (Figure 2.5A). Thus, despite the increased kcat, 
the catalytic efficiency (kcat/KM) of this mutant is approximately 0.5-fold of Naa60 wild-type 
(WT) (Table 2.2). In comparison, the catalytic efficiency of the P35A, I36A, and I167A point   
mutants had approximately 6-fold, 6-fold, and 3-fold reduction compared with the Naa60 WT, 
respectively (Table 2.2). We also created a P35A/I36A/I167A triple mutant, but were unable to 
detect any catalytic activity for this mutant in our assay (Table 2.2). Together, these data show 
that the M1p hydrophobic pocket is important for substrate-specific acetylation. 
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Figure 15 Catalytic Parameters of Naa60 WT and Mutants:  
(A) kcat values (black bars) and KM values (yellow bars) of wild-type Naa60 and selected Naa60 
mutants toward the substrate polypeptide MKAV24. (B) Catalytic efficiency of Naa60 (black bars) 
and Naa50 (blue bars) toward different substrate polypeptides representing previously identified 
Naa60 or Naa50 substrates in vivo. All experiments were performed in triplicate and data are 
represented as means ± SEM. 
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 Table 2.2 Catalytic Efficiency of Naa60 WT and mutants 
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To probe the importance of substrate polypeptide anchoring in the active site, we   
mutated tyrosines Y38 and Y165 that showed hydrogen bonds with the peptide substrate 
backbone (Figure 2.4C). Y165 also forms parts of the hydrophobic pocket surrounding the   side-
chain peptide substrate M1p; however, by creating a Y165F point mutant only the hydroxyl   
group involved in peptide anchoring will be removed and the hydrophobic pocket will remain   
unaffected. The Naa60 Y38A variant resulted in a complete loss of catalytic activity, while the 
Naa60 Y165F mutant had an approximately 4-fold reduction in catalytic efficiency (Table 2.2). 
Together, these studies show that Y38 and Y165 play important roles in peptide binding. 
 To probe the substrate selectivity of Naa60 for comparison with Naa50, we determined 
kinetic constants for both Naa60 and Naa50 toward several different peptides representing N-
termini that were previously identified as substrates of either Naa60 or Naa50 in vivo (Van 
Damme, Hole, et al. 2011b; Aksnes, Van Damme, Goris, Starheim, Marie, Støve, et al. 2015). 
The catalytic efficiency of the two enzymes is similar for several of the tested substrates, but 
there are also differences (Figure 2.5B). As expected, Naa50 has the highest catalytic efficiency 
for the substrate polypeptides MLGP24 and MVSM24. Naa60, on the other hand, has the highest 
catalytic efficiency for peptide substrates MAPL24, MVSM24, MKAV24, and MKQY24. 
Interestingly, while Naa60 had approximately the same catalytic efficiency for MKAV24 and 
MKQY24 with larger more bulky side chains in position 3p and 4p, Naa50 had a 3-fold lower 
catalytic efficiency for MKQY24 compared with MKAV24. This is consistent with the larger and 
more solvent-exposed cavity seen in Naa60 relative to Naa50 around the K2p, A3p, and 
V4p residues of the bisubstrate analog. 
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2.2.4 The Naa60 specific β3-β4 loop plays a role in protein stability 
The elongated 22-residue β3-β4 loop (residues 73-94) is a structure not found in most 
NATs. In Naa10 and Naa50, β3 and β4 are linked together with only a short beta hairpin. In 
contrast, in both ssNAT and Naa60, β3 and β4 are linked together by a large elongated loop, with 
the loop being significantly larger inNaa60 (Figure 2.6A). The β3-β4 loop of Naa60 folds back 
towards the enzyme core and peptide portion of the bisubstrate inhibitor to make multiple 
hydrogen bonds and van der Waals contacts to residues in β-strands 5, 6 and 7 (Figure 2.6A).  
D81 and D83 of the β3-β4 loop make hydrogen bonds to H138 and H157 of the β5 and β7 strands 
respectively (Figure 2.6B) and the backbone amide nitrogen of I77 makes a water mediated 
hydrogen bond to the phenol oxygen of Y136 (not shown). In addition E80, D81 and the 
backbone carbonyl of I84 forms a hydrogen bonds with Y164, T176 and Y180 of the β6 strand 
respectively (Figure 2.6B). Several residues of the β3-β4 loop (I77, I84, L85) also participate in 
van der Waals interactions with residues of the β5-β6-β7 core (Y136, V178, Tyr180) (Figure S4). 
Interestingly, despite the large number of contacts between the β3-β4 loop and β5, β6 and β7 
strands, mutational analysis suggest that the positioning of this loop is easily disrupted. Mutating 
some of the residues that forms these contacts (D81A, D83A or Y164A/F) all result in a 3-6 fold 
increase in kcat, but also a 2-4 fold increase in the KM of the reaction (Figures 2.5A and 2.5B), 
resulting in a modest overall effect on catalytic efficiency (Table 2). This could indicate that 
mutating residues involved in the contact between the β3-β4 loop and β5, β6 and β7 strands is 
altering the structure of the enzyme in a way that only affects substrate peptide binding and 
catalysis in subtle ways. 
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Figure 16 The Naa60-Specific β3-β4 Loop  
(A) Residues D81 and D83 (pink sticks) of the extended β3-β4 loop of Naa60 (shown in pink) 
that form salt bridges with residues H138 and H159 (yellow sticks) of β5 and β7 are shown. E80 
and D81 (pink sticks) that form hydrogen bonds with Y164 and T176 (yellow sticks) of β6 and 
the carbonyl backbone of I84 (pink sticks) that form a hydrogen bond with Y180 (yellow sticks) 
are also shown. The CoA-Ac-MKAV is shown as green sticks. (B) Residues I77, I84, and L85 
(pink sticks) that form a hydrophobic interior of the loop and participate in van der Waals 
interactions with residues V95, A134, Y136, and V178 (yellow sticks) of β5, β6, and β7 strands is 
shown. 
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To further investigate the effects of mutating these residues, we analyzed the stability of 
these point mutants by differential scanning fluorimetry as has been described previously   
(Figure 2.7) (Bustad et al., 2012). Apo Naa60 WT had a melting point of 47.9 °C and was clearly 
stabilized both by the addition of Ac-CoA (Tm increased gradually from 48 °C to 54.7 °C by 
addition of 0.16x–10x Ac-CoA) and the bisubstrate analog CoA-Ac-MAPL7 (Tm ranging from 
47.6 °C–53.2 °C with increasing bisubstrate analog concentrations) (Figures 2.7A and 2.7B). As 
expected, the I36A point mutant that had severe catalytic effects due to disruption of the M1p 
hydrophobic pocket did not show	any signs of destabilization, while Naa60 mutants involved in 
forming contacts between the β3-β4 loop and β5, β6 and β7 strands, D81A, I84A, and Y164F, 
were all clearly destabilized compared with Naa60 WT (Figures 2.7C–2.7F). Furthermore, a 
higher initial fluorescence was seen for both Naa60 D81A and I84A, indicating that more 
hydrophobic areas are exposed to the solvent, most likely due to a destabilized β3-β4 loop. 
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Figure 17 Thermal stability of wild-type Naa60 and mutants  
DSF- monitored thermal denaturation of wild-type Naa60 and mutants. Enzymes were mixed 
with SYPRO Orange and either CoA or CoA-Ac-MAPL7 at a molar ratio varying from 0.16:1 – 
10:1, and the stability was measured at temperatures increasing from 22 to 95°C. (A) Thermal 
denaturation of Apo wild type Naa60 and wild-type Naa60 in the presence of increasing 
concentration of Ac- CoA. (B) Thermal denaturation of Apo wild-type Naa60 and wild-type 
Naa60 in the presence of increasing concentration of the bisubstrate analogue CoA-Ac-MAPL7. 
(C) – (F) Thermal denaturation of Apo Naa60 mutants I36A, D81A, I84A and Y164F and Naa60 
mutants I36A, D81A, I84A and Y164F respectively in the presence of increasing concentration of 
Ac-CoA. 
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2.2.5 Naa60 dimerizes through the Naa60-specific β6-β7 loop in the absence of substrate peptide. 
In order to determine if Naa60 undergoes any structural changes upon N-terminal peptide 
substrate binding, we determined the crystal structure of the Naa60/CoA complex. We obtained 
crystals that formed in the P21 space group and determined the structure by molecular 
replacement using the protein portion of ssNAT (PDB: 4LX9) as a search model. The crystals 
contained four Naa60/CoA complexes per asymmetric unit cell and refined to an Rwork/Rfree of 
0.2072/0.2547 with good geometry at 1.95 Å resolution (Table 2.1).  Interestingly, in contrast to 
the monomeric Naa60/CoA-Ac-MKAV7 complex, the Naa60/CoA structures shows two 
symmetrical protein dimers, where dimer interactions are nucleated by the β6-β7 loops that form 
a four stranded sheet that extends into the peptide-binding sites of both subunits of the dimer 
(Figures 2.8A).  A superposition of the Naa60/CoA-Ac-MKAV7 complex with a subunit of the 
Naa60/CoA complex shows that the only significant structural change is a rotation of the β6-β7 
loop in the Naa60/CoA-Ac-MKAV7 out by about 45° to accommodate the insertion of the β6-β7 
loop from the opposing subunit of the Naa60/CoA dimer (Figure 2.8B). The superimposition also 
reveals that the Naa60 homodimer is incompatible with peptide binding by Naa60. Specifically, 
the β6-β7 loop of the first protomer protrudes into the catalytic site of the second protomer of the 
dimer, leaving no room for a substrate peptide to bind. 
Numerous contacts mediate Naa60/CoA homodimerization, several of which participate 
in peptide substrate anchoring in the Naa60 monomer (Figure 2.8D). L171 from each subunit 
make van der Waals contacts across the dimer. van der Waals contacts are also mediated between 
Y165 and Y38b and P39b of the core (b designates the second protomer of the dimer), and I167 
and V170 with L140b and I36b of the core, respectively. In addition, I36b of the core makes van 
der Waals interactions with the main chain of the β hairpin formed by residues S166, I167, R168, 
and G169. R168 also hydrogen bonds to the main-chain carbonyls of P162b and K172b of the 
core. Many of the residues in the β6-β7 loop that interact with the opposing subunit are specific 
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for Naa60 (Figure 2.1) and no other NAT structure determined to date shows this type of 
homodimerization. 
To investigate whether Naa60 dimers are formed in solution, we performed size-
exclusion chromatography and analytic ultracentrifugation (AUC). On a size exclusion 
chromatography column, Naa60 (1-184) with AcCoA elutes at a column volume corresponding to 
twice the theoretical size of the enzyme (Figure 2.8F). However, upon addition of 2 equivalents 
of the bisubstrate analogue CoA-Ac-MAPL7, more than 50% of the enzymes elutes as an 
apparent monomer from a size exclusion chromatography column. To further corroborate these 
findings, we performed AUC on the fractions of Naa60 bound to AcCoA that eluted off the size 
exclusion column in an apparent dimer peak (Figure 2.8F), and on the fractions of Naa60 bound 
to CoA-Ac-MAPL7 which eluted as an apparent monomer peak (Figure 2.8G). We performed the 
centrifugation at three different speeds and three different concentrations. The data fit extremely 
well to a Naa60/CoA-Ac-MAPL7 monomer with a molecular weight of 22.9 kD, and a Naa60/ 
CoA dimer with a molecular weight of 39.9 kD, which are very close to the theoretical molecular 
weights of 22.6 kD and 43.6 kD, respectively. These data support the peptide substrate-dependent 
dimer to monomer transition of Naa60 suggested by the crystal structures. 
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Figure 18 Naa60 dimerization (from previous page)  
(A) Crystal structure of the Naa60-CoA homodimer complex. CoA is shown as green sticks. (B) 
Superimposition of the β6-β7 loop in a monomeric state (shown in yellow) and in a dimeric state 
(shown in red). (C) Superimposition of the Naa60/CoA-Ac-MKAV7 structure (only showing 
CoA-Ac-MKAV7) with the Naa60/CoA dimer. (D) Contacts between the two Naa60 protomers. 
The side chain of K172b was omitted for clarity. (E) Size-exclusion chromatography of Naa60(1–
184) mixed with either 2× or 10× excess of Ac-CoA or 0.5×, 2×, or 10× excess of the bisubstrate 
analog CoA-Ac-MAPL7. The first peak corresponds to an Naa60 homodimer and the second peak 
to an Naa60 monomer. (F) Sedimentation equilibrium analytical ultracentrifugation experiments 
of Naa60 mixed with the bisubstrate analog CoA-Ac-MAPL7, which eluted as a dimer. RMS, 
root-mean-square. (G) Sedimentation equilibrium analytical ultracentrifugation experiments of 
Naa60 mixed with the bisubstrate analog CoA-Ac-MAPL7, which eluted as a monomer. 
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2.3 Discussion  
In this study, we have crystallized and biochemically characterized Naa60, the only 
human NAT identified so far with distinct organellar localization, and the only NAT identified 
that primarily acetylates membrane proteins. As previously shown in vivo, Naa60 has an 
organellar localization that is dependent on the C-terminal 60 amino acids (residues 182-242) 
(Aksnes, Van Damme, Goris, Starheim, Marie, Stove, et al. 2015). The present study reveals that 
Naa60 1-184 forms a GNAT fold that highly resembles the Naa50 structure. Our studies also 
show that the C-terminus of Naa60 is not necessary for its biochemical function. Indeed, 
subsequent experiments have shown that the C-terminus of Naa60 forms two alpha helices, which 
facilitates the peripheral anchoring of Naa60 to the membrane via interaction with ionic lipids 
(Aksnes, Van Damme, Goris, Starheim, Marie, Stove, et al. 2015; Aksnes et al. 2017).  
To study the molecular basis for substrate-specific acetylation by Naa60, we designed 
and synthesized two bisubstrate analogs, one of which was co-crystallized with Naa60. This 
approach was chosen as a result of difficulties in obtaining a crystal structure of a 
Naa60/CoA/peptide ternary complex. A similar approach was previously used in the 
crystallization of the p300/CBP transcriptional co-activator (Liu et al. 2008), using a bisubstrate 
analog with CoA attached to the side chain of lysine, which both facilitated crystallization of this 
enzyme and enabled investigation of substrate-enzyme interactions and mechanisms. Bisubstrate 
analogs have also been successfully used as enzyme-specific and potent NAT inhibitors (Foyn et 
al. 2013), and were also used to crystallize and study the NatA complex (Liszczak et al. 2013). 
The bisubstrate analogs presented here represent the first Naa60-specific bisubstrate analogs and 
the second case whereby such analogs have been used as a tool for the investigation of amino 
acid substrate interactions in NAT enzymes. 
The overall structure of Naa60 aligns very well with other available NAT structures and 
is very similar to the overall structure of Naa50 (RMSD=1.59 Å). Of particular interest to us was 
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the active site of Naa60, and whether there were any differences in its substrate peptide binding 
and catalytic mechanism compared with Naa50 and other NATs. Our data reveal that Naa60 
utilizes the same catalytic mechanism as Naa50, and that all residues directly associated with 
catalysis are conserved between the two enzymes. Substrate peptide anchoring is also highly 
conserved, in addition to key residues involved in forming a hydrophobic pocket surrounding the 
M1 side chain of the substrate peptide. However, there are notable differences. In Naa50, a 
second hydrophobic pocket is formed around substrate peptide residue 2p, enabling Naa50 to 
efficiently acetylate substrates with a methionine in position 1p followed by a hydrophobic 
residue in position 2p. In comparison, the corresponding region of Naa60 is more solvent exposed 
and has more room for substrates with larger charged side chains. Whether Naa60 evolved to 
acetylate many, or some of these substrates compared to the other NATs remains to be 
determined.  
 Despite the large overall structural similarity between Naa50 and Naa60, there are several 
features that are specific for Naa60. A prominent difference maps to the β3-β4 loop, which is 
extended by 10–15 residues in Naa60 compared with the other NATs. The elongated loop 
interacts with residues in β-strands β5, β6, and β7, and point mutation of key residues in this loop 
resulted in a slightly increased catalytic efficiency of the enzyme. The exact function of this loop 
is still unclear, and interestingly, we show that loss of the interaction between the β3-β4 loop and 
β-strands β5, β6, and β7 not only results in altered acetyltransferase activity, but also cause a 
substantial drop in protein stability with a melting point that is 5°C–10°C lower than for WT 
Naa60. 
A second structural feature that is unique to Naa60 is the elongated β6-β7 loop. Sequence 
alignments of Naa60 and NAT-homologues show that the loop is extended by 3-5 residues 
(Figure 2.1). Interestingly these residues mediate dimerization of Naa60 in the absence of 
substrate peptide, a feature that to our knowledge has never been seen for any other NAT. The 
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β6-β7 loop of each monomer extends into the peptide-binding site of the second subunit of the 
dimer and is stabilized by hydrogen bond and van der Waals interactions. As the Naa60 
dimerization is mediated by the β6-β7 loop of both monomers extending into the active site of 
each other, it seems very unlikely that Naa60 can be catalytically active in its dimeric form. 
However, our size exclusion chromatography and AUC data also shows that Naa60 can 
dynamically shift between a monomeric and dimeric state. This is also reflected in enzymatic 
assays; although Naa60 is purified as a homodimer, this dimer is catalytically active. The 
substrate peptide therefore likely competes with the β6-β7 loop of the other Naa60 subunit for 
binding in the active site. This could be a way to regulate substrate-specificity, as the affinity for 
a potential substrate may have to be higher than the affinity for the other subunit of the monomer. 
In vivo, Naa60 is not freely diffusible through the cytoplasm, but rather specifically associates 
with the Golgi membrane through the C-terminus (Aksnes et al. 2017). These membrane 
interactions may therefore also contribute to formation of the Naa60 dimer in the absence of 
peptide substrate. Consistent with this model, in the Naa60 homodimer the C-terminal end of both 
Naa60 1-184 monomers are pointing in the same direction, supporting that dimerization is 
compatible with Naa60 attachment to organellar membranes (Figure 2.9).  
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Figure 19 Schematic illustration of the potential positioning of the Naa60 homodimer 
relative to organellar membranes  
Naa60 is known to associate with Golgi membranes through its C-terminus. In the structure of the 
Naa60 homodimer, both C-termini are pointing in the same direction, suggesting that Naa60 
homodimerization also can occur in vivo at the Golgi. Note the position of the β3-β4 loop in this 
model is close to the membrane, suggesting a role for aiding localization or substrate interaction. 
 
 
 
 
 
55 
	
The majority of proteins that are N-terminally acetylated are modified co-translationally 
as they emerge from the ribosomal exit tunnel, and several NATs have previously been shown to 
associate with the ribosome As Naa60 was shown to localize to the cytosolic side of Golgi 
membranes, and as the bulk of all detected Naa60 is associated with membranes, it is likely that 
Naa60 does not directly associate with ribosomes but rather acts post-translationally, acetylating 
transmembrane proteins with N-termini facing the cytosol. What role the unique β3-β4, and β6-
β7 loops have on the in vivo substrate profile of Naa60 remain to be determined.  
 
2.4 Materials and methods 
2.4.1 Naa60 cloning, expression and protein purification 
A C-terminal truncation construct coding for His-SUMO-Naa60(1–184) was expressed in 
Rosetta (DE3) pLys competent cells overnight at 17°C. Cells were lysed in lysis buffer (25 mM 
Tris-HCl [pH 8.0], 1 M NaCl, 10 mM β-mercaptoethanol, and 10 µg/ml PMSF) by sonication, the 
cell lysate was centrifuged at 17,000 × g for 30 min, and overexpressed His-tagged proteins were 
isolated by passing the supernatant over nickel resin. The resin was washed with wash buffer 
(25 mM Tris-HCl [pH 8.0], 250 mM NaCl, 20 mM imidazole, 10 mM β-mercaptoethanol) and 
bound proteins eluted by slowly increasing the imidazole concentration to 300 mM. The His-
SUMO tag was cleaved by adding SUMO protease (Ulp-1) to the eluted protein while the protein 
was dialyzed into a buffer without imidazole (25 mM Tris-HCl [pH 8.0], 250 mM NaCl, and 
10 mM β-mercaptoethanol), and the tag was removed from the sample by reverse nickel 
purification. The flow-through was collected and dialyzed into size-exclusion buffer (25 mM 
HEPES [pH 7.5], 300 mM NaCl, and 1 mM DTT). The dialyzed sample was concentrated to a 
final volume of 1 ml and loaded on a HiLoad Superdex 200 size-exclusion chromatography 
column. Fractions containing Naa60 (1–184) were collected and used for protein crystallization. 
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2.4.2 Synthesis of bisubstrate analogues 
As previously reported, bisubstrate analogues can be very potent inhibitors (Foyn et al. 
2013). Based on the substrate specificity profile determined by Naa60 knock-down and 
overexpression followed by proteomics (Aksnes, Van Damme, Goris, Starheim, Marie, Stove, et 
al. 2015; Van Damme, Hole, et al. 2011a), we selected two polypeptide sequences from known 
Naa60 substrates and used the peptide sequence of the 7 first residues as a template for Naa60 
bisubstrate analogues. The bisubstrate analogues were synthesized as described previously (Foyn 
et al. 2013). Briefly, peptides were synthesized by automated solid phase peptide synthesis using 
the Fmoc strategy. Amino acids were coupled to Knorr amide MBHA resin on the 0.2 mmol scale 
and synthesized peptides were treated with bromoacetic acid in the presence of 
diisopropylcarbodiimide before the peptides were cleaved from the resin with trifluoroacetic acid 
(TFA):triisopropylsilane:ddH2O (95:2.5:2.5). Peptides were precipitated, purified by reverse-
phase high performance liquid chromatography, lypholized and Coenzyme A (CoA) was attached 
by reacting bromoacetylated peptide with two eq. CoA in triethylammonium bicarbonate buffer 
pH 8.0. Synthesized compounds were purified to a typical purity of >95% by RP-HPLC, verified 
by MALDI-MS and lyophilized.  
 
2.4.3 Crystallization and data collection 
The Naa60/CoA structure was obtained by mixing 18 mg/ml purified Naa60 (1-184) with 
1:3:5 molar ratio of Naa60:CoA:MAPL7 peptide (although electron density corresponding to the 
MAPL7 peptide was not observed in the final structure). Crystals were obtained by hanging-drop 
vapor diffusion at 20˚C for 1-3 days against a reservoir solution of 3% Tascimate, 0.1 M Bis-Tris 
pH 6.5 and 16% PEG 3350. For the Naa60/CoA-Ac-MKAV7 bisubstrate analog structure, the N- 
and C-terminal truncation variant Naa60 (5–184) was purified, concentrated to 13 mg/ml, and 
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mixed with the bisubstrate analog CoA-Ac-MKAV7 at a 1:3 molar ratio. Crystals were obtained 
by hanging-drop vapor diffusion at 20 ˚C over 3 months against a reservoir solution of 4% 
Tacsimate (pH 4.0) and 12% PEG 3500. Naa60/CoA crystals were transferred to a series of 
cryoprotectant solutions containing well solution supplemented with 300 mM NaCl and 5%, 10%, 
and 25% glycerol prior to flash-freezing in liquid nitrogen. Naa60/CoA-Ac-MKAV7 crystals were 
transferred into a cryoprotectant containing its reservoir solution supplemented with 20% 
glycerol. Both datasets were collected at beamline X29A at the National Synchrotron Light   
source (Brookhaven National Laboratory) and were processed using HKL2000 (Otwinowski and 
Minor 1997). 
 
2.4.4 Structure determination and refinement 
The binary Naa60/CoA complex was determined by molecular replacement using a 
structure of ssNAT prepared with CHAINSAW (Stein 2008) without solvent molecules or 
cofactors as a search model. Molecular replacement was performed with Phaser in the CCP4 
suite. Initial rounds of manual model building were performed with Coot (Emsley and Cowtan 
2004), and all subsequent rounds of refinement were performed using Phenix refine and Coot 
interchangeably. The binary Naa60/CoA-Ac-MKAV7 complex was determined by molecular 
replacement using the binary Naa60/CoA complex as a search model and refined essentially as 
described above. For both binary complexes, the cofactor/bisubstrate analogue was built into F0 - 
Fc electron density maps. Refinement statistics are shown in Table 1.  
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2.4.5 In Vitro Acetylation Assays 
A colorimetric acetylation assay (Thompson et al. 2004) was used to measure the 
catalytic activity of Naa60 variants. Purified enzymes were mixed with substrate peptides and Ac-
CoA in acetylation buffer (50 mM HEPES [pH 7.5], 100 mM NaCl, and 2 mM EDTA), and 
reactions were quenched with quenching buffer (3.2 M guanidinium-HCl and 100 mM sodium 
phosphate dibasic [pH 6.8]). For measurement of CoA production, 5,5′-dithio-bis-(2-nitrobenzoic 
acid) (2 mM final, dissolved in 100 mM sodium phosphate dibasic [pH 6.8] and 10 mM EDTA) 
was added to the quenched reaction, and the absorbance at 412 nm was measured. Background 
absorbance was determined in negative controls and subtracted from the absorbance determined 
in each individual reaction. Thiophenolate production was quantified assuming ɛ = 13.7 × 
103 M−1 cm−1. Product formation was measured in the linear phase of the reaction, and kinetic 
constants were determined by GraphPad Prism. In the quantitative acetylation assay the following 
oligopeptides (synthesized by Biogenes) were used: 
MKAV24: MKAVQADRWGRPVGRRRRPVRVYP 
MAPL24: MAPLDLDRWGRPVGRRRRPVRVYP  
MKQY24: MKQYQGSRWGRPVGRRRRPVRVYP  
MVM24: MVSMSFKRWGRPVGRRRRPVRVYP 
MLGP24: MLGPEGGRWGRPVGRRRRPVRVYP 
  
2.4.6 Determination of IC50 values 
Purified SUMO-Naa60 1-184 (500 nM) was mixed with MAPL24 substrate peptide (300 
mM), acetyl-CoA (300 mM) and inhibitor (0-15 mM) or desulfoCoA (0-400 mM) in a total of 50 
mL at 37°C for 45 min. IC50 values were determined by fitting the data using Grafit 7 and the 
equation activity(%) = 100%/(1+([I]/IC50)s), where [I] is the concentration of inhibitor and s is a 
slope factor (Hill coefficient).  
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2.4.7 Differential scanning fluoremetry (DSF)  
Purified wild-type Naa60 and mutants were diluted to a final concentration of 0.1 mg/mL 
in a 25 mM HEPES (pH 7.5) buffer containing 300 mM NaCl and 1 mM DTT. Enzymes were 
mixed with 5x SYPRO Orange and added to a 1:2 dilution series of either Ac- CoA or the CoA-
Ac-MAPL7 bisubstrate analogue. Thermal denaturation was studied in 8 different conditions; 
enzyme without any cofactor and enzyme in 7 different concentrations of CoA or CoA-Ac-
MAPL7. Samples were heated from 22 to 95°C at a scan rate of 2°C/min and fluorescence was 
quantified with a data pitch of 0.2°C on a LightCycler 480 Real-Time PCR System from Roche 
Applied Science (F. Hoffmann–La Roche Ltd., Basel, Switzerland).  
 
2.4.8 Analytical Ultracentrifugation 
Sedimentation equilibrium analytical ultracentrifugation experiments were performed at 4 
°C with absorbance optics at 280 nm using a Beckman Optima XL-I analytical ultracentrifuge. 
We employed the use of a 4-hole rotor containing six-channel centerpieces with quartz windows, 
spinning at 6000, 18000 and 26000 rpm. Naa60 was mixed with a five molar excess of either 
acetyl-CoA or CoA-Ac-MKAV7 and run on a superdex 75 gel filtration column. Protein samples 
were analyzed at A280 = 0.7, 0.5, and 0.3 in gel filtration buffer (25 mM HEPES pH 7.5, 300 mM 
NaCl, 1 mM DTT). Data for each speed were collected in quadruplicate. The viscosity of the 
samples were estimated using Sedenterp (http://sednterp.unh.edu/) and the most representative 
runs were included to calculate a theoretical molecular weight using the program HeteroAnalysis 
(http://www.biotech.uconn.edu/auf/?i=aufftp) 
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CHAPTER 3: The Molecular Basis for Histone H4- and H2A-Specific Amino-Terminal 
Acetylation by NatD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work was originally published in Structure (Magin, Liszczak, and Marmorstein 2015b) © 
Cell Press 
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3.1 Introduction 
NatD (also known as Nat4, Naa40, or Patt1) activity was first observed in the yeast S. 
cerevisiae when a NatA yeast knockout strain was noted to harbor N-terminal acetylated histones 
H2A and H4, which contain an N-terminal serine residue that is typically N-terminally acetylated 
by NatA (Mullen et al. 1989). NatD from S. cerevisiae was subsequently cloned (Song et al. 
2003), and the human homolog was later characterized (Hole et al. 2011). The only NatD 
substrates known to date are histones H2A and H4, making it the most substrate selective NAT 
enzyme so far characterized. The biological role of N-terminal H4 acetylation has only recently 
come to light. Schiza et al demonstrated that the presence of an N-terminal acetyl group on H4 
downregulates asymmetric dimethylation on H4 Arg-3 by the Hmt1 arginine methyltransferase. 
(Schiza et al. 2013). The absence of asymmetric Arg-3 methylation in turn negatively regulates 
ribosomal DNA transcription. In this way, the presence of an acetyl group on H4 could act as a 
sensor for cell growth. NatD has also been implicated in disease. NatD is downregulated in 
hepatocellular carcinoma, and overexpression of NatD in the cancerous cells enhances apoptosis 
(Liu et al. 2009). NatD liver-specific knockout male mice have decreased body mass and are 
protected from age-associated hepatic steatosis (Liu et al. 2012).    
 In this study, we set out to understand the molecular basis for H4 and H2A specific 
acetylation by NatD. To do so, we crystallized NatD in binary complex with acetyl-CoA, and in 
ternary complex with CoA and an N-terminal histone H4/H2A substrate peptide, and performed 
biochemical and enzymatic characterization of the enzyme. A novel N-terminal segment wraps 
around the catalytic core domain to make stabilizing interactions, and the α1-α2 and β6-β7 loop 
adopt novel conformations to properly orient the histone N-termini in the binding site. Ser1 and 
Arg3 sit in complementary substrate binding pockets to make extensive contacts to highly 
conserved and mutationally sensitive NatD residues, and flanking glycine resides appear to 
contribute to substrate-specific binding by NatD, together defining a Ser-Gly-Arg-Gly 
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recognition sequence. These studies have implications for understanding substrate-specific 
acetylation by the broader family of NAT enzymes. 
 
3.2 Results 
3.2.1 Overall structure of NatD  
An alignment of NatD sequences from various organisms reveals a ~150 residue region 
(residues 55-216 in human) of high sequence conservation, which we hypothesized mapped to the 
acetyltransferase domain (Figure 3.1). In order to prepare recombinant NatD protein variants for 
biochemical and structural studies, we bacterially overexpressed several NatD protein variants 
derived from S. pombe or human. This led to the identification of S. pombe NatD (SpNatD, 
residues 13-204) and human NatD (hNatD, residues 17-220) that formed cocrystals with 
substrate(s) suitable of X-ray structure determinations. Crystals were prepared of SpNatD and 
hNatD in the presence of acetyl-CoA, and of hNatD in the presence of CoA and an N-terminal 
histone H4/H2A pentapeptide (SGRGK). Selenomethionine-labeled SpNatD was prepared to 
determine the SpNatD/Ac-CoA structure using single-wavelength anomalous diffraction, and this 
structure was used to determine the hNatD/Ac-CoA and hNatD/CoA/peptide structures using 
molecular replacement. The structures were refined to high quality and to medium/high resolution 
(Table 3.1). The overall SpNatD and hNatD structures are essentially superimposable, with an 
RMSD of 1.08 Å (Figure 3.2A). The remainder of this manuscript will describe the human NatD 
structures, NatD/Ac-CoA (Resolution=1.78 Å, Rfree/Rwork=20.6%/16.9%) and NatD/CoA/peptide 
(Resolution=2.5 Å (Rfree/Rwork=22.3/17.5).  
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Figure 3.1 Sequence alignment of NatD orthologs  
The sequence alignment contains the following NatD orthologs: human (Homo sapiens), fission 
yeast (Schizosaccharomyces pombe), fruit fly (Drosophila melanogaster), spikemoss (Selaginella 
moellendorffii), and sea anemone (Nematostella vectensis). The blue boxes represent conserved 
patches of sequence alignment. Residues in red are highly conserved, and residues in white with a 
red background are strictly conserved. Above the sequence alignment are indicated amino acid 
numbering for H. sapiens and secondary structure elements. Amino acid residues are indicated 
that make contacts to the substrate peptide (●), show mutational sensitivity (+), or are proposed to 
play catalytic roles (*). 
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Table 3.1 Data Statistics for NatD crystal structures 
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Figure 3.2 Overall structure of NatD complexes  
(A) Superposition of the SpNatD/acetyl-CoA (violet), hNatD/acetyl-CoA (brown), and 
hNatD/CoA/H4-H2A peptide (cyan) complexes. CoA is shown as sticks, and the H4-H2A peptide 
is omitted for clarity. (B) Overall structure of hNatD/CoA/H4-H2A peptide with structurally 
unique elements of NatD relative to other NATs highlighted in yellow. CoA is shown in orange 
and H4 is shown in magenta. 
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The overall NatD structure has a mixed alpha/beta GCN5-like fold (Figure 3.2B) similar 
to the other reported NAT structures (Liszczak, Arnesen, and Marmorstein 2011; Liszczak et al. 
2013; Liszczak and Marmorstein 2013). However, there are notable differences between NatD 
and the other solved NAT structures, NatA and NatE (Figure 3.3A). In particular, differences are 
noted in the loops forming the peptide-binding site, and that NatD contains a unique N-terminal 
segment. 
A striking divergent feature of NatD is its loops flanking the substrate binding site, β6-  
β7 and α1-α2. A characteristic feature of the peptide-binding site of the NAT proteins is that these 
loops appear to be used to prevent internal lysines from inserting into the active site. This is in 
contrast to the more open loop configuration of lysine acetyltransferases such as Gcn5 (Rojas et 
al. 1999) and Hat1 (Li et al. 2014). In the case of NatA and NatE, a β6-β7 hairpin loop serves this 
function. In NatD, the corresponding β6-β7 hairpin loop is flipped away from the substrate-
binding site and instead the binding pocket is blocked by an extended α1-α2 loop on the opposite 
side (Figure 3.3B). As will be discussed below, this difference appears to be critically important 
for substrate-specific binding by NatD. 
The novel NatD N-terminal segment (residues 24-51) adopts a helix-loop-strand topology 
that wraps around the catalytic core domain, making complementary interactions with a 
hydrophobic patch that appears to be important for stability of the protein (Figure 3.3C). The 
interface between the N-terminal segment and a cleft on a surface of the catalytic core domain is 
largely hydrophobic. Specifically, residues Pro-38, Leu-39, Phe-42, Phe-45, Tyr-48 of the N-
terminal segment make Van der Waals contacts to residues Leu-53, Ile-57, Cys-59, Trp-107, Leu-
109, Phe-124, Phe-126, Leu-151, Phe-154, Ile-158, Leu-161, and Met-162 of the core domain 
(Figure 3.3D). Consistent with the importance of these contacts for stability of the catalytic core 
domain, N-terminally truncated proteins beginning at residue 47 were not stable through 
purification, yet constructs beginning at residue 37 were (data not shown). The region from 
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residues 37-48 contains the key hydrophobic residues that interact with the hydrophobic surface 
cleft of the core domain. Notably, the residues that line this hydrophobic cleft are replaced with 
more hydrophilic residues in the other NAT proteins, which would explain why they lack the 
extended N-terminus. We have designated the alpha helix and beta strand in this novel N-terminal 
region α0 and β0, respectively, in order to keep secondary structure nomenclature consistent with 
the other NAT proteins (Liszczak and Marmorstein 2013; Liszczak et al. 2013; Liszczak, 
Arnesen, and Marmorstein 2011).   
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Figure 3.3 Unique structural features of NatD  
(A) Superposition of hNatD (cyan), SpNatA (orange), and hNatE (green) complexes. The H4-
H2A peptide is shown in magenta. Only the CoA from the hNatD/CoA/H4-H2A peptide structure 
is shown for clarity. (B) Close-up view of the substrate binding groove of NatD in comparison 
with NatA and NatE. The color coding is as in Figure 3.3A. NatA substrate (SASE) and NatE 
substrate (MLGP) are shown as orange and green sticks, respectively. (C) View of the interaction 
of the NatD N-terminal segment (yellow cartoon representation) with the catalytic core domain 
(cyan surface representation). (D) Detailed interactions between the N-terminal segment and 
catalytic core domain of NatD. Residues from the N terminus that mediate interactions are 
labeled in black, and residues from the core domain are colored in dark blue and labeled in white. 
Met-162 is omitted for clarity. 
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3.2.2 Substrate recognition by NatD 
 The structure of NatD in complex with CoA and the N-terminus of histones H4/H2A 
provides important insights into substrate binding. The overall structure of the protein from the 
ternary complex is very similar to the binary complex, with an RMSD of 0.313 Å. The density for 
the peptide is well defined, and we were able to unambiguously place all atoms expect for the 
Lys5p side chain. The binding pocket for the peptide is highly acidic, which is in line with the 
basicity of the histone tails (Figure 3.4A). The ternary complex reveals extensive interactions 
with the substrate peptide and NatD (Figure 3.4B). Notably, contacts occur along the entire length 
of the peptide; each amide nitrogen and oxygen is hydrogen bonded except for the Arg3p amide 
oxygen. There are direct hydrogen bonds to the backbone amide groups on the peptide from 
residues Tyr-138, Thr-174, Ser-197 and Tyr-211 of NatD. In addition, there are water-mediated 
contacts between residues Glu-100, Tyr-136, and Thr-174 to the backbone amides of the peptide. 
The aliphatic region of Trp-90 interacts with Gly2p and Gly4p of the peptide via van der Waals 
contacts. Ile-213 makes van der Waals contacts with the backbone of Lys5p. 
The residues along the peptide path are poised to confer specificity for recognition by the 
enzyme. Ser1p sits in a pocket which would not accommodate residues with larger side chains, as 
they would be occluded by Met-81, Tyr-85, and Glu-139. There are two water molecules in an 
extended network of hydrogen bonds that fill the other side of the pocket (Figure 3.4C). In 
addition to the size restrictive pocket, the side chain of Ser1p makes hydrogen bonds to Tyr-85 
and Glu-139. Arg3p makes numerous contacts with NatD as well (Figure 3.4B). The aliphatic 
region of the Arg3p side chain sits on top of Tyr-136 in an extensive van der Waals interaction. 
The two terminal nitrogens in the guanidino group of the side chain make hydrogen bonds with 
the NatD side chains Asp-127, Glu-129, and Tyr-138. The glycines at positions 2 and 4 also 
appear to be playing important roles in peptide substrate recognition by NatD. It is notable that 
Gly2p is in a conformation with torsion angles that are unfavorable for any residues other than 
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glycine in the Ramachandran plot (Phi: 69.59, Psi: -171.02). In addition, both Gly2p and Gly4p 
are in grooves that are sterically tailored for glycines. Gly2p lies in a narrow tunnel which 
connects Ser1p with the rest of the peptide and is in close contact with Lys-97 and Glu-100. Gly4p 
makes intimate contacts with Trp-90, Thr-174 and Tyr-211. It appears that residues with side-
chains in position 2 or 4 would thus lead to unfavorable clashes (Figure 3.4B). The majority of 
the residues making contacts with the peptide are highly conserved among NatD homologs 
(Figure 3.1).  
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Figure 3.4 Peptide binding site of NatD (from previous page)  
(A) Electrostatic surface of the NatD peptide binding site with the peptide shown in magenta stick 
figure. Residues from NatD are labeled in black and residues from the peptide are labeled in 
yellow with their corresponding one-letter codes and numerical positions in the peptide. The side 
chain of Lys5p was disordered and not modeled into the crystal structure. (B) Detailed 
interactions between NatD and the H4-H2A peptide. NatD is shown as a transparent cyan surface, 
and residues that interact with the peptide are yellow. Hydrogen bonds are shown as dashed lines 
and waters are shown as red spheres. (C) Close-up view of the NatD active site highlighting 
interactions made by Ser1p. Acetyl-CoA was modeled into the figure by aligning the binary and 
ternary NatD structures. 
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3.2.2 NatD mutational analysis 
To address the contribution of specific residues in substrate recognition, we prepared 
point mutants to alanine for residues of interest, and assayed them for acetyltransferase activity 
against a 19-residue peptide of the H4 N-terminus (Figure 3.5A). All of the mutants assayed were 
purified to homogeneity in the same manner as the wild type enzyme, and displayed the same gel 
filtration elution profile, suggesting that the mutants did not perturb overall protein folding. 
Notably, individual mutations of residues that contribute to the intimate Gly4p interaction 
(T174A, and Y211A) show wild-type catalytic efficiency (Figures 3.5A and 3.5B), consistent 
with the role of these residues in specifying a glycine in position 4 of the peptide. In contrast, 
mutations of residues that contact Arg3p (Y136A, Y138A, and D127A/E129A) show significantly 
decreased catalytic efficiency (1.6 to 18-fold) (Figures 3.5A and 3.5B), highlighting the particular 
importance of this residue for substrate-specific binding. The W90A and Y85A mutants also 
exhibited significantly decreased catalytic efficiency (2.8 and 5.8-fold, respectively). The W90A 
mutant lacks the stabilizing van der Waals contacts with the peptide. The decrease in activity in 
the Y85A mutant is likely due to the absence of hydrophobic stabilization provided by Tyr-85 in 
the α1-α2 loop that forms a part of the cavity for histone recognition, in addition to its hydrogen 
bond to Ser1p (Figures 3.5A and 3.5B). Glu-100 is a highly conserved residue that may act to 
position α1 and α2 through an interaction with Lys-97, another conserved residue. This is 
supported by the observation that an E100A mutation exhibits a 5-fold reduction in catalytic 
efficiency. Notably, Lys-97 mutants were not stable through purification (data not shown). 
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Figure 3.5 Mutational analysis of NatD  
(A) Catalytic efficiency of selected NatD mutants. Mutations that have negligible effect are in 
blue, while those that decrease the catalytic efficiency of the enzyme are in pink. (B) Residues 
targeted for mutagenesis are mapped onto the NatD structure. The color scheme is the same 
as Figure 3.5A. (C) The catalytic efficiency of wild-type NatD toward N-terminal histone H4 
peptides of varying length. Data are represented as mean ± SEM. Each mutant and peptide of 
varying length was assayed in triplicate. 
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3.2.2 NatD Catalysis  
The structure of NatD suggests several potential catalytic residues. Classically, 
acetyltransferases in the GNAT family use a general base residue to deprotonate the lysine side 
chain or N-terminus, which carries out a nucleophilic attack on the acetyl group of acetyl-CoA 
(Yuan and Marmorstein 2013). Interestingly, the type and relative location of residue that is 
employed to carry out this function can differ between acetyltransferase enzymes (Vetting et al. 
2005; Liszczak and Marmorstein 2013; Liszczak, Arnesen, and Marmorstein 2011). In the NatD 
structure, both Tyr-136 and Glu-139 are positioned to potentially play a role as important 
catalytic residues (Figure 3.4B and 3.4C). Although Tyr-136 is not close enough to deprotonate 
the N-terminus directly, there is an ordered water molecule bridging its phenol oxygen and the 
peptide N-terminus. This water molecule is positioned similarly to one that appears to be 
involved in catalysis in NatE, which uses a tyrosine as one of its general bases (Liszczak, 
Arnesen, and Marmorstein 2011). In order to distinguish between the two residues, we mutated 
Tyr-136 to phenylalanine and Glu-139 to glutamine and tested the activity of these mutants. 
While the catalytic efficiency of the enzyme is modestly affected by the Y136F mutation, it is 
effectively abolished in the E139Q mutant, demonstrating that the catalytic residue of NatD is 
likely Glu-139 (Figure 3.5A). This is in agreement with a previous study (Liu et al. 2009), and 
consistent with the functional importance of Glu-139, as it is strictly conserved among NatD 
proteins (Figure 3.1). As Glu-139 is not positioned to directly deprotonate the N-terminus, it may 
not act as a general base but instead increase the nucleophilicity of the N-terminus through an 
induced dipole effect from the carboxylic acid side-chain. Glu-139 may also be important for 
orienting the amino group properly across from the acetyl-CoA. This is similar to Glu-24 in 
NatA, which is not directly positioned to deprotonate the N-terminus, but is still essential for 
catalysis (Liszczak et al. 2013).  
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Our results are in contrast to previous reports on the catalytic requirements of NatD. A 
previous modeling study predicted that Cys-137 could also act as an important residue in the 
catalytic mechanism of NatD (Jedrzejewski and Kazmierkiewicz 2013), in a mechanism similar 
to MYST family acetyltransferases (Yan et al. 2002). However, the cysteine is not in a suitable 
position in the structure to act as an acetyl group acceptor, and while the C137A mutant does 
show a decrease in activity, it still retains much of its catalytic power (Figure 3.5A). Previous 
studies also suggested that NatD requires a longer N-terminal tail than other NATs in order to 
recognize its histone H4 and H2A substrates. In particular, in an in vivo assay in S. cerevisiae, it 
was found that a chimeric cytochrome C with H4 N-termini showed complete acetylation with 
chimeric proteins containing 50 N-terminal H4 residues, and only incomplete acetylation with 
chimeric proteins containing 30 N-terminal H4 residues (Polevoda, Hoskins, and Sherman 2009).  
However, when we tested synthetic H4 peptides of varying length (five, eight, and nineteen 
residues) we did not see a significant difference in catalytic efficiency (Figure 3.5C). This result 
is in agreement with the crystal structure suggesting that the determinants for NatD-specific 
binding and acetylation is contained within the first four N-terminal residues. It also is consistent 
with a previous study that showed that NatD substrate specificity is not affected by residues past 
the 5th position in a peptide when the enzyme was tested against a library of oligopeptides (Hole 
et al. 2011). 
 
3.3 Discussion and Future Directions 
The structures and biochemical activities of two of the six NAT proteins have recently 
been characterized, NatE (Liszczak, Arnesen, and Marmorstein 2011) and NatA (Liszczak et al. 
2013). Here we report the molecular characterization of the most substrate-selective NAT 
enzyme, NatD, which has been reported to acetylate the N-terminus of only two substrates 
(histones H4 and H2A) that harbor the identical sequence of SGRGK in humans. We find that the 
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overall fold of NatD is similar to other NATs; however, there are structural differences that 
appear to be critical for maintaining protein integrity and cognate substrate binding. A novel N-
terminal segment wraps around the catalytic core domain to make numerous stabilizing 
interactions, and deletion analysis suggests that this N-terminal segment is required for 
maintaining the stability of the catalytic core domain. We note that several NAT proteins (NatA, 
NatB and NatC) require auxiliary subunits for activity and ribosome association; the NatA 
structure reveals that the Naa15 auxiliary subunit wraps around the Naa10 catalytic subunit to 
increase stability of the catalytic subunit to induce a conformation of Naa10 that is compatible for 
catalysis (Liszczak et al. 2013). In this regard, the N-terminal segment of NatD may be playing an 
analogous role as the NatA auxiliary subunit. 
The N-terminal sequence requirements of NatD are quite different than other NATs. In 
particular, most other NATs show the greatest specificity for residue 1 with reduced preference 
for residue 2 and significantly reduced preference for residues 3 on (Starheim, Gevaert, and 
Arnesen 2012). This is born out by the crystal structures of NatA and NatE bound to cognate 
peptides showing the most extensive side chain interactions with residue 1 followed by residue 2 
of the cognate substrate (Liszczak, Arnesen, and Marmorstein 2011; Liszczak et al. 2013). NatD, 
in contrast, has sequence requirements for the first 4 residues of its substrate peptide (Hole et al. 
2011). Unique structural features of NatD appear to play direct roles in substrate-specific binding 
by NatD. In particular, the β6-β7 loop of NatD is oriented away from the peptide substrate-
binding site relative to the corresponding loops in the other NATs. Instead, the extended α1-α2 
loop of NatD flips toward the peptide-binding site and in so doing tilts the path of the NatD 
peptide by about 75° relative to the paths of the NatA and NatE substrates (Figure 3.3B). An 
important consequence of this is that Arg3p is forced into a unique and complementary pocket of 
NatD that is not present in the other NATs, and particularly not in NatA, which also acetylates N-
termini that contain a serine in position 1 (Figure 3.6A). Indeed, both NatA and NatE contain a 
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conserved tyrosine (Tyr-138 in both proteins) that would sterically block peptides to be oriented 
toward the β6-β7 loop as in NatD. This may be a mechanism by which NatA and NatE ensure a 
broader substrate profile, as orienting the peptide away from the enzyme surface prevents 
significant interaction beyond the first two residues of the N-terminus.  
Similarly to NatA, the peptide-binding pocket of NatD can only accommodate residues 
with small side chains as position 1 in the peptide. However, unlike NatA, the pocket is more 
tailored to accommodate a serine. Tyr-85 and Glu-139 are oriented to have their side chains 
precisely where the side chain of the N-terminal residue will lie in the pocket (Figure 3.4C). 
Whereas the active site of NatA lacks significant electrostatic potential (Figure 3.6B), the 
presence of these polar and charged residues in the active site likely makes it unfavorable for 
residues with small aliphatic side chains to be the N-terminal residue in the peptide (Figure 3.6C). 
In addition, the active site of pocket of NatD is even more constricted than NatA, particularly due 
to the placement of Glu-139. This helps explain the preference for serine over threonine, a residue 
that NatA can acetylate. Gly2p and Gly4p of the H4/H2A peptide also appear to contribute to 
substrate-specific binding by NatD. Gly2p contains unusual phi/psi angles that are only favorably 
accommodated by a glycine residue, and it does not appear that a residue with a side chain would 
be well accommodated in positions 2 or 4 of a substrate. hNatD therefore appears to be specific 
for a Ser-Gly-Arg-Gly sequence in its cognate substrate. Notably, S. cerevisiae and S. pombe 
H2A have a divergent sequence of SGGKG. It was shown that heterologous expression of human 
NatD in an S. cerevisiae NatD knockout strain restored N-terminal acetylation of yeast H4, but 
not yeast H2A in vivo (Hole et al. 2011). Therefore, the substrate specificities of NatD 
correspond to the sequences of H2A and H4 in the organism, and yeast NatD has likely evolved 
to accommodate both N-termini.   
 
79 
	
 
Figure 3.6 Comparison between substrate recognition of NatD and NatA  
(A) Overlay of the peptide binding site of NatA (orange) and NatD (cyan with magenta histone 
substrate). (B) Electrostatic potential surface of the NatA active site with a bound covalently 
linked bisubstrate inhibitor. The N-terminal serine of the substrate peptide is shown in orange, 
and the acetyl-CoA moiety of the bisubstrate inhibitor is in white. (C) Electrostatic potential 
surface of the NatD active site. The N-terminal serine of the substrate peptide is shown in 
magenta, and acetyl-CoA is in orange. Waters are shown as red spheres. Acetyl-CoA was 
modeled into the figure by aligning the binary and ternary NatD structures. 
 
 
 
 
 
80 
	
When we screened purified HsNatD and SpNatD against a panel of potential substrates, 
we found that while SpNatD could acetylate the sequences SGRGK, SGKAH (S. cerevisiae 
H2A.Z), and SGGKG equally well, HsNatD disfavored the SGGKG substrates (Figure 3.7). The 
molecular basis for the contrasting substrate preference is unclear, as are any potential functional 
consequences of H2A N-terminal acetylation in vivo. More research will be required to answer 
these questions.  
Given the fairly short consensus sequence of NatD, we wondered why NatD is specific 
for histones H4 and H2A. We first performed a Uniprot search to query what other proteins share 
an N-terminal SGRGK sequence. To our surprise, the only proteins containing this N-terminal 
sequence in the human proteome are H2A, H4 and H2A.X. If we decrease our specificity by 
removing Lys-5 (which does not appear to make sequence specific interactions in the structure), 
there is only one other protein with an N-terminus of SGRG, SMARCD2, a SWI/SNF- related 
chromatin regulator (Ring et al. 1998). There is no evidence that SMARCD2 is acetylated by 
NatD, but our studies would predict that this would be the case. If we broaden the scope of 
potential NatD substrates even further by searching for proteins with N-termini of SG[R/K], there 
are an additional 22 proteins that meet those criteria. Although this method does not account for 
N-termini generated through proteolytic cleavage, it still appears that the N-terminal proteome of 
potential NatD substrates is limited relative to other NAT proteins. Further studies will have to be 
carried out to establish if the pool of NatD client proteins are indeed broader than previously 
appreciated.  
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Figure 3.7 Substrate profiling of NatD homologues  
Normalized CPM counts of HsNatD and SpNatD. Peptides are the N-termini of various 
substrates. H4:19mer is a 19 residue peptide corresponding to the N-terminus of human H4, and 
H4:5mer is just the pentameric N-terminus of H4. ScH2A.Z corresponds to the 19 N-terminal 
residues of S. cerevisiae histone variant H2A.Z, which contains an N-terminus starting SGKAH. 
ScH2A corresponds to the 19 N-terminal residues of S. cerevisiae H2A, whose first five residues 
are SGGKG. SASE is a peptide with the sequence SASE at the N-terminus, which is a NatA 
substrate, but not a NatD substrate. 
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3.4 Materials and Methods 
3.4.1 H. sapiens NatD (hNatD) expression and purification 
The full-length hNatD gene (encoding residues 1–237) was a gift from Dr. Thomas 
Arnesen from the University of Bergen. Several N-terminal and C-terminal truncation constructs 
were engineered into a modified PCDF vector containing an N-terminal tobacco etch virus (TEV) 
protease–cleavable His tag. All constructs were transformed into Rosetta (DE3)pLysS competent 
E. coli cells, which were grown to an OD600 of 0.7-0.9 and induced with 0.5 mM IPTG at 16 °C 
for ~16 h. All subsequent purification steps were carried out at 4°C. Cells were isolated by 
centrifugation and lysed by sonication in lysis buffer containing 25 mM Tris, pH 8.0, 1 M NaCl, 
10 mM β-mercaptoethanol (βME) and 10 µg/mL PMSF. The lysate was clarified by 
centrifugation and passed over nickel resin (Thermo Scientific), which was subsequently washed 
with >20 column volumes of lysis buffer supplemented with 25 mM imidazole. The protein was 
eluted in lysis buffer supplemented with 300 mM imidazole. His tagged TEV protease was added 
to the eluent containing the target protein for the duration of a 14-h dialysis into dialysis buffer 
containing 25 mM Tris, pH 8.5, 200 mM NaCl, 10 mM βME. This solution was passed through 
an additional nickel column to remove TEV protease as well as any uncut NatD. The resin was 
then washed with approximately seven column volumes of dialysis buffer supplemented with 25 
mM imidazole, which was pooled with the initial flow through. This solution was dialyzed into 
ion exchange buffer containing 25 mM Tris, pH 8.5, 50 mM NaCl and 1 mM DTT and loaded 
onto a 5-mL HiTrap Q ion-exchange column (GE Healthcare). The protein was eluted in the same 
buffer with a salt gradient (50–750 mM NaCl) over the course of 20 column volumes. Peak 
fractions were pooled and dialyzed into sizing buffer containing 25 mM HEPES, pH 7.0, 200 mM 
NaCl, and 1 mM DTT for ~16 hours. This was concentrated to a volume of 500 µl (10-kDa 
concentrator; Amicon Ultra, Millipore), and loaded onto and run on an s75prep gel-filtration 
column (GE Healthcare) in sizing buffer. Peak fractions were concentrated to 10 mg/mL as 
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measured by UV280 for crystallization trials. 
 
3.4.2 S. pombe NatD (SpNatD) expression and purification 
The full-length SpNatD gene (encoding residues 1–204) was cloned out of the S. pombe 
genome (ATCC), and several N-terminal truncation constructs were engineered into a modified 
pETDUET vector containing a TEV protease–cleavable His tag. All constructs were transformed 
into Rosetta (DE3)pLysS competent E. coli cells, which were grown to an OD600 of 0.7-0.9 and 
induced with 0.5 mM IPTG at 16 °C for ~16 h. These constructs all expressed as insoluble 
inclusion bodies in Rosetta (DE3)pLysS E. coli cells. To improved solubility, a number of 
constructs of the SpNatD gene were subcloned into a modified pETDUET vector containing an 
N-terminal SUMO tag. These constructs were transformed and induced with IPTG in the same 
way and were soluble in E. coli cells. All subsequent studies were carried out at 4°C and are 
identical to the purification protocol used for purifying the human protein with the following 
changes. After the nickel column, His tagged Ulp1 protease was used in place of TEV protease to 
cleave the SUMO tag. The ion exchange buffer contained 25 mM HEPES, pH 7.0, 50 mM NaCl 
and 1 mM DTT, and a 5-mL HiTrap SP ion-exchange column (GE Healthcare) was used. The 
selenomethionine derivative was produced by expressing the SUMO tagged SpNatD (resdiues 
13-204) in minimal media (Molecular Dimensions) with 50 µg/L selenomethionine (Sigma) 
purified in the same manner as above.  
 
3.4.3 NatD crystallization and data collection  
hNatD (8 mg/mL) was incubated with acetyl-CoA (Sigma-Aldrich) at a 1:3 molar ratio. 
Crystals were obtained with hanging-drop vapor diffusion in a drop containing a 1:1 mixture of 
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protein to a well solution containing 20% PEG 3350, 200 mM sodium citrate tribasic dihydrate, 
100 mM citric acid, pH 4.0. Diffraction-quality crystals grew in 2-3 days. The ternary complex 
was crystallized using an hNatD construct containing residues 17-220 at 10 mg/ml. The protein 
was incubated with CoA, and the C-terminally amidated substrate peptide (SGRGK— GenScript) 
at a 1:3:5 molar ratio of protein:CoA:peptide. Crystals were obtained through hanging-drop vapor 
diffusion at 20 °C at a 1:1 ratio of protein to a well solution containing 20% PEG 3350 and 200 
mM sodium malonate, pH 6.0. Crystals grew after 1 day. SpNatD was crystallized at a 
concentration of 10 mg/ml using a construct that contained residues 13-204. The protein was 
mixed with acetyl-CoA at a molar ratio of 1:3 protein to acetyl-CoA. Crystals were obtained with 
hanging-drop vapor diffusion at 20 °C at a 1:1 ratio of protein to well solution containing 20% 
PEG 3350 and 200 mM potassium formate. Crystals grew after 1 day. Selenomethionine crystals 
of SpNatD were generated in the same manner. All crystals were cryoprotected by transferring 
them to their respective well solutions supplemented with 20% glycerol before being flash frozen 
in liquid nitrogen. Data for the hNatD ternary complex was collected at a home source using a 
MicroMax-007 HF rotating anode (Rigaku). Data for all other crystals were collected at beamline 
X29A at the National Synchrotron Light Source (Brookhaven National Laboratory). All datasets 
were processed using HKL2000 (Otwinowski and Minor 1997).  
 
3.4.4 Structure Determination and Refinement 
Initially, a number of full length and truncated search models based on known structures 
of NATs (Liszczak and Marmorstein 2013; Liszczak et al. 2013; Liszczak, Arnesen, and 
Marmorstein 2011) were used in an attempt to solve either hNatD or SpNatD structure through 
molecular replacement (Mccoy et al. 2007). However, these attempts were unsuccessful in 
generating a suitable starting model for either hNatD or SpNatD. A dataset was collected on the 
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selenomethionine-labeled SpNatD crystals at the selenium peak wavelength (0.9788 Å), and 
heavy atoms were places in the asymmetric unit and initial phases were generated using single-
wavelength anomalous diffraction (SAD) phasing using SOLVE in the Phenix suite (Adams et al. 
2011). The SpNatD structure was initially built into the resulting density by AutoBuild in the 
Phenix suite. The rest of the structures described were solved using molecular replacement. The 
selenomethionine-labeled SpNatD structure was used as a search model for the wild-type SpNatD 
crystals. However, these crystals did not yield a model of sufficient quality, so only the 
selenomethionine data set was refined fully. The program CHAINSAW (Stein 2008) was used to 
generate a search model from the SpNatD structure for the binary hNatD structure, and the final 
refined hNatD structure was used as a search model for the ternary hNatD crystals. For all of the 
structures, the ligands acetyl-CoA/CoA and the substrate peptide for the ternary complex were 
built into the Fo - Fc electron density map. All of the structures were refined iteratively by using 
Phenix refine and manual model building in the molecular graphics program Coot (Emsley et al. 
2010). The SpNatD/acetyl-CoA complex crystallized as a dimer with the N-terminus of one 
monomer in the active site of another. The N-terminal serine of the enzyme is acetylated and CoA 
is bound to the enzyme. This is likely an artifact of crystallization, wherein the subunit packing 
positions the N-terminus of SpNatD (SRRMK), which superficially resembles the natural 
substrate, in the active site. The final model and structure factors for all of the structures were 
submitted to the Protein Data Bank. Refinement statistics and PDB IDs can be found in Table 3.1. 
 
3.4.5 Acetyltransferase assays 
Acetyltransferase assays were carried out in 25 mM HEPES pH 7.0, 100 mM NaCl, and 1 
mM DTT. The substrate peptide used in the assay for the mutant enzymes corresponds to the first 
19 residues of human H4 (NH2-SGRGKGGKGLGKGGAKRHR-COOH; GenScript). In the 
86 
	
assay, a saturating amount (400 µM) of radiolabeled [14C]acetyl-CoA (4 mCi/mmol; PerkinElmer 
Life Sciences) and varying concentrations of the substrate peptide (6.25 µM-200 µM) were 
incubated with 75 nM NatD (500 nM for E139A and E139Q mutants) in 75 µL reaction volume 
for 20-180 min. at 37 °C. To quench the reaction, 20 µL of the reaction mixture was added to 
negatively charged P81 paper discs (Whatman), and the paper discs were immediately placed in 
wash buffer (10 mM HEPES, pH 7.5). The paper discs were washed three times, at five minutes 
per wash to remove unreacted acetyl-CoA. The papers were then dried with acetone and added to 
4 ml of scintillation fluid, and the signal was measured with a Packard Tri-Carb 1500 liquid 
scintillation analyzer. Background control reactions were performed in the absence of enzyme or 
in the absence of substrate peptide to ensure that any possible signal due to autoacetylation was 
negligible. Each reaction was done in triplicate. By keeping the substrate concentration far below 
KM, we were able to plot velocity versus [substrate] and use the slope of the resulting line to 
obtain kcat/KM values for the mutants based on the equation: v = (kcat/KM)[E][S]. The counts per 
minute were converted to molar units using a standard curve of known [14C]acetyl-CoA 
concentrations in scintillation fluid. The assay was performed in the same manner for substrate 
peptides corresponding to the first five and eight residues of human H4 (SGRGK and 
SGRGKGGK, respectively) with wild-type hNatD, and for the assays against the range of 
substrates in Figure 3.7. The sequences for those peptides are as follows (H4:19mer and 5mer 
sequence in same as above): 
ScH2A.Z: SGKAHGGKGKSGAKDSGSL 
ScH2A: SGGKGGKAGSAAKASQSRS 
SASE: SASEAGVRWGRPVGRRRRP 
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CHAPTER 4: The N-terminal Acetyltransferase Naa10/ARD1 Does Not Acetylate Lysine 
Residues 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This research was originally published in The Journal of Biological Chemistry (Magin, March, 
and Marmorstein 2016) © the American Society for Biochemistry and Molecular Biology 
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4.1 Introduction 
There are five conserved NATs found in eukaryotes termed NatA-NatE. These enzymes 
differ in their N-terminal substrate profiles (Starheim, Gevaert, and Arnesen 2012). NatA, which 
is responsible for the plurality of N-terminal acetylation (Starheim, Gevaert, and Arnesen 2012), 
is a heterodimeric complex consisting of a catalytic subunit termed Naa10 (previously known as 
Ard1) and an auxiliary subunit termed Naa15 (previously known as NATH or Nat1) (Mullen et 
al. 1989). NatA acetylates N-termini containing an N-terminal residue that has a small radius of 
gyration: alanine, cysteine, glycine, serine, threonine, and valine (Polevoda and Sherman 2003). 
Structural and enzymatic studies reveal that the enzymatic subunit Naa10 has a different substrate 
profile when it is not in complex with the auxiliary subunit Naa15. As a monomer, Naa10 
acetylates N-termini in which the N-terminal residues are acidic, such as actin, whose first three 
N-terminal residues are glutamates (Liszczak et al. 2013; Van Damme, Evjenth, et al. 2011).  
 Recent reports claim to have identified lysine substrates for monomeric Naa10. These 
include the transcription factor Runx2 (Yoon et al. 2014), the enzyme methionine sulfoxide 
reductase A (MSRA) (Shin et al. 2014), and myosin light chain kinase (MLCK) (Shin et al. 
2009). These findings were surprising to us since the structure of all NATs determined to date 
(Vetting et al. 2008; Liszczak, Arnesen, and Marmorstein 2011; Liszczak et al. 2013; Liszczak 
and Marmorstein 2013), including Naa10 (Liszczak et al. 2013), contain an extended loop, which 
seem to occlude lysine side chains within a polypeptide from lying across the active site as they 
do in KATs (Dorfel and Lyon 2015; Liszczak, Arnesen, and Marmorstein 2011; Magin, Liszczak, 
and Marmorstein 2015a; Liszczak and Marmorstein 2013). In addition, other reports 
demonstrating that Naa10 acetylates a lysine residue on Hif-1α have failed to be replicated (Jeong 
et al. 2002; Murray-Rust et al. 2006; Arnesen et al. 2005), making the question of whether Naa10 
is able to acetylate lysine residues controversial. We therefore performed a number of 
experiments to investigate this question. We found that the addition of acetyl-CoA did indeed 
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promote the acetylation of MSRA and Runx2, but that this acetylation was Naa10-independent. 
Based on this observation, we conclude that lysine residues on these substrates are not acetylated 
by Naa10 but are instead acetylated by chemical means. 
 
4.2 Results 
4.2.1 The structure of Naa10 and other NATs are incompatible with lysine acetylation 
A superposition of Naa10 (Liszczak et al. 2013) and the Gcn5 KAT (Rojas et al. 1999) 
bound to their cognate N-terminal and lysine peptide substrates, respectively, illustrates why 
these enzymes are tailored to acetylate their respective substrate (Figure 4.1A). Specifically, the 
Gcn5 KAT bound to a histone tail peptide centered on the lysine 14 target reveals that the peptide 
sits across a wide surface groove of the enzyme with the central lysine 14 residue inserting into 
an a narrow active site cavity (Rojas et al. 1999) (Figure 4.1A). The Hat1 histone 
acetyltransferase KAT bound to a histone H4 peptide shows a similar substrate-binding 
configuration (Li et al. 2014). The Naa10 NAT and Gcn5 KAT superimpose fairly well (RMSD = 
6.4) except for the substrate binding sites (RMSD = 10.17). Most notably, Naa10 contains an 
extended loop between β-strands β6 and β7, that is not present in Gcn5, that blocks peptide 
binding across the surface groove that is present in Gcn5 (Figure 4.1A). Instead, Naa10 contains 
an active site cavity that can only accommodate an N-terminal peptide (Figure 4.1A). A 
superposition of all available NAT structures (Vetting et al. 2008; Liszczak, Arnesen, and 
Marmorstein 2011; Liszczak et al. 2013; Liszczak and Marmorstein 2013; Magin, Liszczak, and 
Marmorstein 2015a) reveal that they contain substrate binding sites that are tailored for N-
terminal substrate binding oriented similar to Naa10 and incompatible with binding lysine-
containing substrates oriented similar to Gcn5 (Figure 4.1B).   
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Figure 4.1 The structure of NATs is incompatible with lysine acetylation  
(A) Superposition of the Gcn5 KAT-histone H3 peptide complex (dark and light blue, 
respectively) with the Naa10 N-terminal peptide complex (yellow and wheat, respectively). The 
proteins are shown as cartoon and the peptide ligands are shown as sticks. Naa10 is shown with 
its β6-β7 loop in orange. (B) Superposition of NAT/N-terminal peptide complexes with Naa10 
(yellow), Naa40 (salmon) Naa50 (green), and the NAT from Sulfolobus solfataricus (ssNAT, 
purple). 
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4.2.2 Naa10 does not acetylate lysine residues within peptides from MLCK, MSRA, or RUNX2 
 Although the structural superpositions described above argue against Naa10 acetylation 
of lysine substrates, it remains possible that Naa10p may be able to adopt an alternative 
conformation to accommodate lysine substrate acetylation. To address this possibility, we first 
tested whether recombinant Naa10 was able to acetylate peptides corresponding to published 
lysine substrates (Yoon et al. 2014; Shin et al. 2014; Shin et al. 2009). These peptides were 
approximately 20 residues long, and contained the reported lysine in the center of the peptide. We 
assayed three reported substrates: MLCK, MSRA and Runx2, and a peptide corresponding to the 
N-terminus of actin, a known Naa10 substrate, as a positive control (Liszczak et al. 2013; Van 
Damme, Evjenth, et al. 2011). We carried out acetyltransferase assays with a saturating 
concentration of peptide (1 mM) and radiolabeled acetyl-CoA and measured the signal by 
scintillation counting. While Naa10 robustly acetylated its canonical actin substrate, there was no 
difference in the levels of acetylation in the three substrates in the absence or presence of Naa10 
(Figure 4.2A). These experiments reveal that Naa10 does not contribute to the acetylation of 
MLCK, MSRA and Runx2 lysine peptide substrates. 
 
 
 
 
 
 
 
92 
	
Figure 4.2 Naa10 does not acetylate peptides or proteins corresponding to reported lysine 
substrates  
Recombinant human Naa10 was used for these experiments. (A) Radioactive filter binding assay 
of peptide acetylation in the presence or absence of Naa10. An N-terminal actin peptide was used 
as a positive control. (B) Radioactive TCA precipitation assay of protein acetylation with Runx2 
and MSRA in the presence of absence of Naa10. The experiments were carried out in triplicate, 
and error bars are indicated. CPM, counts per minute. 
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4.2.3 Naa10 does not acetylate lysine residues within MSRA and RUNX2 proteins 
To address the possibility that an expanded recognition motif on the substrates might be 
required for acetylation by Naa10, we subsequently performed the acetylation reactions using 
intact protein substrates or domains. To do this, we recombinantly expressed the Runt domain 
from Runx2, and full length MSRA. We incubated the proteins or actin peptide (50 uM) with 
radiolabeled acetyl-CoA in the presence and absence of Naa10. After allowing the reaction to 
take place for 4 hours, we added trichloroacetic acid (TCA) to precipitate protein and quantified 
acetylated protein in the pellet by scintillation counting. Once again, we did not observe any 
difference in the level of acetylation of the substrates with or without Naa10 present, in contrast 
to the acetylation of actin, which showed enzyme dependence (Figure 4.2B). The difference in 
the counts for the actin control in Figure 4.2 are due to the use of 1 mM substrates in the 
experiments done in Figure 4.2A and the use of 50 uM substrates in Figure 4.2B. The different 
concentrations reflect the nature of the experiments done. 
To evaluate the nature of acetylation of the substrates that was observed, we carried out 
reactions with increasing concentrations of acetyl-CoA in the presence and absence of Naa10. 
This analysis revealed that while Naa10 displayed Michaelis-Menten kinetics against its actin 
substrate (Figure 4.3A), it showed first order kinetics against Runx2 and MSRA (Figures 4.3B 
and 4.3C). When Naa10 was omitted from the reaction, the acetylation against actin was 
negligible, while the acetylation of Runx2 and MSRA did not change (Figure 4.3). These data 
strongly suggest that the acetylation of Runx2 and MSRA are independent of Naa10, and are 
therefore not enzymatic events, but instead are chemical events. 
 
 
 
94 
	
 
Figure 4.3 The kinetic profiles of Naa10 against MSRA and Runx2 are indicative of 
chemical acetylation  
Radioactive assay against (A) N-terminal actin peptide, (B) MSRA, and (C) Runx2 at increasing 
concentrations of acetyl-CoA in the presence (circles) and absence (squares) of Naa10. The 
experiments were carried out in triplicate, and error bars are indicated. CPM, counts per minute. 
 
95 
	
 To perform an orthogonal assay for potential Naa10p-mediated lysine acetylation, we 
also performed a Western blot with two different antibodies that recognize acetylated lysines 
(Cell Signaling – Cat No. 9681 and ImmuneChem – Cat No. ICP0380). In the previously reported 
studies claiming Runx2 and MSRA acetylation by Naa10, the antibody from Cell Signaling was 
employed (Yoon et al. 2014; Shin et al. 2014). We also used the same buffer conditions in the 
assay that were reported in the prior studies. Since there is no known lysine substrate of Naa10, 
we used acetylation of the histone tetramer H3/H4 by hMOF as a positive control, as this is a 
well-studied enzyme-dependent lysine acetylation event (Yuan et al. 2012). In agreement with the 
radioactive assays, there was no difference in the signal between lysine acetylation whether 
Naa10 was present or not for both Runx2 and MSRA (Figure 4.4), confirming that the larger 
intact protein substrates or domains could not be acetylated by Naa10. In fact, the Cell Signaling 
antibody detected a signal in the samples without any acetyl-CoA added, suggesting that the 
Runx2 and MSRA proteins may undergo chemical acetylation while overexpressed in E. coli. 
This contrasts with H4, which was only efficiently acetylated in the presence of both hMOF and 
acetyl-CoA (Figure 4.4). 
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Figure 4.4 Western blotting detection of acetylated MSRA and Runx2 shows independence 
of Naa10  
(A, B) Western blotting analyses using two different antibodies from (A) Cell Signaling 
Technology (catalog no. 9681) and (B) ImmuneChem (catalog no. ICP0380) in the absence or 
presence of acetyl-CoA and Naa10 with MSRA and Runx2 as substrates. The hMOF KAT with 
histone H3/H4 substrate was used as a positive control. Coomassie staining of the gel is shown at 
the bottom. 
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4.2.4 Naa10 in the context of the NatA complex cannot acetylate lysine residues 
To address the possibility that Naa10 requires assembly into the Naa10/Naa15 NatA 
complex for acetylating lysine substrates, we prepared a recombinant human NatA complex in 
insect cells and assayed its ability to acetylate lysine residues in the context of peptide and protein 
substrates. As shown in Figure 4.5, these results are identical to those with Naa10, indicating that 
Naa10 in the NatA complex is unable to acetylate Runx2 and MSRA. 
 
4.2.5 Naa10 and NatA do not interact with MRSA and Runx2  
Previous reports have claimed that Naa10 directly interacts with MRSA and Runx2 
(Yoon et al. 2014; Shin et al. 2014).  To address the possibility that Naa10 or NatA may at least 
interact with the putative lysine containing substrates in MRSA and Runx2, we carried out 
pulldown studies. We performed the pulldown by using GST-tagged MSRA and Runx2. In 
contrast to previous reports, we were unable to detect an interaction between Naa10 and either 
substrate (Figure 4.6A). Similar studies with the NatA complex also failed to show an interaction. 
Specifically, while Naa50 successfully pulled down NatA as previously reported (Gautschi et al. 
2003), MSRA and Runx2 did not (Figure 4.6B-C).  Taken together, these studies failed to detect a 
direct interaction of Naa10p and NatA with MRSA or Runx2. 
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Figure 4.5 NatA does not acetylate peptides or proteins corresponding to reported lysine 
substrates  
Recombinant human Naa10/Naa15 (NatA) was used for these experiments. (A) radioactive filter 
binding assay of peptide acetylation in the presence or absence of Naa10. An N-terminal SASE 
peptide was used as a positive control. (B) Radioactive TCA precipitation assay of protein 
acetylation with Runx2 and MSRA in the presence of absence of Naa10. The experiments were 
carried out in triplicate, and error bars are indicated. 
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Figure 4.6 Naa10 and NatA do not interact with MSRA or Runx2  
(A) GST pulldown assays of Naa10 using GST tagged Runx2 and MSRA. Coomassie staining of 
SDS-PAGE is shown for both the input (left) and elution (right). Corresponding migrating 
proteins in the gels are labeled. (B) GST pulldown assays of NatA using GST-tagged Runx2 and 
MSRA. The experiment was carried out as described in (A). (C) As a positive control, pulldowns 
of NatA were carried out using GST-tagged Naa50. Asterisks indicate free hydrolyzed GST. 
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4.3 Discussion 
Acetylation has long been recognized as an important protein modification (Allfrey, 
Faulkner, and Mirsky 1964). Although much of the early research examined its role as a histone 
modification (Verdin and Ott 2015), studies have found that thousands of non-histone proteins are 
acetylated in cells, showing that the modification is much more widespread than initially thought 
(Choudhary et al. 2009). Despite the expansion in the number of lysines targeted for acetylation, 
the enzymes responsible for, and the functional consequences of the majority of these marks 
remains unknown.  
 The data presented here suggest that the acetylation of Runx2 and MSRA is not an 
enzymatic event, but rather a chemical one. As a moderately reactive high-energy acetyl-donor, 
acetyl-CoA can acetylate lysines in the absence of an enzyme under the right. This is particularly 
true if the lysine is located in close proximity to other basic residues, which lowers the pKa of the 
epsilon amino group to allow for a nucleophilic attack on the acetyl group (Baeza, Smallegan, 
and Denu 2015; Olia et al. 2015). Indeed, the lysines reported for both Runx2 and MSRA cluster 
within a basic patch on the proteins (Tahirov et al. 2001; Lowther et al. 2000) (Figure 4.7).  
 The results presented here are in contrast to previous reports claiming that Naa10 is able 
to acetylate lysine residues within several protein targets including Runx2, MSRA, and 
MLCK (Yoon et al. 2014; Shin et al. 2014; Shin et al. 2009). This discrepancy can be explained 
by a number of factors. The authors of the previous studies generated knockouts of Naa10 in mice 
and tissue culture for many of the assays performed. However, as the NatA complex targets 
hundreds of proteins for acetylation, pleiotropic effects can occur upon depletion or 
overexpression of the protein, the causes for which can be difficult to decipher. This is reflected 
in the diverse phenotypes found in NatA null yeast (Mullen et al. 1989).  Therefore, the in vivo 
and cell-based results must be interpreted with caution. In the in vitro system described here, 
neither Naa10 alone nor Naa10 in the context of the NatA complex is observed to acetylate or 
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interact with these putative lysine substrates. Instead, we found that these substrates are 
chemically acetylated. Chemical acetylation of lysines has been shown to be an important 
modification in its own right, and it may be significant for regulating these proteins as well. 
 
 
 
Figure 4.7 The acetylated lysines in MSRA and Runx2 are found in proximity to basic 
residues that could facilitate chemical acetylation  
Crystal structures of (A) bovine MSRA and (B) murine Runx1 (90% identity to Runx2), 
highlighting the lysines within these proteins reported to be acetylated by Naa10 (yellow) as well 
as proximal basic residues (salmon). 
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4.4 Materials and methods 
4.4.1 Cloning and purification of Naa10 
The gene encoding full length human Naa10 (residues 1-235) was cloned into a 
pETDUET vector containing an N-terminal His6-SUMO tag. The resulting construct was 
transformed into Rosetta (DE3)pLysS competent E. coli. Cells were grown to OD600 0.7-0.9 prior 
to inducing protein expression with 0.5 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) at 
16°C for ~16 hr. All subsequent purification steps were carried out at 4°C. Cells were isolated by 
centrifugation and lysed by sonication in lysis buffer containing 25 mM Tris, pH 8.0, 1 M NaCl, 
10 mM β-mercaptoethanol (βME) and 10 µg/ml phenylmethanesulfonylfluoride (PMSF). The 
lysate was clarified by centrifugation and passed over 6 ml of Ni-NTA resin (Thermo Scientific), 
which was subsequently washed with 500 ml of lysis buffer supplemented with 25 mM 
imidazole. The protein was eluted in 50 ml of lysis buffer supplemented with 300 mM imidazole 
and dialyzed into ion exchange buffer containing 25 mM Tris pH 8.5, 50 mM NaCl, and 10 mM 
βME and loaded onto a 5 ml Q ion exchange column (GE Healthcare). The protein was eluted in 
the same buffer with a salt gradient (50-750 mM NaCl) over the course of 20 column volumes. 
Peak fractions were pooled, concentrated to 500 µl, and loaded onto an s200 gel filtration column 
(GE Healthcare) in sizing buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl, and 1 mM 
DTT. Peak fractions were pooled and concentrated. Proteins were aliquotted, snap-frozen in 
liquid nitrogen, and stored at -80 °C for further use. A portion of the protein was then incubated 
with Ulp1 protease overnight to cleave off the His6-SUMO tag in sizing buffer. After cleavage, 
this solution was subjected to an additional Ni-NTA purification step to remove Ulp1, His6-
SUMO, and any uncut Naa10 fusion protein. The resin was then washed with approximately ten 
column volumes of dialysis buffer supplemented with 25 mM imidazole, which was pooled with 
the initial flow-through. The protein was concentrated to 500 µl and run on a Superdex 75 gel 
filtration column. Peak fractions were pooled and concentrated. Proteins were aliquotted, 
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supplemented with 5% glycerol, snap-frozen in liquid nitrogen, and stored at -80 °C for further 
use. 
 
4.4.2 Cloning and purification of NatA and GST-Naa50 
Human Naa10 (residues 1-160) and Naa15 (residues 1-866) constructs were engineered 
using a pFastBac dual vector. The Naa15 subunit contained an N-terminal His6-tag. A bacmid 
was generated by transposition into DH10 bac competent Escherichia coli cells using the bac-to-
bac system (Invitrogen). Spodoptera frugiperda (Sf9) cells cultured in SFM II medium were 
transfected with the Naa10/Naa15 bacmid using cellfectin reagent (Invitrogen). The resulting 
baculovirus was amplified until reaching a high titer. Sf9 cells were grown to a density of 
1x106 cells/ml and infected using the amplified Naa10/Naa15 baculovirus to an MOI (multiplicity 
of infection) of ~1-2. The cells were grown at 27°C and harvested 48 hours post-infection. All 
subsequent purification steps were carried out at 4°C. Cells were isolated by centrifugation and 
lysed by sonication in lysis buffer containing 25 mM Tris, pH 8.0, 1 M NaCl, 10 mM βME, 10 
µg/ml PMSF, and DNase. The lysate was clarified by centrifugation and passed over 6 ml of Ni-
NTA resin (Thermo Scientific), which was subsequently washed with 500 ml of lysis buffer 
supplemented with 25 mM imidazole. The protein was eluted in 50 ml of lysis buffer 
supplemented with 300 mM imidazole. The protein was concentrated to 500 µl, and loaded onto a 
Superdex 200 gel filtration column (GE Healthcare) in sizing buffer containing 25 mM HEPES 
pH 7.0, 200 mM NaCl, and 1 mM DTT. Peak fractions were pooled and concentrated. Proteins 
were aliquotted, snap-frozen in liquid nitrogen, and stored at -80 °C for further use. Human GST-
Naa50 was purified as described (Liszczak, Arnesen, and Marmorstein 2011) with the following 
changes: the protein was not cleaved with TEV protease and was run on a Superdex200 gel 
filtration column. 
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4.4.3 Cloning and purification of Runx2 and MSRA 
The genes encoding the runt domain of mouse Runx2 (residues 186-315), and full length 
human MSRA (residues 1-235) were ordered from Bio Basic. These were both cloned into a 
modified pETDUET vector containing a TEV-cleavable, N-terminal GST tag. The resulting 
constructs were transformed into Rosetta (DE3)pLysS competent E. coli. Cells were grown to 
OD600 0.7-0.9 prior to inducing protein expression with 0.5 mM IPTG at 16°C for ~16 hr. All 
subsequent purification steps were carried out at 4°C, and were identical for both proteins except 
where noted. Cells were isolated by centrifugation and lysed by sonication in lysis buffer 
containing 25 mM Tris, pH 8.0, 1 M NaCl, 10 mM βME and 10 µg/ml PMSF. The lysate was 
clarified by centrifugation and incubated with 6 ml glutathione resin (Thermo Scientific) for one 
hour. The resin was subsequently washed with 500 ml of lysis buffer. The protein was eluted in 
50 ml lysis buffer supplemented with 20 mM reduced glutathione (Sigma) and dialyzed into ion 
exchange buffer containing 25 mM sodium citrate pH 5.5, 25 mM NaCl, and 10 mM βME and 
loaded onto a 5 ml SP ion exchange column (GE Healthcare). The protein was eluted in the same 
buffer with a salt gradient (25-750 mM NaCl) over the course of 20 column volumes. Peak 
fractions were pooled, concentrated to 500 µl, and loaded onto an s200 gel filtration column (GE 
Healthcare) in sizing buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl, and 1 mM DTT. 
Peak fractions were pooled and concentrated. Half of the protein was then incubated on 
glutathione resin with TEV protease overnight in sizing buffer to cleave off the GST tag. After 
cleavage, the resin was washed with approximately ten column volumes of sizing buffer, and the 
untagged protein was collected. The protein was concentrated to 500 µl and run on a 
Superdex200 gel filtration column. Peak fractions were pooled and concentrated. Proteins were 
aliquotted, supplemented with 5% glycerol, snap-frozen in liquid nitrogen, and stored at -80 °C 
for further use. 
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4.4.4 Acetyltransferase assays against peptides  
Acetyltransferase assays were carried out in sizing buffer. All peptides were ordered from 
GenScript. The peptides for the reported lysine substrates corresponded to ~20 residues 
surrounding putative acetylated lysine. These peptides were ordered with acetylated N-termini to 
ensure that signal would not result from N-terminal acetyltransferase activity. Tryptophan was 
added to the C-terminus to allow for accurate concentration determination. The peptides were as 
follows: MLCK- TVHEKKSSRKSEYLLPVAW, MSRA- RKEQTPVAAKHHVNGNRTVW, 
Runx2- QVATYHRAIKVTVDGPRW. The actin substrate peptide used was previously described 
in (Liszczak et al. 2013). In the assays, 300 µM of radiolabeled [14C]acetyl-CoA (4 mCi/mmol; 
PerkinElmer Life Sciences), 1 µM Naa10 or NatA, and 1 mM peptide were reacted in 50 µl of 
total reaction volume for 4 hours at 37 °C. To quench the reaction, 15 µl of the reaction mixture 
was added to negatively charged P81 paper (Millipore), and the paper disks were immediately 
placed in wash buffer (10 mM HEPES, pH 7.5). The papers were washed three times, at 5 
minutes per wash, to remove unreacted acetyl-CoA. The papers were then dried with acetone and 
added to 4 ml of scintillation fluid, and the signal was measured with a Packard Tri-Carb 1500 
liquid scintillation analyzer.  
4.4.5 Acetyltransferase assays against protein domains 
Reactions were performed as above but with 50 µM substrate (Actin peptide, 
recombinant Runx2, or recombinant MSRA). 15 µl of 20% trichloroacetic acid (TCA) was added 
to 15 µl reaction mixture to precipitate acetylated substrates. The substrates were allowed to 
precipitate on ice for 10 minutes. The precipitated substrates were pelleted by centrifuging for 5 
minutes at 13,000 rpm. The supernatant was discarded and 200 µl of cold acetone was added to 
wash the pellets. These were incubated on ice for 5 minutes before centrifuging at 13,000 rpm. 
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This wash step was repeated twice more. The pellets were added to 4 ml scintillation fluid, and 
the signal was measured with a Packard Tri-Carb 1500 liquid scintillation analyzer. 
 
4.4.6 Acetyltransferase assays with increasing concentrations of acetyl-CoA 
The assays were done as the TCA precipitation assays with the following changes. 1 mM 
of substrate (Actin peptide, recombinant Runx2, or recombinant MSRA) was used, and the 
amount of acetyl-CoA was varied (150 µM- 1000 µM). The reactions took place for 20 minutes at 
37°C. 
  
4.4.7 Protein pull downs 
All pull downs were performed in sizing buffer. 1 µM of GST, GST-Runx2, GST-
MSRA, or GST-Naa50 (positive control for NatA) were incubated with either 5 µM Naa10 or 5 
µM NatA and 75 µl of glutathione resin in a total volume of 400 µl for 1 hour at 4 °C. The resin 
was washed with 5 ml of sizing buffer and eluted with 100 µl of buffer supplemented with 20 
mM glutathione.  
 
4.4.8 Acetyltransferase assay followed by Western blot 
300 µM of acetyl-CoA (Sigma), 1 µM enzyme (Naa10 or hMof), 50 µM substrate 
(Runx2, MSRA, or the histone dimer H3/H4) were reacted in 20 µl of reaction volume for 4 
hours at 37 °C. The reaction was performed in a buffer containing 50 mM Tris pH 8.0, 0.1 mM 
EDTA, 1 mM DTT, 10 mM sodium butyrate, 100 mM NaCl, and 10% glycerol. To quench the 
reaction, loading dye was added. Reactions were diluted to 200 µl, and 20 µl of the dilution were 
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run on the gel. Two different anti-acetyl-lysine antibodies were used (Cell Signaling (#9681) and 
ImmuneChem (ICP0380)). hMof and histones were prepared as described (Daniel Ricketts et al. 
2015; Yuan et al. 2012).  
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5.1 Introduction 
As has been discussed above, many NATs act co-translationally. They interact with the 
ribosome near the exit tunnel and acetylate the nascent protein chain as it is being translated. 
While the structures of many of the NATs have been determined, the molecular basis for the 
interaction with ribosome has remained elusive. A significant amount of research has also been 
done on other peptide modifying enzymes which bind near the ribosome exit tunnel 
Based on this previous research, we sought to determine the molecular basis for the 
interaction of NatA with the ribosome, particularly in the structural determinants of NatA that 
mediate this interaction. We chose NatA, since it is the best characterized NAT both structurally 
and functionally (Liszczak et al. 2013; Aksnes et al. 2016; Weyer et al. 2017). By using the 
rationale that the NATs are likely to act similarly to MAP and PDF, we found that NatA forms a 
stable complex with the ribosome in the absence of other stabilizing factors and through two 
conserved regions; primarily through an N-terminal domain and an internal basic helix. These 
regions may orient the active site of the NatA to face the peptide emerging from the exit tunnel. 
These findings will contribute to future studies to decouple NatA N-terminal acetyltransferase 
activity from ribosome association.   
 
5.2 Results 
5.2.1 NatA mediates a salt-dependent interaction with the ribosome  
 In order to study the NatA-ribosome interaction, we developed a purification for 
Schizosaccharomyces pombe ribosome, as the structure of S. pombe NatA is known and is readily 
recombinantly expressed in E. coli (Liszczak et al. 2013). We first tested whether NatA and the 
ribosome would co-elute from a Superose 6 size exclusion column as a stable complex. When run 
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alone, NatA elutes from the column at fraction 12 (Figure 5.1A). However, when an excess of 
NatA is run with the ribosome, there is a clear shift in the position of the NatA, which coelutes 
with the ribosome earlier in the column. Importantly, the excess NatA eluted at the same volume 
as NatA alone (Figure 5.1B), suggesting that the complex is stoichiometric and that the ribosome 
does not non-specifically mediate aggregation of NatA. This result indicates that the purified 
NatA and ribosome can form a complex in vitro with no other mediating factors.  
 We then performed co-sedimentation analysis on the NatA-ribosome complex. We first 
carried out a sedimentation assay with increasing concentration of ribosome to observe the 
binding profile of NatA and the ribosome (Figure 5.2A). We calculated the proportion of NatA in 
the pellet and supernatant fractions after spinning down in an ultracentrifuge. We assumed the 
stoichiometry of the NatA:ribosome complex to be 1:1, based on a number of factors. First, many 
proteins that bind near the exit tunnel of the ribosome have 1:1 stoichiometry (Bingel-Erlenmeyer 
et al. 2008; Kohler et al. 2009; Ataide et al. 2011; Ferrández-Ayela et al. 2013). Second, in pull 
down assays, the band intensity indicated a 1:1 stoichiometry of the Naa15 band with the rest of 
the ribosome bands (see WT sample for Figure 5.7 below). When we compared the band intensity 
of the Naa15 and the first two ribosomal proteins around 41 kD, we obtained a ration of 1.13, and 
1.28, which agrees best with a 1:1 stoichiometry. Third, the curve fit very well to a 1:1 model, 
with an R2 value of 0.94. Despite this reasoning, we cannot definitively state that the binding is 
1:1, and more research will be necessary to conclusively determine the stoichiometry. After 
fitting the curve, we found that the complex had a Kd of 0.85 ± 0.23 µM, which is similar to the 
calculated Kd of both methionine aminopeptidase (Sandikci et al. 2013), and the signal 
recognition particle (Bornemann et al. 2008), which are both in the low µM- mid nM range 
(Figure 5.2B).  
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Previous studies showed that the NatA-ribosome interaction is salt dependent in vivo. We 
performed the same analysis with our purified NatA and ribosome. We found that the same held 
true in our experiment. As the salt concentration increased, the interaction weakened until the 
ribosome no longer pulled down any NatA (Figure 5.2C).  
 
Figure 5.1 NatA binds to the ribosome in vitro  
(A) Fractions of NatA eluting off of a Superose 6 column and visualized on SDS-PAGE. The 
upper band is Naa15 and the lower band is Naa10. (B) Fractions of the ribosome and an excess of 
NatA eluting off of a Superose 6 column and visualized on SDS-PAGE. Note the excess NatA 
eluting in fraction 12.  
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Figure 5.2 The NatA ribosome interaction has low µM affinity and is salt dependent  
(A) Western blot of NatA/ribosome co-sedimentation assay. P stands for pellet, and S stands for 
supernatant. The western blot targets the His tag on the Naa15 subunit (Naa10 is untagged) (B) 
An affinity curve of the ribosome NatA interaction quantified from the co-sedimentation assay 
(C) Co-sedimentation assay in increasing salt concentrations. The first two lanes are NatA 
without ribosome present.  
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5.2.2 Cryo-EM reconstruction of the NatA ribosome complex showed no density for NatA 
 In order to determine the mode of binding of NatA to the ribosome, we performed EM 
analysis on the complex. We performed GraFix (Stark 2010) to stabilize the complex, and ran the 
crosslinked and uncrosslinked samples side by side to ensure that the NatA and ribosome 
sedimented together and that the Naa15 band crosslinked to higher molecular weight bands 
(Figure 5.3).. Negative staining revealed distinct, homogenous ribosomal particles (data not 
shown).  
 After obtaining good classes from negative staining, subjected the samples to cryo-Em 
analysis (Figure 5.4A). We froze the samples on thin carbon and picked 54645 particles after 
motion correcting the images. Only 30,000 of these particles were subsequently analyzed for 
computational ease. After class averaging, our 2D classes were highly converged and displayed 
obvious features of the ribosome, such as its large and small subunits (Figure 5.4B), and we then 
went on to generate 3D reconstructions. The program VIPER generated five separate 3D classes, 
with two classes having fewer than 2000 particles that did not converge on a structure (Figure 
5.5A). The other three classes converged to ribosome structures, with the first class of 10073 
particles being the best representation of the ribosome (Figure 5.5A). Unfortunately, although the 
density was clear for both the 40S and 60S subunits of the ribosome, no additional density for the 
NAT was apparent (Figure 5.5B). This could be due to a number of factors. Although NatA 
appeared to be crosslinked to the ribosome in the gel from the GraFix (Figure 5.3), this wasn’t 
necessarily the case. NatA could have been crosslinked to other contaminants in the sample, or to 
itself, and only appeared to be crosslinked to the ribosome. In addition, the NAT may not have 
been homogeneously bound to the ribosome, and the density was therefore lost during class 
averaging. It may be that NatA was only successfully bound to a small subset of the ribosomes, 
and many more particles will need to be picked for a successful reconstruction. Finally, it may be 
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that the thin carbon on the surface of the grid affected the interaction between the ribosome and 
NatA, and further screening of cryo-EM conditions will be required in the future.  
 
 
Figure 5.3 GraFix of the ribosome/NatA complex  
(A) Purified NatA and ribosome run on a sucrose gradient with an excess of NatA. Note the 
excess NatA sedimenting at a higher sucrose than the ribosome/NatA complex as in Figure 5.1A. 
Asterisks indicate fractions which are shown in Figure 5.3B (B) Indicated fractions of the 
NatA/ribosome complex run in a sucrose gradient in the presence of 0.25% glutaraldehyde. Note 
the Naa15 band, and some ribosomal protein bands are no longer present in these fractions, 
indicating that they have been crosslinked to higher molecular weight species.  
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Figure 5.4 Cryo-EM images and2D class averages of the NatA/ribosome sample  
(A) Cryo-electron micrographs of NatA/ribosome samples on thin carbon imaged with a Falcon II 
direct electron detector (FEI) equipped with an F20 electron microscope (FEI) operated at 200 kV 
acceleration voltage. (B) Representative 2D class averages of NatA/ribosome samples using a 
subset of 30,000 particles from 1351 images using RELION. Red Xs indicate class averages that 
were not used for the 3D reconstruction. 
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Figure 5.5 3D Reconstruction of the NatA/ribosome complex  
(A) Five 3D classes were generated using the program VIPER (SPARX), by using a 60 Å low 
pass filter of the ribosome as a reference model. Two of these classes, indicated by red Xs did not 
converge on a final model. We chose the best fitting model to the ribosome, indicated by a 
rectangle for further analysis. (B) Analysis of the electron density from model 1 in Figure 5.5A. 
Ribosomal features are indicated. Note that there is no extra density around the peptide exit 
tunnel. 
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5.2.3 Two conserved electropositive regions in NatA are responsible for ribosome interaction  
In the absence of structural data, we based our hypothesis on the nature of the interaction 
from the similarity of the ribosome affinities of methionine aminopeptidase, signal recognition 
particle, and NatA. Their shared ribosomal binding site and salt dependence for ribosome 
interaction led us to hypothesize that the NatA-ribosome interaction was similar to other protein 
interactions at the exit tunnel, and was largely dependent on electrostatic interactions. Therefore, 
we searched for conserved electropositive regions on the surface of NatA, which could account 
for this (Figure 5.6). We reasoned that electropositive regions would likely interact with the 
ribosome via L23 and rRNA. We generated a conservation map onto NatA (Ashkenazy et al. 
2016) and compared that to the calculated vacuum electrostatics on the protein (Figure 5.6B and 
5.6C). We focused on Naa15, as this subunit has previously been shown to mediate the 
interaction with the ribosome (Polevoda et al. 2008). There were two notable regions that we 
found on the surface of Naa15 that were conserved and electropositive. One was within an N-
terminal domain of Naa15, located in the first three TPR repeat of the protein (which we call 
electropositive region 1, EPR1), and the other was in a long, basic α-helix near the C-terminus of 
the protein (EPR2) (Figure 5.6C and Figure 5.7A). Intriguingly, both EPR1 and EPR2 are on the 
same side of the enzyme, and would orient the active site of Naa10 toward an emerging N-
terminus if bound to the ribosome. Moreover, both of these regions are dynamic in crystal 
structures of NatA, having high B-factors, and are often positioned in different orientations 
compared to the rest of the core of the complex in different structures of NatA (Liszczak et al. 
2013; Weyer et al. 2017) (and unpublished data). This may indicate a conformational flexibility 
required for these regions to properly orient themselves to interact with the ribosome.  
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Figure 5.6 Conservation analysis and electrostatic surface of NatA show two regions 
important for ribosome binding  
(A) Cartoon representation of the NatA complex. Naa10 is shown in cyan, Naa15 in green, and 
the peptide substrate in magenta. The N-terminus and internal basic helix are indicated, as is the 
active site where N-termini are acetylated. (B) Conservation map of the NatA complex. Magenta 
areas represent regions of high sequence conservation and cyan areas represent regions of low 
sequence conservation. (C) Electrostatic potential map of NatA. Blue areas represented regions 
that are electropositive, and red areas represent regions that are electronegative. 
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 In order to test the contribution of EPR1 and EPR2 on ribosome binding, we made a 
number of different mutations targeting these regions. (Table 5.1 and Figure 5.7A). We mutated 
three lysines to glutamates in EPR1 (K3E), six lysines to glutamates in EPR2 (K6E), and 
combined all nine of these mutations into one construct (K9E). We also deleted the first three N-
terminal TPR repeats (∆N in Figure 5.7A), and also made a mutant combining this with the 
mutations in EPR2 (∆N-K6E). We decided to delete the entire N-terminal domain since this 
entire region displayed higher conservation than most of the Naa15 subunit (Figure 5.6B).  
The mutations in these regions had negative effects on binding to the ribosome. Both the 
mutations targeting lysines in EPR1 (K3E) and EPR2 (K6E) displayed weaker binding to the 
ribosome than WT (Figure 5.7B), and combining the two regions together (K9E) displayed an 
even greater effect. The ∆N mutations displayed a slightly most severe effect than K9E (Figure 
5.7B), and thus the N-terminal region seems to be a major contributor to the interaction. This 
suggests that regions in the N-terminus outside of EPR1 in the N-terminus also strongly 
contribute to ribosome binding, and that the electrostatic interactions predicted are not a complete 
description of the interaction.  
We also constructed a number of lysine to glutamate mutations in other regions of Naa15 
as controls to test if disrupting other regions of positive charge on the protein would have the 
same effect (Figure 5.8A). Two of these mutants (K2EA and K2EC, Table 5.1) behaved as the WT 
enzyme (Figure 5.8B), but interestingly, one did not (K2EB, Table 5.1). We do not know why the 
mutations of K342E, K345E in NatA (K2EB) are sensitive for ribosome binding, since they are 
poorly conserved among NatA orthologues and are not oriented in the same interface as the EPR1 
and EPR2 regions we identified. Nonetheless, this data indicates that other surfaces of NatA 
outside of EPR1 and EPR1 may also contribute to ribosome binding. 
 
 
120 
	
Table 3.1 NatA mutants used in this study  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
NatA variant Mutations in variant 
WT N/A 
K3E K27E, K28E, K31E 
K6E K605E, K606E, K609E, K610E, K612E, K613E 
K9E K27E, K28E, K31E, K605E, K606E, K609E, K610E, K612E, K613E 
∆N ∆1-109 
∆N-K6E ∆1-109, K605E, K606E, K609E, K610E, K612E, K613E 
K2EA K216E, K217E 
K2EB K342E, K345E 
K2EC K398E, K401E 
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Figure 5.7 Pull down analysis of NatA mutants  
(A) Location of NatA mutants used in this study. Mutated regions are shown in yellow. Lysines 
mutated in K3E and K6E constructs are shown as sticks, and the N-terminal domain deleted in 
the ∆N constructs is indicated in yellow. K9E is a combination of the mutations K3E and K6E. 
(B) Sedimentation assay with NatA mutants visualized on SDS-PAGE. Naa15 is indicated. Note 
that for the ∆N mutants, Naa15 runs lower than WT Naa15. The faint bands above 80 kD in these 
lanes is not Naa15, but rather impurities from the ribosome prep. These lanes are marked with 
asterisks. The Naa10 band is obscured by the ribosomal proteins in the gel.  
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Figure 5.8 Pull down analysis of controls  
(A) A surface view of the NatA complex. Mutated lysine residues are indicated in orange and 
labeled with their mutant name. (B) Pull down analysis of the NatA mutants visualized on SDS-
PAGE. Asterisks are used as in Figure 5.7. (C) Activity analysis of mutants. SASE is a peptide 
corresponding to a known NatA substrate, and MLGP is a peptide corresponding to a NatE 
substrate. Assays were done in triplicate.  
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We tested all of the mutants with an activity assay to ensure that they were properly 
folded and found that each of the mutants retained catalytic activity within ~2-fold of the wild-
type enzyme (Figure 5C). We tested the activity against two different peptides. The first, which 
we refer to as SASE, after the four first N-terminal residues, is a strong NatA substrate. The 
second, MLGP, is a NatE substrate, which NatA cannot acetylate. We used SASE as a positive 
control, and MLGP as a negative control for the folding of the NatA complex. Note that Naa10 is 
not active in the absence of Naa15, which wraps around Naa10 and repositions one of its 
substrate binding loops. These assays indicate that all of the mutants contained a properly folded 
Naa15-Naa10 interaction, and that the ∆N mutant retained activity suggests that this region is not 
required for the Naa15-Naa10 interaction. Thermal melts were also performed and demonstrated 
that each of the mutants had comparable melting temperature of about 40 oC, consistent with 
wild-type folding properties of the mutant proteins (data not shown).  
After the co-sedimentation assays, we focused on the ∆N-K6E (Table 1) mutant, since it 
displayed one of the most severe pulldown defects. We decided to pursue this mutant even though 
the ∆N mutation alone was almost as severe in ablating the interaction (Figure 4B) because due to 
the weaker binding of K9E than either K3E or K6E alone, which indicates that this region is 
important, despite the N-terminus appearing to be a more crucial region in the interaction. We 
performed co-sedimentation over a range of ribosome concentrations to determine the affinity of 
this mutant to the ribosome. The resulting data could not be fit to a curve, yet the ribosome only 
began significantly pulling down the mutant at 10 µM, which indicates a significant decrease in 
affinity between the ribosome and the mutant complex (Figure 5.9A). We also performed gel 
filtration with the mutant and observed essentially no binding between the ribosome and the 
mutant (Figure 5.9B). These data indicate that the ∆N-K6E mutant (Table 5.1) highly disrupts the 
interface between the ribosome and NatA.  
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Figure 5.9 ∆N-K6E does not bind to ribosomes  
(A) Binding curves of WT NatA and ∆N-K6E using the sedimentation assay shown in Figure 5.2. 
∆N-K6E could not be fit to a curve. (B) Comparison of WT and ∆N-K6E eluting with the 
ribosome from Superose 6 and visualized on SDS-PAGE. Note that the binding of ∆N-K6E is 
weakened. Data for WT NatA has been reproduced from Figures 5.1 and Figure 5.2 for readers 
ease.  
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5.3 Discussion and future directions 
Here we have presented data on the interaction between the ribosome and NatA. Studies 
with purified ribosomes and NatA reveal a salt dependent interaction with dissociation constant 
of about 1 µM similar to other enzymes which bind near the exit tunnel of the ribosome (Bingel-
Erlenmeyer et al. 2008; Rutkowska et al. 2008; Sandikci et al. 2013). Conservation analysis led 
us to identify two regions of the protein important for ribosome binding: the N-terminus, and a 
positively charged helix near the C-terminus. Importantly, these regions are on the same side of 
NatA, and would orient the active site of Naa10 to face the peptide coming out of the exit tunnel. 
The deletion of the entire N-terminus in this work precludes us from specifically identifying the 
residues in this region that mediate the interaction. In addition, the finding that the K2EB mutant is 
also defective in ribosome binding suggests that this model is still incomplete, and more work 
will be necessary to dissect other contributions to the NatA/ribosome interaction. 
 Other lines of evidence from other recent studies also support the notion that NatA 
regions EPR1 and EPR2 are important for ribosome binding. NatA has two known binding 
partners, Naa50 and HYPK. The crystal structures of both of these enzymes bound to NatA have 
been solved (Neubauer 2012; Weyer et al. 2017), and neither interface would occlude EPR1 or 
EPR2 from binding to the ribosome. Naa50 is positioned in such a way that its active site would 
similarly face the peptide emerging from the exit tunnel, which is consistent with the model 
proposed here. Moreover, the NatB structure, which was also recently reported, shows a similar 
molecular “nest” of Naa25 around Naa20 (Hong et al. 2017). The TPR repeats of Naa25 are 
arranged differently than Naa15, particularly in the region where the ribosomal binding 
determinants are found in NatA. Notably however, there are two regions on Naa25 that contain 
positively charged regions in the same positions as Naa15 (Figure 5.11). This suggests that the 
mode of ribosome binding could be similar between the different NATs. An open question in the 
field is whether the NATs have the same binding site on the ribosome, or if they can bind 
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simultaneously. These results, along with the fact that all of the NATs are substoichiometric with 
the ribosome in the cell (Raue, Oellerer, and Rospert 2007), may point to the NATs competing 
for the same binding sites on the ribosome and quickly sampling the peptides being translated.   
 
 
Figure 5.10 NatB has positively charged regions in the same configuration as NatA  
(A) Cartoon representation of the NatA and NatB complex. Naa10 is shown in cyan and Naa15 in 
green. Naa20 is shown in yellow and Naa25 in orange. (B) Electrostatic surface representation of 
Naa15 and Naa25 with EPR1 and EPR2 on the Naa15 structure, and putative areas on Naa25 
corresponding to these regions indicated with arrows.  
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These studies raise a number of questions about the interaction of NatA and the 
ribosome. Does NatA compete with the other NATs, and the other N-terminal processing 
enzymes, which bind to the exit tunnel. For NatA in particular, methionine aminopeptidase needs 
to act on iMet before NatA can acetylate the N-terminus (Van Damme, Evjenth, et al. 2011). 
Whether NatA binds simultaneously with MAP and if the presence of one increases the affinity of 
the other is an open question. Why did we not see any density for the NAT in the cryo-EM 
structure? This could be due to a number of factors. In addition to what was discussed above in 
the results section, the other N-terminal processing enzymes are highly dynamic, and 
substoichiometric to the ribosome in the cell. Although NatA can bind to the non-translating 
ribosome there may be an ordering only upon binding to ribosomes that are translating. It may be 
that NatA needs to be trapped with a peptide emerging from the exit tunnel in order for it to be 
sufficiently homogeneous for structural studies. Indeed, SRP affinity for the ribosome increases 
significantly when there is a peptide emerging from the tunnel (Akopian et al. 2013). Trigger 
factor also displays increased affinity and slower on/off kinetics for the ribosome in the presence 
of a nascent peptide (Raine et al. 2006; Rutkowska et al. 2008). 
To begin to address this issue, we have incorporated p-benzoyl-L-phenylalanine (pBpa) 
into NatA using amber suppression (Chin et al. 2002) to specifically crosslink NatA to the 
ribosome. Briefly, this method allows for incorporation of unnatural amino acids into proteins by 
simultaneously expressing an aminoacyl-tRNA synthetase/tRNA pair targeting amber stop 
codons and NatA in E. coli. This allows for site-selective incorporation of pBpa into NatA. pBpa 
readily forms covalent crosslinks when exposed to UV light, and if it is in complex with a binding 
partner, we reasoned that it could crosslink to the ribosome in a site-specific manner. We made 
two mutants of NatA with pBpa substitutions. We made a negative control at position K401, a 
residue on the opposite interface of the ribosome binding site that we showed did not affect 
ribosome binding if mutated to a glutamic acid (K2EC mutation in Figure 5.8). The other 
128 
	
mutation was at position K605, located in the charged helix of EPR2 (Figure 5.6). After 
irradiating the proteins with UV light in the presence and absence of ribosome, there are a 
number of new bands which appear in the 605/ribosome lanes, which do not appear in the protein 
lane alone, or in the lanes with WT NatA (lanes 1) or 401 NatA (Figure 5.11). This suggests that 
the K605 variant is crosslinking to ribosomal proteins (or rRNA) in a specific manner. While still 
low efficiency, and crosslinking validation is necessary, this method may be useful is the future 
for stabilizing the complex for cryo-EM studies and for identifying the binding partners in the 
ribosome. 
 Together, these studies provide the first molecular framework for understanding how 
NatA interacts with the ribosome for co-translational protein N-terminal acetylation. This work 
will allow more research into the significance of co-translational N-terminal acetylation for a 
plethora of biological processes.  
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Figure 5.11 Crosslinking of p-benzoyl-L-phenylalanine (pBpa)-incorporated NatA with the 
ribosome  
(A) Gel of crosslinking pBpa labeled NatA with the ribosome. Sample 1 is WT NatA, without 
pBpa. Sample 2 is NatA K401pBpa; K401 is one of the lysines from K2EC from Figure 5.8A, as a 
negative control. Sample 3 is NatA K605pBpa, a lysine from EPR2, Figure 5.6C. Novel bands are 
shown with asterisks, and only show up when K605 and the ribosome are irradiated with UV 
light. (B) Complete gel from Figure 5.11A 
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5.4 Material and methods 
5.4.1 Schizosaccharomyces pombe ribosome purification 
Ribosomes were purified from S. pombe based on a modified preparation described for 
the S. cerevisiae ribosome (Ben-Shem et al. 2011). S. pombe (strain 972 h-) was grown to an 
OD600 of 5 in YPD at 30oC. Cells were pelleted by centrifugation, re-suspended with YP (i.e. 
without glucose) and incubated in flasks with vigorous shaking (250 rpm) for 10 minutes. This 
glucose starvation step was done to ensure that the ribosomes were not translating protein, and 
would be in the apo form when purified. All further steps were performed at 4oC. Cells were 
pelleted by centrifuged and washed in buffer M (30 mM Hepes pH 7.5, 50 mM KCl, 10 mM 
MgCl2, 8.5% mannitol, 2 mM DTT, 0.5 mM EDTA). Cells were pelleted again, the supernatant 
was removed, and the cells were frozen in liquid nitrogen. The cells were lysed using a Mixer 
Mill MM 400 (Retsch) and the resulting cell powder was resuspended in buffer M and 
supplemented with one complete protease inhibitor tablet (without EDTA, Thermo), 100 µL 
RNasin, Pefablock (final concentration 2 mM) and Na-heparin (final concentration 0.8 mg/ml) 
The resulting lysate was clarified by centrifugation (31,000g for 9 min). The supernatant was 
saved, and PEG 20,000 (Hampton Research) was added to a final concentration of 4.5% w/v and 
the solution was left to stand for 5 minutes on ice. The solution was clarified by centrifugation 
(20,000g for 5 min) and the supernatant was decanted to a new tube. Residual solution was 
“squeezed” out from the pellet by an additional short 1 min. centrifugation. The KCl 
concentration was then adjusted to 130 mM. After 5 min on ice, the PEG 20,000 concentrations 
were adjusted to 8.5% and the solution was left to stand for 10 min on ice. Ribosomes were 
precipitated (17,500g for10 min), the supernatant was discarded and residual solution was 
removed by a short spin of the pellet (14,500g for 1 min). The pellets were stored at -80oC until 
needed.  
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Ribosomes were suspended in buffer M2 (buffer M with KCl concentration adjusted to 
150 mM and supplemented with protease inhibitors and heparin). Ribosomes were further 
purified by a 15-30% sucrose gradient in buffer A (20 mM Hepes-K pH 7.5, 120 mM KCl, 8.3 
mM MgCl2, 2 mM DTT, 0.3 mM EDTA) using a VTi 50 rotor (Beckman) at 40,000 rpm for 1.5 
h. After the appropriate fractions were collected based on A260 monitoring, KCl and MgCl2 
concentrations were adjusted to 150 mM and 10 mM respectively, PEG 20% was then added to a 
final concentration of 7% w/v and the solution was left to stand 10 min. on ice. Ribosomes were 
precipitated (17,500g for 10 min), the supernatant was discarded and residual solution was 
removed by a short spin of the pellet (14,500g for 1 min.). Ribosomes were suspended (20 
mg/ml) in buffer G (10 mM Hepes pH 7.5, 50 mM KOAc, 10 mM NaCl, 2 mM DTT, 5 mM 
Mg(OAc)2). The concentrations of ribosomes were determined by the absorbance at 260 nm and 
using the extinction coefficient 5×107 cm-1M-1 (Matasova et al. 1991).  
 
5.4.2 Purification of NatA and enzyme assays 
NatA was purified and assayed as described (Liszczak et al. 2013) with the following 
changes. After the protein was eluted from the nickel column, the His-tag was not cleaved off of 
the Naa15 subunit with TEV protease (Naa10 does not have a tag). Leaving the His-tag on the 
protein did not affect enzyme activity (data not shown). After elution from the nickel column, the 
protein was directly dialyzed into ion exchange buffer containing 25 mM sodium citrate 
monobasic pH 5.5, 10 mM NaCl, and 1 mM βME. The subsequent ion exchange and gel filtration 
steps were performed as described.  
Mutants of NatA were generated using standard site directed mutagenesis using the wild-
type NatA as a template. The purification of these mutants was identical to the wild type enzyme.  
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Acetylation assays were performed as described (Liszczak et al. 2013). SASE refers to a 
NatA substrate, and MLGP refers to a NatE substrate. The first seven N-terminal residues of 
these peptides corresponds to protein substrates identified in vivo from proteomic studies and the 
remaining residues contain a poly-Arginine track to ensure that the peptides adhere to the 
phosphocellulose used in the assays. The full peptides are: SASE- 
SASEAGVRWGRPVGRRRRP, and MLGP-MLGPEGGRWGRPVGRRRRP 
 
5.4.3 Sedimentation assays of NatA-ribosome complex 
Sedimentation assays were carried out by combining ribosomes and NatA to final 
concentrations of 1 µM and 1.2 µM, respectively. 35 µl of this solution was added on top of 80 ul 
of Buffer G supplemented with 30% sucrose. Samples were centrifuged at 120,000 rpm in an 
S120-AT2 rotor (Thermo) in an ultracentrifuge. The supernatant was removed and ribosomal 
pellets were suspended in 110 µl of Buffer G. Samples were run on SDS-PAGE to analyze the 
amount of NatA that co-sedimented with the ribosome. When necessary, a Western blot was 
performed using an anti-His antibody (GE Healthcare Life Sciences catalogue #27-4710-01) 
against the His-tag of the Naa15 subunit. For salt-sensitivity assays, the buffers were 
supplemented with the appropriate amount of KCl and performed as described.  
 
5.4.4 Kd determination of NatA-ribosome association 
Co-sedimentation assays were performed as above, with the following changes. A total of 
120 µl of 30% sucrose was used, and 40 µl of sample was placed on top of that. A constant NatA 
concentration of 0.5 µM was used, and ribosome concentration varying from 0.1-11 µM was 
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used. A western blot was performed, and the ratio of NatA in the pellet was quantified using 
ImageJ. The resulting curve was fit using Prism, and the Kd was calculated using the equation 
Y=Kd+0.5+X-sqrt((Kd+0.5+X)^2-2X),	where X is the concentration of ribosome in µM, and Y is 
the proportion of NatA in the pellet. This equation takes into account the non-negligible 
concentration of NatA and ribosome in the experimental set up. It also assumes a 1:1 
stoichiometry of NatA:ribosome (see results section for more discussion), and that all of the 
ribosomes in the sample are capable of binding to NatA. 
 
5.4.5 Size exclusion chromatography assays  
 A total of 500 µl of NatA (6 µM) and ribosome (1.8 µM) was injected onto a superpose 6 
column and monitored with both 260 nm and 280 nm light. Appropriate fractions were run on 
SDS-PAGE and stained with colloidal coomassie blue for imaging.  
 
5.4.6 Preparation and 3D reconstruction of the NatA-ribosome complex 
 Negative staining and cryo-EM specimen were prepared at the Electron Microscopy 
Resource Laboratory (EMRL) at the University of Pennsylvania. The NatA-ribosome complex 
was fixed using GraFix (Kastner et al. 2008), a gradient fixation method during which the NatA-
ribosome complex was exposed to a low concentration of a chemical cross-linker (0.25 % 
glutaraldehyde) during sedimentation in a sucrose gradient to minimize compositional 
heterogeneity and secure the NatA-ribosome interface. To verify the stoichiometry of the 
complex, the sedimentation was repeated without fixation and analyzed by SDS-PAGE. The 
negative stained samples were prepared on carbon formvar and stained in 2% uranyl acetate 
(UA). They were imaged with a FEI Tecnai 12 at 69,680x on a Gatan US1000 high speed 
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acquisition camera. The particles were semi-automatically selected with Boxer2 in the EMAN2 
software package (Tang et al. 2007) and 2D class averages were calculated using the ISAC 
clustering algorithm (Yang et al. 2012) and RELION (Scheres 2012). 
 The cryo-EM samples were prepared by applying crosslinked NatA-ribosome to carbon 
formvar grids with thin carbon, which were then flash frozen in liquid ethane. The cryo-EM data 
was collected on a Falcon II direct electron detector (FEI) equipped with an F20 electron 
microscope (FEI) operated at 200 kV acceleration voltage at the EMRL. The collected images 
stacks were motion corrected with MotionCorr (Li et al. 2013). Cryo-EM particles were again 
semi-automatically selected with Boxer2 and the CTF (Contrast Transfer Function) was corrected 
in the EMAN2 software package. 2-D class averages were calculated using the ISAC clustering 
algorithm and RELION. Once class averages were obtained, five 3D classes were generated using 
the program VIPER (SPARX), by using a 60 Å low pass filter model of the ribosome as a 
reference (Penczek, Grassucci, and Frank 1994).  
 
5.4.7 Preparation of p-benzoyl-L-phenylalanine labeled NatA and crosslinking assays 
Preparation of p-benzoyl-L-phenylalanine (pBpa) labeled NatA was performed by using 
site directed mutagenesis on specified NatA residues to TAG (amber stop codons). The plasmid 
expressing the aminoacyl-tRNA synthetase/tRNA pair for pBpa was a gift from Dr. James 
Petersson from the University of Pennsylvania. This plasmid (streptomycin resistant) was co-
transformed into E. Coli with the mutagenized NatA constructs (ampicillin resistant), and was 
plated on LB plates containing both antibiotics. Bacteria were grown in minimal media, and upon 
reaching an OD of 0.8, p-benzoyl-L-phenylalanine was added to a final concentration of 0.5 mM. 
After shaking for 15 minutes to allow for uptake of the unnatural amino acid, the temperature was 
reduced to 16 °C, IPTG was added, and the bacteria were grown for 16 hours. After growth, the 
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pBpa-incorperated NatA mutants were purified in the same manner at the WT, except everything 
was done in the dark to avoid pBpa photoactivation. The crosslinking assays were done by 
mixing NatA with the ribosome at 1 µM and 2 µM, respectively, and were irradiated with 365nm 
UV light for 30 minutes at 4 °C. Samples were then run on SDS-PAGE, and stained for analysis.  
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CHAPTER 6: A Theory on the Evolution of N-terminal Acetylation  
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6.1 Why are there NATs? 
 
  
 Throughout the course of graduate school, the most common question I received, and 
indeed, the most enduring question in the field, is why are there NATs at all? What is the purpose 
of this widespread modification in eukaryotic cells? After all, acetylating the N-terminus of most 
proteins, the thinking goes, is energetically costly through the consumption of acetyl-CoA, which 
could be used for other cellular processes. Although N-terminal acetylation has been known about 
for many decades (Narita 1958; Strous, Westreenen, and Bloemendal 1973), there is still a desire 
in the field to find a general reason for its universal presence in eukaryotes. Some early 
investigators believed that the general reason was to promote stability and protect proteins from 
proteolytic degradation (Jornvall 1975). However, it has long been known that this is not the 
general function of the modification. Indeed, papers from the 1970s challenged this view by 
showing that this wasn’t the case through early proteomic studies (Strous, Westreenen, and 
Bloemendal 1973; Brown 1979). Therefore, although this was an attractive hypothesis, it never 
received widespread experimental support.  
 Since then, the most studied explanation for a general purpose of N-terminal acetylation 
has been the Ac/N-end rule. Varshavsky and colleagues discovered the N-end rule in the 1980s, 
when they demonstrated that the stability of proteins in the cell depended on their N-terminal 
residues. Some residues, like methionine, serine, or alanine, were stabilizing, while others, like 
charged or large hydrophobic residues, were destabilizing. These destabilizing N-termini were 
deemed N-degrons (Bachmair, Finley, and Varshavsky 1986). Although the N-end rule is not the 
only determinant of protein stability (there are hundred of E3 ubiquitin ligases in the human 
proteome that target other degrons (Teixeira and Reed 2013)), it does affect half-lives for a 
number of proteins (Tasaki et al. 2012). In 2010, it was discovered that acetylated N-termini 
could also act as N-degrons, in a new pathway called the Ac/N-end rule (Hwang, Shemorry, and 
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Varshavsky 2010). It is now understood that both free and acetylated N-termini can act as 
degradation signals for proteins. The Ac/N-end rule has been shown to regulate the proper 
stoichiometry of protein complexes and protein folding (Shemorry, Hwang, and Varshavsky 
2013; Park et al. 2015). This is achieved by sterically shielding acetylated N-termini that are 
properly folded or are in complex with other proteins. Therefore, unfolded proteins, or those out 
of their appropriate complexes in the cell can be preferentially targeted for degradation through 
their exposed acetylated N-termini.  
This model has since been expanded to bacteria, where all proteins begin with a formyl-
methionine (fMet) instead of a regular methionine as in archaea and eukaryotes. Although most 
peptides are rapidly co-translationally deformylated in bacteria (Kramer et al. 2009), it was 
recently proposed by Varshavsky and coworkers that the formyl group on fMet can also act as a 
degradation signal (Piatkov et al. 2015). They argue that in bacterial proteins that misfold while 
being translated, the formyl group is inaccessible, and peptide deformylase cannot cleave it. The 
retained fMet acts as a degradation signal through an unknown mechanism. The formyl group and 
acetyl group of bacterial and eukaryotic proteins, respectively, act as analogous degradation 
signals at N-termini. Varshavsky and coworkers posit that the slower speed of eukaryotic 
translation allows the acetyl group to be added post-translationally, instead of pre-translationally 
as in bacteria, and that regulation of protein degradation is, in part, what drove the evolution of N-
terminal acetylation (Piatkov et al. 2015). 
 Although this framework for the evolution and function of NATs has been invaluable for 
the field, the Ac/N-end rule has only been observed experimentally in a handful of proteins 
(Tasaki et al. 2012; Park et al. 2015). In this chapter, I propose a hypothesis about NAT function 
and evolution. I base my reasoning both on Varshavsky’s work, and on an emerging model of 
eukaryotic evolution in general. I argue that the evolution of NATs can be explained in part as a 
result of the symbiosis between a bacteria cell and an archaeal cell that formed an early 
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eukaryote. The NATs arose due to the incompatible types of translational initiation between the 
two types of cells, which led to the development of N-terminal acetylation, which only later grew 
to obtain its specified function in various systems. If this is the case, the functions of N-terminal 
acetylation observed in modern eukaryotes, including protein degradation, are not a driver of the 
evolution of the ubiquitous nature of N-terminal acetylation, but rather, the cellular functions are 
a result of its ubiquity from evolutionary necessity. In the following sections, I will outline the 
history of classifying life, how translation differs between different domains, and new ideas 
regarding the emergence of eukaryotes and how this relates to NAT evolution.   
 
6.2 Taxonomy and translation 
 Before the 1970s, life was broadly divided into two categories: the prokaryotes, which 
are morphologically simple, single-celled organism lacking nuclei, and the eukaryotes, which 
have true nuclei, membrane bound organelles, and are morphologically complex (Stanier and Van 
Niel 1962). Although they share many features indicative of a common ancestor, like a shared 
genetic code and basic metabolisms, their fundamental differences indicate that the two groups 
had diverged billions of years ago (Woese and Fox 1977).  
One of the most fundamental differences is in the way they translate protein. Although 
both utilize ribosomes, the ribosome architecture differs between the two groups. This remains 
the basis for the use of many antibiotics, which target the 70S bacterial ribosome, but are 
innocuous against the 80S eukaryotic ribosome (Wilson 2014). In addition to the differences in 
ribosome architecture, the amino acid used to start translation also differs. Prokaryotic cells 
initiate translation with fMet, while eukaryotes use regular methionine (Kramer et al. 2009). 
Translation is just one of the many differences between prokaryotes and eukaryotes, and because 
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of these differences, the two domain system of life was long considered a fundamental part of 
phylogenetic taxonomy (Stanier and Van Niel 1962).  
 However, in 1977, Carl Woese published a landmark paper that upended this view of life 
(Woese and Fox 1977). By sequencing 16S rRNA from a number of diverse organisms, Woese 
realized that instead of two main branches on the tree of life, there were three. Woese named this 
third group archaebacteria, based on the assumption that they were older than what he termed 
eubacteria (later shown not to be true). This was a momentous discovery. It reorganized the entire 
tree of life based on rRNA sequences alone, and is still used today as one of the fundamental 
methods to classify living things.  
Archaea had previously been characterized as methanogenic bacteria, as they do not have 
nuclei, and are single celled, and morphologically simple. However, biochemically, they are quite 
distinct from bacteria (Woese and Fox 1977). They have no peptidoglycan in their cell wall, and 
distinct lipids in their cell membranes. Notably, some of their features are closer to eukaryotes 
than to bacteria (Table 6.1). Of particular note for us, is that their ribosomes and system of 
translation is closer to eukaryotes rather than bacteria. The structure of their ribosomes and 
elongation factors more closely resembles eukaryotes, and they do not begin translation with 
fMet, but with regular methionine (Cavicchioli 2011).  
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Table 4.1 Comparison of features in bacteria, archaea, and eukaryotes.  
Table taken from (Barton 2007) 
 
 
 
 
 
For many years, the placement of archaea and eukaryotes in the tree of life was 
challenging; how were the two related? While eukaryotes share many features with archaea, they 
also have properties that are closer to prokaryotes (Table 6.1). In addition, certain eukaryotic gene 
families had unambiguously evolved from archaeal proteins, while other were from bacteria. 
Horizontal gene transfer can obscure phylogenetics for the microbial family tree, and many 
different hypotheses abounded (Koonin 2015). Some claimed that eukaryotes were nested within 
the archaea, while others maintained that archaea were truly monophyletic (Figure 6.1). 
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Ultimately, the answers to these questions, and what guides my hypothesis about NAT evolution, 
are beginning to come to light. 
 
 
Figure 6.1 Competing phylogenetic models concerning the relationship between archaea 
and eukaryotes  
(A) Model of archaea as monophyletic. The rooted three-domains tree depicts cellular life divided 
into three major monophyletic groups or domains: the bacteria, archaea and eukaryota. In this tree 
the archaea and eukaryota are most closely related to each other because they share a common 
ancestor that is not shared with bacteria. This is the model originally developed by Woese (Woese 
and Fox 1977) (B) The rooted eocyte tree recovers the eukaryotic lineage nested within the 
archaea as a sister group to the eocytes; this implies that, on the basis of the small set of core 
genes, there are only two primary domains of life—the Bacteria and the Archaea. In its modern 
formulation shown here the eocyte hypothesis implies that the closest relative of the eukaryotic 
nuclear lineage is one, or all, of the TACK archaea. Figure and legend adapted from (Williams et 
al. 2013). 
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6.3 NATs driven by eukaryogenesis 
 In 1967 Lynn Margulis (then Lynn Sagan) proposed her endosymbiosis theory (Sagan 
1967). While many aspects of the theory had been written about before (Zimorski et al. 2014), 
Margulis used the latest microbiological and biochemical evidence to form the basis of the 
modern model of endosymbiosis. She argued that mitochondria and chloroplasts were the results 
of symbiosis between an early eukaryotic and prokaryotic cell. That some type of symbiosis did 
occur in evolutionary history underlying both mitochondria and chloroplasts is a widely accepted 
model today based on the fact that both of these organelles contain their own circular genomes, 
contain ribosomes similar to 70S ribosomes from bacteria, and have inner membranes with lipid 
composition close to bacterial membranes (Zimorski et al. 2014). There is also the noted 
phenomenon of lateral gene transfer, whereby organllar DNA is transferred to the nucleus, 
thereby reducing the genomic content of these organelles over evolutionary time (Huang 2013).  
 In recent years, an adjustment to the hypothesis has emerged based on genomic data, 
which has major implications for eukaryotic phylogeny. Instead of an early eukaryotic cell 
ingesting a bacterial cell to form these organelles, the origin of eukaryotes itself depended on an 
archaeal cell ingesting a bacterial cell, which became an early mitochondrion (Archibald 2015). 
Indeed, this event is the driving force behind the development of the eukaryotes as a separate 
domain. This reorganizes the tree of life once more, and fundamentally alters the placement of the 
eukaryotes (Figure 6.2). Instead of being solely nested within the archaeal lineage, all eukaryotes 
evolved from a merger of the two primary domains of life- the bacterial and archaea (McInerney, 
O'Connell, and Pisani 2014). 
 
 
 
 
144 
	
 
 
Figure 6.2 Modern model of eukaryogenesis  
Schematic representation of the flow of genetic material from the two major prokaryotic groups 
into the base of the eukaryotes and the separate flow of genetic material from cyanobacteria into 
plastid-containing eukaryotes (Chloroplast origin). Figure taken from (McInerney, O'Connell, and 
Pisani 2014) 
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This hypothesis is attractive for many reasons. First, it explains why all eukaryotes have 
mitochondria, or belong to lineages that have lost them (Lane and Martin 2010). Second, it 
explains why eukaryotes contain a combination of bacterial and archaeal traits and genes. The 
early mitochondrion lost many of its genes by lateral gene transfer to the nucleus (Huang 2013). 
Third, it explains what drove the evolution of many universal eukaryotic traits. The last common 
eukaryotic ancestor (LECA) already had a nucleus, complex vesicular transport, a dynamic 
cytoskeleton, and exons and introns (Lane 2017). In order to successfully combine the two 
genomes into one organism, changes like formation of a nucleus to separate transcription and 
translation were necessary (Lane 2015). Although not universally accepted in scale or scope, this 
hypothesis has the support of metagenomic data (Spang et al. 2015) and is a leading model 
regarding the evolution of eukaryotes.  
 How does this inform our understanding of the evolution of the NATs? Comparative 
genomic studies show that all of the NATs were present in LECA (Figure 6.3) (Rathore, Faustino, 
and Prudêncio 2016), suggesting that their evolution may have been an important part of the 
archaeal/bacterial merger. Why would this have been the case? If there was a massive gene 
migration event that combined bacterial and archaeal proteins (Huang 2013), then there would 
have to be mechanisms to incorporate them into a unified system. As mentioned, bacterial 
proteins are translated with an initial fMet, while archaeal proteins are not. Modern eukaryotes 
use a translation system derived from archaea, and do not use fMet to initiate translation. The 
formyl group is cleaved off on the majority of modern day bacterial proteins. However, a recent 
study showed that rapidly folding proteins, or proteins which are secreted or destined for the 
membranes retain their formyl group (Ranjan et al. 2017). It would also be a mistake to assume 
that the modern day extensive deformylation of proteins seen in model organisms like E. Coli was 
necessarily as widespread in early bacteria. Therefore, it is not difficult to imagine bacterial  
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proteins that retained the formyl group, and came to depend on it for a variety of reasons, whether 
for folding, protein-protein interactions, stability, or localization. However, when these proteins 
were expressed in early eukaryote, the translational machinery couldn’t use fMet to initiate 
protein synthesis, and therefore, this functional group could not be added before translation 
began. As Varshavsky and colleagues noted, however, an acetyl group is quite similar to a formyl 
group, and the pool of acetyl-CoA provided a ready supply to take the place of the formyl group 
co-translationally instead of pre-translationally (Piatkov et al. 2015). Therefore, due to the 
combination of incompatible protein expression system, the ubiquitous fMet in bacteria may have 
been replaced with an acetyl group in early eukaryotes.  
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Figure 6.3 All six NATs were likely present in the last common eukaryotic ancestor (from 
previous page) 
Catalytic and regulatory subunits of all six major human NATs complexes were identified across 
the eukaryotic tree of life, suggesting they were all present in the LECA. NATs subunit orthologs 
were identified in 27 species representative of the eukaryotic tree of life. Naa60 (NatF) was 
apparently secondarily lost in fungi. Results are indicated according to reciprocal blastp E-value 
score (“filled dot” = E-value score lower than e−8; “open dot” = E-value score between e−8-e−3; “no 
dot” = E-value score higher than e−3. Black dot indicates NAT was identified using H. 
sapiens ortholog; orange dot indicates that NAT was identified using S. cerevisiae ortholog; 
green, yellow and red dots indicate that NATs were identified, respectively, using the 
phylogenetically closest plant, excavate and chromalveolata species ortholog. In the case of 
species-specific gene duplication, the number of dots is equivalent to the number of identified 
NAT paralogs. Figure and legend adapted from (Rathore, Faustino, and Prudêncio 2016). 
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 One might argue that this line of reasoning only shifts the burden of the presence for a 
general function onto fMet in bacteria. I do not believe that this is the case. The evolution of fMet 
as the initiating residue can be explained by the uniqueness of the start site of translation. Indeed, 
the unique feature in the mRNA around the start codon called the Shine-Dalgarno sequence also 
imparts a unique character to the first residue (Nakamoto 2009). Therefore, the use, (or not, as in 
archaea) of a unique residue for the first amino acid in a polypeptide does not need, in my view, a 
complex explanation as would describing the function of N-terminal acetylation without the 
benefit of evolutionary hindsight.  
 Another potential criticism of this model is the energetic cost associated with acetylating 
almost all of the N-termini in the proteome. There are a number of reasons I believe this is not the 
case, and that the discussion of this cost of N-terminal acetylation in the literature is 
overemphasized without evidence. First, the cost of acetylating proteins in early eukaryotes was 
arguably already present from the synthesis of fMet, which also required an input of energy for 
all proteins in bacteria. Therefore, instead of creating a new energy cost, the cell was simply 
shifting the cost from a formyl-based system to an acetyl-based system. Second, the energetic 
cost of protein production is already quite high, and takes up a large portion of the cells energy 
reserves (Lane and Martin 2010). Considering the synthesis of each residue, charging of the 
tRNA, and elongation factors used, each residue in a protein comes out to about 30 equivalents of 
ATP (or GTP) on average (Wagner 2005). The TCA cycle can generate about 13-15 ATP 
equivalents from one molecule of acetyl-CoA (Ebenhoh and Heinrich 2001). This is negligible to 
the 3000 equivalents used for the synthesis of a 100 residue protein. Finally, the early eukaryotes 
may have had an increased overall energy budget from the compartmentalization of the 
mitochondria, although this remains a controversial claim (Lane and Martin 2010; Booth and 
Doolittle 2015).   
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6.4 Mechanism of NAT evolution and specialized NATs 
 There are NATs in all three domains of life, even though only eukaryotes acetylate most 
of their proteome (Aksnes et al. 2016). This suggests that a NAT type enzyme may have already 
been present in the early eukaryote after the symbiosis of the archaeal and bacterial cells. If it 
were acting to replace the universal fMet on the proteins, this early NAT would have needed a 
way to target much of the proteome as it was being translated. It could have evolved a binding 
partner that would become the auxiliary subunits of the NATs to allow it to bind to the ribosome 
(Figure 6.4A). The early NAT (and modern eukaryotic NATs) necessarily has minimal binding 
interactions with few specificity determinants between the enzyme and the peptide in order for it 
to bind many different substrates. However, these minimal binding interactions mean a lower 
affinity with the substrates. NatA for example, has a KM of about 300 µM for the model peptide 
beginning with SASE (Liszczak et al. 2013). This is a poor KM value for a substrate, and many 
proteins in the cell that are acetylated by NatA will be well below this concentration. By making 
the NAT bind the ribosome, however, the local concentration of substrate is high as it emerges 
from the ribosome exit tunnel, and will be more likely to be acetylated (Figure 6.4B). In this 
manner, the early NATs may have solved the problem of low affinity by bringing the substrate to 
the enzyme on the universal platform of the ribosome. 
Interestingly, an archaea, Sulfalobus solfataricus expresses a NAT which can acetylate 
both NatA and NatE-type N-termini (Liszczak and Marmorstein 2013). After a small number of 
gene duplication events, this early generalist could have evolved into the specialist NATs we see 
today, with their substrate specificity directed by the first two residues of the peptide (Figure 
6.4C).  
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Figure 6.4 Model of NAT evolution (from previous page) 
(A) An early promiscuous NAT evolved a binding partner which (B) allowed it to associate with 
the ribosome and acetylate nascent peptides. (C) Gene duplication events led to the specialization 
observed in the modern NATs. (D) The early NAT also evolved into Naa50 and Naa60 which 
took on specialized roles of their own. (E) Due to its unique structural features and substrate-
specificity, NatD may have evolved from a different GNAT family member, and later converged 
on the function of N-terminal acetylation. Figure adapted from (Starheim, Gevaert, and Arnesen 
2012). 
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 Then, once widespread, the evolution of eukaryotic proteins came to depend on the 
presence of an acetyl group on the N-terminus, and this quickly became used for different 
purposes for diverse proteins. Therefore, instead of one factor driving the evolution of N-terminal 
acetylation, it was rather the unique evolution of eukaryotes which caused it to be widespread, 
and only later did it become specialized and essential for a number of systems. In this way, 
searching for the “general function” of N-terminal acetylation may be a misguided question. Just 
because it is widespread does not mean that it has a general function; its widespread nature may 
very well be an artifact from the unique evolutionary history of eukaryotes.  
This leaves the question of the evolution of the more specialized NATs. Naa50 and 
Naa60 are closely related, and both have the classical NAT fold with the β6-β7 loop, which 
suggests that they, too, are homologues from an early NAT. However, unlike the major NATs, 
this occurred independently of an auxiliary subunit, and each evolved unique features that 
allowed it to be specialized (Figure 6.4D). Naa50 associates with the NatA complex and also acts 
co-translationally. Naa60’s extended loop regions and C-terminus allow is to be localized to the 
Golgi and acetylate membrane proteins. Interestingly, both of these NATs are implicated in cell 
division, and have a limited number of substrates compared to the major NATs (Aksnes et al. 
2016). What drove the evolution of these NATs is an open question. 
NatD, on the other hand, may not have evolved from the same family as the other NATs, 
even though it is grouped with them today based on a common function. The lack of the 
characteristic β6-β7 loop in this NAT, and extended α1-α2 loop suggest that NatD evolved from 
another family of GNAT acetyltransferases, and converged on the function of N-terminal 
acetylation (Figure 6.4E). NatD only acetylates H2A and H4, substrates that are highly abundant, 
regulated, and also integral to the evolution of eukaryotic gene regulation. From this perspective, 
it is therefore not surprising that histones evolved their own dedicated NAT.   
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 Although deciphering the precise evolutionary pathway of N-terminal acetylation is 
difficult, its widespread presence in eukaryotes, similarity in function to iMet formylation in 
bacteria, and diverse functional consequences all point to an early adoption in the eukaryotic 
lineage. This may be explained by the emerging view that eukaryogenesis resulting from the 
symbiosis of a bacterial and archaeal cell, which then needed to evolve ways to overcome this 
merger. Future research will undoubtedly uncover additional functions of N-terminal acetylation, 
which will guide research tools and therapeutic strategies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
	
REFERENCES 
 
Adams, P. D., P. V. Afonine, G. Bunkoczi, V. B. Chen, N. Echols, J. J. Headd, L. W. Hung, S. 
Jain, G. J. Kapral, R. W. Grosse Kunstleve, A. J. McCoy, N. W. Moriarty, R. D. Oeffner, R. J. 
Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, and P. H. Zwart. 2011. 'The Phenix 
software for automated determination of macromolecular structures', Methods, 55: 94-106. 
Akopian, David, Kuang Shen, Xin Zhang, and Shu-ou Shan. 2013. 'Signal Recognition Particle: 
An Essential Protein-Targeting Machine', Biochemistry, 82: 693-721. 
Aksnes, H., P. Van Damme, M. Goris, K. K. Starheim, M. Marie, S. I. Stove, C. Hoel, T. V. 
Kalvik, K. Hole, N. Glomnes, C. Furnes, S. Ljostveit, M. Ziegler, M. Niere, K. Gevaert, and T. 
Arnesen. 2015. 'An organellar nalpha-acetyltransferase, naa60, acetylates cytosolic N termini of 
transmembrane proteins and maintains Golgi integrity', Cell Rep, 10: 1362-74. 
Aksnes, Henriette, Adrian Drazic, Michaël Marie, and Thomas Arnesen. 2016. 'First Things First: 
Vital Protein Marks by N-Terminal Acetyltransferases', Trends in biochemical sciences, 41: 746-
60. 
Aksnes, Henriette, Marianne Goris, Øyvind Strømland, Adrian Drazic, Qaiser Waheed, Nathalie 
Reuter, and Thomas Arnesen. 2017. 'Molecular determinants of the N-terminal acetyltransferase 
Naa60 anchoring to the Golgi membrane', The Journal of biological chemistry, 292: 6821-37. 
Aksnes, Henriette, Petra Van Damme, Marianne Goris, Kristian K. Starheim, Michaël Marie, 
Svein I. Støve, Camilla Hoel, Thomas V. Kalvik, Kristine Hole, Nina Glomnes, Clemens Furnes, 
Sonja Ljostveit, Mathias Ziegler, Marc Niere, Kris Gevaert, and Thomas Arnesen. 2015. 'An 
organellar nα-acetyltransferase, naa60, acetylates cytosolic N termini of transmembrane proteins 
and maintains Golgi integrity', Cell reports, 10: 1362-74. 
Allfrey, V. G., R. Faulkner, and A. E. Mirsky. 1964. 'Acetylation and Methylation of Histones 
and Their Possible Role in the Regulation of Rna Synthesis', Proceedings of the National 
Academy of Sciences of the United States of America, 51: 786-94. 
Appel, M. J., and C. R. Bertozzi. 2015. 'Formylglycine, a post-translationally generated residue 
with unique catalytic capabilities and biotechnology applications', ACS chemical biology, 10: 72-
84. 
Archibald, J. M. 2015. 'Endosymbiosis and Eukaryotic Cell Evolution', Current biology : CB, 25: 
R911-21. 
156 
	
Arnaudo, N., I. S. Fernández, and S. H. McLaughlin. 2013. 'The N-terminal acetylation of Sir3 
stabilizes its binding to the nucleosome core particle', Nature structural & …. 
Arnesen, T., X. Kong, R. Evjenth, D. Gromyko, J. E. Varhaug, Z. Lin, N. Sang, J. Caro, and J. R. 
Lillehaug. 2005. 'Interaction between HIF-1 alpha (ODD) and hARD1 does not induce 
acetylation and destabilization of HIF-1 alpha', FEBS Lett, 579: 6428-32. 
Arnesen, Thomas, Kristian K. Starheim, Petra Van Damme, Rune Evjenth, Huyen Dinh, Matthew 
J. Betts, Anita Ryningen, Joël Vandekerckhove, Kris Gevaert, and Dave Anderson. 2010. 'The 
chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation 
and prevention of Huntingtin aggregation', Molecular and cellular biology, 30: 1898-909. 
Ashkenazy, H., S. Abadi, E. Martz, O. Chay, I. Mayrose, T. Pupko, and N. Ben-Tal. 2016. 
'ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in 
macromolecules', Nucleic acids research, 44: W344-50. 
Ataide, Sandro F., Nikolaus Schmitz, Kuang Shen, Ailong Ke, Shu-ou Shan, Jennifer A. Doudna, 
and Nenad Ban. 2011. 'The crystal structure of the signal recognition particle in complex with its 
receptor', Science (New York, N.Y.), 331: 881-86. 
Bachmair, A., D. Finley, and A. Varshavsky. 1986. 'In vivo half-life of a protein is a function of 
its amino-terminal residue', Science, 234: 179-86. 
Baeza, J., M. J. Smallegan, and J. M. Denu. 2015. 'Site-specific reactivity of nonenzymatic lysine 
acetylation', ACS chemical biology, 10: 122-8. 
Barton, Nicholas H. 2007. Evolution (Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 
N.Y.). 
Becker, T., S. Bhushan, A. Jarasch, P. J. Armache, S. Funes, F. Jossinet, J. Gumbart, T. Mielke, 
O. Berninghausen, K. Schulten, E. Westhof, R. Gilmore, E. C. Mandon, and R. Beckmann. 2009. 
'Structure of Monomeric Yeast and Mammalian Sec61 Complexes Interacting with the 
Translating Ribosome', Science, 326: 13691373. 
Behnia, R., B. Panic, J. R. C. Whyte, and S. Munro. 2004. 'Targeting of the Arf-like GTPase 
Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p', Nature cell 
biology. 
157 
	
Ben-Shem, Adam, Nicolas de Loubresse, Sergey Melnikov, Lasse Jenner, Gulnara Yusupova, 
and Marat Yusupov. 2011. 'The structure of the eukaryotic ribosome at 3.0 Å resolution', Science 
(New York, N.Y.), 334: 1524-29. 
Bingel-Erlenmeyer, Rouven, Rebecca Kohler, Günter Kramer, Arzu Sandikci, Antoli, cacute, 
Snje, zcaron, ana, Timm Maier, Christiane Schaffitzel, Brigitte Wiedmann, Bernd Bukau, and 
Nenad Ban. 2008. 'A peptide deformylase–ribosome complex reveals mechanism of nascent 
chain processing', Nature, 452: 108-11. 
Booth, A., and W. F. Doolittle. 2015. 'Eukaryogenesis, how special really?', Proceedings of the 
National Academy of Sciences of the United States of America, 112: 10278-85. 
Bornemann, Thomas, Johannes Jöckel, Marina V. Rodnina, and Wolfgang Wintermeyer. 2008. 
'Signal sequence-independent membrane targeting of ribosomes containing short nascent peptides 
within the exit tunnel', Nature structural & molecular biology, 15: 494-99. 
Brown, J. L. 1979. 'A comparison of the turnover of alpha-N-acetylated and nonacetylated mouse 
L-cell proteins', The Journal of biological chemistry, 254: 1447-49. 
Brown, J. L., and W. K. Roberts. 1976. 'Evidence that approximately eighty per cent of the 
soluble proteins from Ehrlich ascites cells are Nalpha-acetylated', Journal of Biological 
Chemistry. 
Cain, J. A., N. Solis, and S. J. Cordwell. 2014. 'Beyond gene expression: the impact of protein 
post-translational modifications in bacteria', J Proteomics, 97: 265-86. 
Casey, J. P., S. I. Stove, C. McGorrian, J. Galvin, M. Blenski, A. Dunne, S. Ennis, F. Brett, M. D. 
King, T. Arnesen, and S. A. Lynch. 2015. 'NAA10 mutation causing a novel intellectual disability 
syndrome with Long QT due to N-terminal acetyltransferase impairment', Sci Rep, 5: 16022. 
Cavicchioli, R. 2011. 'Archaea--timeline of the third domain', Nat Rev Microbiol, 9: 51-61. 
Chin, J. W., A. B. Martin, D. S. King, L. Wang, and P. G. Schultz. 2002. 'Addition of a 
photocrosslinking amino acid to the genetic code of Escherichiacoli', Proceedings of the National 
Academy of Sciences of the United States of America, 99: 11020-4. 
Choudhary, C., C. Kumar, F. Gnad, M. L. Nielsen, M. Rehman, T. C. Walther, J. V. Olsen, and 
M. Mann. 2009. 'Lysine acetylation targets protein complexes and co-regulates major cellular 
functions', Science, 325: 834-40. 
158 
	
Choudhary, C., B. T. Weinert, Y. Nishida, E. Verdin, and M. Mann. 2014. 'The growing 
landscape of lysine acetylation links metabolism and cell signalling', Nature reviews. Molecular 
cell biology, 15: 536-50. 
Daniel Ricketts, M., B. Frederick, H. Hoff, Y. Tang, D. C. Schultz, T. Singh Rai, M. Grazia 
Vizioli, P. D. Adams, and R. Marmorstein. 2015. 'Ubinuclein-1 confers histone H3.3-specific-
binding by the HIRA histone chaperone complex', Nat Commun, 6: 7711. 
Denessiouk, K. A., V. V. Rantanen, and M. S. Johnson. 2001. 'Adenine recognition: a motif 
present in ATP-, CoA-, NAD-, NADP-, and FAD-dependent proteins', Proteins, 44: 282-91. 
Dikiy, I., and D. Eliezer. 2014. 'N-terminal acetylation stabilizes N-terminal helicity in lipid-and 
micelle-bound α-synuclein and increases its affinity for physiological membranes', Journal of 
Biological Chemistry. 
Dong, C., Y. Mao, W. Tempel, S. Qin, L. Li, P. Loppnau, R. Huang, and J. Min. 2015. 'Structural 
basis for substrate recognition by the human N-terminal methyltransferase 1', Genes & 
development, 29: 2343-8. 
Dorfel, M. J., and G. J. Lyon. 2015. 'The biological functions of Naa10 - From amino-terminal 
acetylation to human disease', Gene, 567: 103-31. 
Ebenhoh, O., and R. Heinrich. 2001. 'Evolutionary optimization of metabolic pathways. 
Theoretical reconstruction of the stoichiometry of ATP and NADH producing systems', Bull 
Math Biol, 63: 21-55. 
Emsley, P., and K. Cowtan. 2004. 'Coot: model-building tools for molecular graphics', Acta 
crystallographica. Section D, Biological crystallography, 60: 2126-32. 
Emsley, P., B. Lohkamp, W. G. Scott, and K. Cowtan. 2010. 'Features and development of Coot', 
Acta crystallographica. Section D, Biological crystallography, 66: 486-501. 
Evjenth, R., K. Hole, O. A. Karlsen, M. Ziegler, T. Arnesen, and J. R. Lillehaug. 2009. 'Human 
Naa50p (Nat5/San) displays both protein N alpha- and N epsilon-acetyltransferase activity', The 
Journal of biological chemistry, 284: 31122-9. 
Ferrández-Ayela, Almudena, Rosa Micol-Ponce, Ana Sánchez-García, María Alonso-Peral, José 
Micol, and María Ponce. 2013. 'Mutation of an Arabidopsis NatB N-alpha-terminal acetylation 
complex component causes pleiotropic developmental defects', PloS one, 8. 
159 
	
Fischer, E. H., D. J. Graves, E. R. Crittenden, and E. G. Krebs. 1959. 'Structure of the site 
phosphorylated in the phosphorylase b to a reaction', The Journal of biological chemistry, 234: 
1698-704. 
Forte, G. M., M. R. Pool, and C. J. Stirling. 2011. 'N-terminal acetylation inhibits protein 
targeting to the endoplasmic reticulum', PLoS biology, 9: e1001073. 
Foyn, H., J. E. Jones, D. Lewallen, R. Narawane, J. E. Varhaug, P. R. Thompson, and T. Arnesen. 
2013. 'Design, Synthesis, and Kinetic Characterization of Protein N-Terminal Acetyltransferase 
Inhibitors', ACS chemical biology. 
Gautschi, M., S. Just, A. Mun, S. Ross, P. Rucknagel, Y. Dubaquie, A. Ehrenhofer-Murray, and 
S. Rospert. 2003. 'The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the 
ribosome and interacts with nascent polypeptides', Molecular and cellular biology, 23: 7403-14. 
Gautschi, Matthias, Andrej Mun, Suzanne Ross, and Sabine Rospert. 2002. 'A functional 
chaperone triad on the yeast ribosome', Proceedings of the National Academy of Sciences of the 
United States of America, 99: 4209-14. 
Giglione, Carmela, Sonia Fieulaine, and Thierry Meinnel. 2015. 'N-terminal protein 
modifications: Bringing back into play the ribosome', Biochimie, 114: 134-46. 
Haberland, M., R. L. Montgomery, and E. N. Olson. 2009. 'The many roles of histone 
deacetylases in development and physiology: implications for disease and therapy', Nat Rev 
Genet, 10: 32-42. 
Hole, K., P. Van Damme, M. Dalva, H. Aksnes, N. Glomnes, J. E. Varhaug, J. R. Lillehaug, K. 
Gevaert, and T. Arnesen. 2011. 'The human N-alpha-acetyltransferase 40 (hNaa40p/hNatD) is 
conserved from yeast and N-terminally acetylates histones H2A and H4', PloS one, 6: e24713. 
Holmes, W. M., B. K. Mannakee, R. N. Gutenkunst, and T. R. Serio. 2014. 'Loss of amino-
terminal acetylation suppresses a prion phenotype by modulating global protein folding', Nat 
Commun, 5: 4383. 
Hong, Haiyan, Yongfei Cai, Shijun Zhang, Hongyan Ding, Haitao Wang, and Aidong Han. 2017. 
'Molecular Basis of Substrate Specific Acetylation by N-Terminal Acetyltransferase NatB', 
Structure, 25: 641-649000. 
Hsieh, Y. C., M. C. Chen, C. C. Hsu, S. I. Chan, Y. S. Yang, and C. J. Chen. 2013. 'Crystal 
structures of vertebrate dihydropyrimidinase and complexes from Tetraodon nigroviridis with 
160 
	
lysine carbamylation: metal and structural requirements for post-translational modification and 
function', The Journal of biological chemistry, 288: 30645-58. 
Huang, J. 2013. 'Horizontal gene transfer in eukaryotes: the weak-link model', Bioessays, 35: 
868-75. 
Hwang, C. S., A. Shemorry, and A. Varshavsky. 2010. 'N-terminal acetylation of cellular proteins 
creates specific degradation signals', Science, 327: 973-7. 
Jedrzejewski, R. P., and R. Kazmierkiewicz. 2013. 'Structure of Patt1 human proapoptotic histone 
acetyltransferase', Journal of molecular modeling, 19: 5533-8. 
Jeong, J. W., M. K. Bae, M. Y. Ahn, S. H. Kim, T. K. Sohn, M. H. Bae, M. A. Yoo, E. J. Song, 
K. J. Lee, and K. W. Kim. 2002. 'Regulation and destabilization of HIF-1alpha by ARD1-
mediated acetylation', Cell, 111: 709-20. 
Jornvall, H. 1975. 'Acetylation of Protein N-terminal amino groups structural observations on 
alpha-amino acetylated proteins', J Theor Biol, 55: 1-12. 
Kashina, A. 2014. 'Protein arginylation, a global biological regulator that targets actin 
cytoskeleton and the muscle', Anat Rec (Hoboken), 297: 1630-6. 
Kasten-Jolly, J., and F. Taketa. 1982. 'Biosynthesis and amino terminal acetylation of cat 
hemoglobin B', Archives of biochemistry and biophysics. 
Kastner, B., N. Fischer, M. M. Golas, B. Sander, P. Dube, D. Boehringer, K. Hartmuth, J. 
Deckert, F. Hauer, E. Wolf, H. Uchtenhagen, H. Urlaub, F. Herzog, J. M. Peters, D. Poerschke, 
R. Luhrmann, and H. Stark. 2008. 'GraFix: sample preparation for single-particle electron 
cryomicroscopy', Nat Methods, 5: 53-5. 
Kohler, Rebecca, Daniel Boehringer, Basil Greber, Rouven Bingel-Erlenmeyer, Ian Collinson, 
Christiane Schaffitzel, and Nenad Ban. 2009. 'YidC and Oxa1 form dimeric insertion pores on the 
translating ribosome', Molecular cell, 34: 344-53. 
Koonin, E. V. 2015. 'Origin of eukaryotes from within archaea, archaeal eukaryome and bursts of 
gene gain: eukaryogenesis just made easier?', Philos Trans R Soc Lond B Biol Sci, 370: 
20140333. 
161 
	
Kramer, Günter, Daniel Boehringer, Nenad Ban, and Bernd Bukau. 2009. 'The ribosome as a 
platform for co-translational processing, folding and targeting of newly synthesized proteins', 
Nature structural & molecular biology, 16: 589-97. 
Kramer, Günter, Thomas Rauch, Wolfgang Rist, Sonja Vorderwülbecke, Holger Patzelt, Agnes 
Schulze-Specking, Nenad Ban, Elke Deuerling, and Bernd Bukau. 2002. 'L23 protein functions as 
a chaperone docking site on the ribosome', Nature, 419: 171-74. 
Lane, N. 2017. 'Serial endosymbiosis or singular event at the origin of eukaryotes?', J Theor Biol. 
Lane, N., and W. Martin. 2010. 'The energetics of genome complexity', Nature, 467: 929-34. 
Lane, Nick. 2015. The vital question : energy, evolution, and the origins of complex life (W. W. 
Norton & Company: New York). 
Li, X., P. Mooney, S. Zheng, C. R. Booth, M. B. Braunfeld, S. Gubbens, D. A. Agard, and Y. 
Cheng. 2013. 'Electron counting and beam-induced motion correction enable near-atomic-
resolution single-particle cryo-EM', Nat Methods, 10: 584-90. 
Li, Y., L. Zhang, T. Liu, C. Chai, Q. Fang, H. Wu, P. A. Agudelo Garcia, Z. Han, S. Zong, Y. Yu, 
X. Zhang, M. R. Parthun, J. Chai, R. M. Xu, and M. Yang. 2014. 'Hat2p recognizes the histone 
H3 tail to specify the acetylation of the newly synthesized H3/H4 heterodimer by the 
Hat1p/Hat2p complex', Genes & development, 28: 1217-27. 
Liszczak, G., T. Arnesen, and R. Marmorstein. 2011. 'Structure of a ternary Naa50p 
(NAT5/SAN) N-terminal acetyltransferase complex reveals the molecular basis for substrate-
specific acetylation', The Journal of biological chemistry, 286: 37002-10. 
Liszczak, G., J. M. Goldberg, H. Foyn, E. J. Petersson, T. Arnesen, and R. Marmorstein. 2013. 
'Molecular basis for N-terminal acetylation by the heterodimeric NatA complex', Nature 
structural & molecular biology, 20: 1098-105. 
Liszczak, G., and R. Marmorstein. 2013. 'Implications for the evolution of eukaryotic amino-
terminal acetyltransferase (NAT) enzymes from the structure of an archaeal ortholog', 
Proceedings of the National Academy of Sciences of the United States of America, 110: 14652-7. 
Liu, X., L. Wang, K. Zhao, P. R. Thompson, Y. Hwang, R. Marmorstein, and P. A. Cole. 2008. 
'The structural basis of protein acetylation by the p300/CBP transcriptional coactivator', Nature, 
451: 846-50. 
162 
	
Liu, Y., D. Zhou, F. Zhang, Y. Tu, Y. Xia, H. Wang, B. Zhou, Y. Zhang, J. Wu, X. Gao, Z. He, 
and Q. Zhai. 2012. 'Liver Patt1 deficiency protects male mice from age-associated but not high-
fat diet-induced hepatic steatosis', Journal of lipid research, 53: 358-67. 
Liu, Z., Y. Liu, H. Wang, X. Ge, Q. Jin, G. Ding, Y. Hu, B. Zhou, Z. Chen, B. Zhang, X. Man, 
and Q. Zhai. 2009. 'Patt1, a novel protein acetyltransferase that is highly expressed in liver and 
downregulated in hepatocellular carcinoma, enhances apoptosis of hepatoma cells', The 
international journal of biochemistry & cell biology, 41: 2528-37. 
Lowther, W. T., N. Brot, H. Weissbach, and B. W. Matthews. 2000. 'Structure and mechanism of 
peptide methionine sulfoxide reductase, an "anti-oxidation" enzyme', Biochemistry, 39: 13307-12. 
Lowther, W. Todd, and Brian W. Matthews. 2000. 'Structure and function of the methionine 
aminopeptidases', Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular 
Enzymology, 1477: 157-67. 
Magin, R. S., G. P. Liszczak, and R. Marmorstein. 2015a. 'The molecular basis for histone H4- 
and H2A-specific amino-terminal acetylation by NatD', Structure, 23: 332-41. 
Magin, R. S., Z. M. March, and R. Marmorstein. 2016. 'The N-terminal Acetyltransferase 
Naa10/ARD1 Does Not Acetylate Lysine Residues', The Journal of biological chemistry, 291: 
5270-7. 
Magin, Robert S., Glen P. Liszczak, and Ronen Marmorstein. 2015. 'The molecular basis for 
histone H4- and H2A-specific amino-terminal acetylation by NatD', Structure (London, England : 
1993), 23: 332-41. 
Maier, Raimund, Barbara Eckert, Christian Scholz, Hauke Lilie, and Franz-Xaver X. Schmid. 
2003. 'Interaction of trigger factor with the ribosome', Journal of molecular biology, 326: 585-92. 
Marmorstein, R. 2001. 'Structure of histone acetyltransferases', Journal of molecular biology, 
311: 433-44. 
Marmorstein, R., and M. M. Zhou. 2014. 'Writers and readers of histone acetylation: structure, 
mechanism, and inhibition', Cold Spring Harb Perspect Biol, 6: a018762. 
Matasova, N. B., S. V. Myltseva, M. A. Zenkova, D. M. Graifer, S. N. Vladimirov, and G. G. 
Karpova. 1991. 'Isolation of ribosomal subunits containing intact rRNA from human placenta: 
estimation of functional activity of 80S ribosomes', Anal Biochem, 198: 219-23. 
163 
	
Mccoy, A. J., R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, and R. J. Read. 
2007. 'Phaser crystallographic software', Journal of Applied Crystallography, 40: 658-74. 
McCullough, C. E., and R. Marmorstein. 2016. 'Molecular Basis for Histone Acetyltransferase 
Regulation by Binding Partners, Associated Domains, and Autoacetylation', ACS chemical 
biology, 11: 632-42. 
McInerney, J. O., M. J. O'Connell, and D. Pisani. 2014. 'The hybrid nature of the Eukaryota and a 
consilient view of life on Earth', Nat Rev Microbiol, 12: 449-55. 
Mullen, J. R., P. S. Kayne, R. P. Moerschell, S. Tsunasawa, M. Gribskov, M. Colavito-
Shepanski, M. Grunstein, F. Sherman, and R. Sternglanz. 1989. 'Identification and 
characterization of genes and mutants for an N-terminal acetyltransferase from yeast', The EMBO 
journal, 8: 2067-75. 
Murray-Rust, T. A., N. J. Oldham, K. S. Hewitson, and C. J. Schofield. 2006. 'Purified 
recombinant hARD1 does not catalyse acetylation of Lys532 of HIF-1alpha fragments in vitro', 
FEBS Lett, 580: 1911-8. 
Myklebust, L. M., P. Van Damme, S. I. Stove, M. J. Dorfel, A. Abboud, T. V. Kalvik, C. 
Grauffel, V. Jonckheere, Y. Wu, J. Swensen, H. Kaasa, G. Liszczak, R. Marmorstein, N. Reuter, 
G. J. Lyon, K. Gevaert, and T. Arnesen. 2015. 'Biochemical and cellular analysis of Ogden 
syndrome reveals downstream Nt-acetylation defects', Hum Mol Genet, 24: 1956-76. 
Nakamoto, T. 2009. 'Evolution and the universality of the mechanism of initiation of protein 
synthesis', Gene, 432: 1-6. 
Narita, K. 1958. 'Isolation of acetylpeptide from enzymic digests of TMV-protein', Biochimica et 
biophysica acta. 
Neubauer, Julie Lisbeth. 2012. 'Structural Analysis of the N-Terminal Acetyltransferase A 
Complex', Doctoral Thesis, Duke University. 
Olia, A. S., K. Barker, C. E. McCullough, H. Y. Tang, D. W. Speicher, J. Qiu, J. LaBaer, and R. 
Marmorstein. 2015. 'Nonenzymatic Protein Acetylation Detected by NAPPA Protein Arrays', 
ACS chemical biology, 10: 2034-47. 
Otwinowski, Z., and W. Minor. 1997. 'Processing of X-ray diffraction data collected in oscillation 
mode', Macromolecular Crystallography, Pt A, 276: 307-26. 
164 
	
Pande, V. 2016. 'Understanding the Complexity of Epigenetic Target Space', J Med Chem, 59: 
1299-307. 
Park, Sang-Eun, Jeong-Mok Kim, Ok-Hee Seok, Hanna Cho, Brandon Wadas, Seon-Young Kim, 
Alexander Varshavsky, and Cheol-Sang Hwang. 2015. 'Control of mammalian G protein 
signaling by N-terminal acetylation and the N-end rule pathway', Science, 347: 1249-52. 
Pavlou, Demetria, and Antonis Kirmizis. 2016. 'Depletion of histone N-terminal-acetyltransferase 
Naa40 induces p53-independent apoptosis in colorectal cancer cells via the mitochondrial 
pathway', Apoptosis : an international journal on programmed cell death, 21: 298-311. 
Penczek, P. A., R. A. Grassucci, and J. Frank. 1994. 'The ribosome at improved resolution: new 
techniques for merging and orientation refinement in 3D cryo-electron microscopy of biological 
particles', Ultramicroscopy, 53: 251-70. 
Pestana, Angel, and H. C. Pitot. 1974. 'N-terminal Acetylation of Histone-like Nascent Peptides 
on Rat Liver Polyribosomes in vitro', Nature, 247: 200-02. 
Piatkov, K. I., T. T. Vu, C. S. Hwang, and A. Varshavsky. 2015. 'Formyl-methionine as a 
degradation signal at the N-termini of bacterial proteins', Microb Cell, 2: 376-93. 
Polevoda, B., S. Brown, T. S. Cardillo, S. Rigby, and F. Sherman. 2008. 'Yeast N(alpha)-terminal 
acetyltransferases are associated with ribosomes', Journal of cellular biochemistry, 103: 492-508. 
Polevoda, B., J. Hoskins, and F. Sherman. 2009. 'Properties of Nat4, an N(alpha)-
acetyltransferase of Saccharomyces cerevisiae that modifies N termini of histones H2A and H4', 
Molecular and cellular biology, 29: 2913-24. 
Polevoda, B., J. Norbeck, and H. Takakura. 1999. 'Identification and specificities of N‐terminal 
acetyltransferases from Saccharomyces cerevisiae', The EMBO …. 
Polevoda, B., and F. Sherman. 2003. 'N-terminal acetyltransferases and sequence requirements 
for N-terminal acetylation of eukaryotic proteins', Journal of molecular biology, 325: 595-622. 
Popp, B., S. I. Stove, S. Endele, L. M. Myklebust, J. Hoyer, H. Sticht, S. Azzarello-Burri, A. 
Rauch, T. Arnesen, and A. Reis. 2015. 'De novo missense mutations in the NAA10 gene cause 
severe non-syndromic developmental delay in males and females', Eur J Hum Genet, 23: 602-9. 
165 
	
Prabakaran, S., G. Lippens, H. Steen, and J. Gunawardena. 2012. 'Post-translational modification: 
nature's escape from genetic imprisonment and the basis for dynamic information encoding', 
Wiley interdisciplinary reviews. Systems biology and medicine, 4: 565-83. 
Raine, Amanda, Martin Lovmar, Jarl Wikberg, and Måns Ehrenberg. 2006. 'Trigger factor 
binding to ribosomes with nascent peptide chains of varying lengths and sequences', The Journal 
of biological chemistry, 281: 28033-38. 
Ranjan, Amitabh, Evan Mercier, Arshiya Bhatt, and Wolfgang Wintermeyer. 2017. 'Signal 
recognition particle prevents N-terminal processing of bacterial membrane proteins', Nature 
Communications, 8: 15562. 
Rathore, O. S., A. Faustino, and P. Prudêncio. 2016. 'Absence of N-terminal acetyltransferase 
diversification during evolution of eukaryotic organisms', Scientific …. 
Raue, Uta, Stefan Oellerer, and Sabine Rospert. 2007. 'Association of protein biogenesis factors 
at the yeast ribosomal tunnel exit is affected by the translational status and nascent polypeptide 
sequence', The Journal of biological chemistry, 282: 7809-16. 
Ribeiro, A. L., R. D. Silva, H. Foyn, M. N. Tiago, O. S. Rathore, T. Arnesen, and R. G. Martinho. 
2016. 'Naa50/San-dependent N-terminal acetylation of Scc1 is potentially important for sister 
chromatid cohesion', Sci Rep, 6: 39118. 
Ribet, D., and P. Cossart. 2010. 'Post-translational modifications in host cells during bacterial 
infection', FEBS Lett, 584: 2748-58. 
Ring, H. Z., V. Vameghi-Meyers, W. Wang, G. R. Crabtree, and U. Francke. 1998. 'Five 
SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin (SMARC) genes are 
dispersed in the human genome', Genomics, 51: 140-3. 
Rojas, J. R., R. C. Trievel, J. Zhou, Y. Mo, X. Li, S. L. Berger, C. D. Allis, and R. Marmorstein. 
1999. 'Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide', Nature, 
401: 93-8. 
Rope, A. F., K. Wang, R. Evjenth, J. Xing, J. J. Johnston, J. J. Swensen, W. E. Johnson, B. 
Moore, C. D. Huff, L. M. Bird, J. C. Carey, J. M. Opitz, C. A. Stevens, T. Jiang, C. Schank, H. D. 
Fain, R. Robison, B. Dalley, S. Chin, S. T. South, T. J. Pysher, L. B. Jorde, H. Hakonarson, J. R. 
Lillehaug, L. G. Biesecker, M. Yandell, T. Arnesen, and G. J. Lyon. 2011. 'Using VAAST to 
identify an X-linked disorder resulting in lethality in male infants due to N-terminal 
acetyltransferase deficiency', American journal of human genetics, 89: 28-43. 
166 
	
Rutkowska, Anna, Matthias P. Mayer, Anja Hoffmann, Frieder Merz, Beate Zachmann-Brand, 
Christiane Schaffitzel, Nenad Ban, Elke Deuerling, and Bernd Bukau. 2008. 'Dynamics of trigger 
factor interaction with translating ribosomes', The Journal of biological chemistry, 283: 4124-32. 
Sagan, L. 1967. 'On the origin of mitosing cells', J Theor Biol, 14: 255-74. 
Sandikci, Arzu, Felix Gloge, Michael Martinez, Matthias P. Mayer, Rebecca Wade, Bernd 
Bukau, and Günter Kramer. 2013. 'Dynamic enzyme docking to the ribosome coordinates N-
terminal processing with polypeptide folding', Nature structural & molecular biology, 20: 843-
50. 
Saunier, C., S. I. Stove, B. Popp, B. Gerard, M. Blenski, N. AhMew, C. de Bie, P. Goldenberg, B. 
Isidor, B. Keren, B. Leheup, L. Lampert, C. Mignot, K. Tezcan, G. M. Mancini, C. Nava, M. 
Wasserstein, A. L. Bruel, J. Thevenon, A. Masurel, Y. Duffourd, P. Kuentz, F. Huet, J. B. 
Riviere, M. van Slegtenhorst, L. Faivre, A. Piton, A. Reis, T. Arnesen, C. Thauvin-Robinet, and 
C. Zweier. 2016. 'Expanding the Phenotype Associated with NAA10-Related N-Terminal 
Acetylation Deficiency', Hum Mutat, 37: 755-64. 
Schaffitzel, Christiane, Miro Oswald, Imre Berger, Takashi Ishikawa, Jan P. Abrahams, Henk K. 
Koerten, Roman I. Koning, and Nenad Ban. 2006. 'Structure of the E. coli signal recognition 
particle bound to a translating ribosome', Nature, 444: 503-06. 
Scheres, S. H. 2012. 'RELION: implementation of a Bayesian approach to cryo-EM structure 
determination', J Struct Biol, 180: 519-30. 
Schiza, V., D. Molina-Serrano, D. Kyriakou, A. Hadjiantoniou, and A. Kirmizis. 2013. 'N-alpha-
terminal acetylation of histone H4 regulates arginine methylation and ribosomal DNA silencing', 
PLoS genetics, 9: e1003805. 
Scott, D. C., J. K. Monda, E. J. Bennett, and J. W. Harper. 2011. 'N-terminal acetylation acts as 
an avidity enhancer within an interconnected multiprotein complex', …. 
Scott, Daniel C., Vladislav O. Sviderskiy, Julie K. Monda, John R. Lydeard, Shein E. Cho, J. W. 
Harper, and Brenda A. Schulman. 2014. 'Structure of a RING E3 trapped in action reveals 
ligation mechanism for the ubiquitin-like protein NEDD8', Cell, 157: 1671-84. 
Seet, B. T., I. Dikic, M. M. Zhou, and T. Pawson. 2006. 'Reading protein modifications with 
interaction domains', Nature reviews. Molecular cell biology, 7: 473-83. 
167 
	
Shemorry, A., C. S. Hwang, and A. Varshavsky. 2013. 'Control of protein quality and 
stoichiometries by N-terminal acetylation and the N-end rule pathway', Molecular cell, 50: 540-
51. 
Shin, D. H., Y. S. Chun, K. H. Lee, H. W. Shin, and J. W. Park. 2009. 'Arrest defective-1 controls 
tumor cell behavior by acetylating myosin light chain kinase', PloS one, 4: e7451. 
Shin, S. H., H. Yoon, Y. S. Chun, H. W. Shin, M. N. Lee, G. T. Oh, and J. W. Park. 2014. 'Arrest 
defective 1 regulates the oxidative stress response in human cells and mice by acetylating 
methionine sulfoxide reductase A', Cell Death Dis, 5: e1490. 
Shortreed, M. R., C. D. Wenger, B. L. Frey, G. M. Sheynkman, M. Scalf, M. P. Keller, A. D. 
Attie, and L. M. Smith. 2015. 'Global Identification of Protein Post-translational Modifications in 
a Single-Pass Database Search', Journal of proteome research, 14: 4714-20. 
Song, O. K., X. Wang, J. H. Waterborg, and R. Sternglanz. 2003. 'An Nalpha-acetyltransferase 
responsible for acetylation of the N-terminal residues of histones H4 and H2A', The Journal of 
biological chemistry, 278: 38109-12. 
Spang, A., J. H. Saw, S. L. Jorgensen, K. Zaremba-Niedzwiedzka, J. Martijn, A. E. Lind, R. van 
Eijk, C. Schleper, L. Guy, and T. J. Ettema. 2015. 'Complex archaea that bridge the gap between 
prokaryotes and eukaryotes', Nature, 521: 173-9. 
Spiro, R. G. 2002. 'Protein glycosylation: nature, distribution, enzymatic formation, and disease 
implications of glycopeptide bonds', Glycobiology, 12: 43R-56R. 
Stanier, R. Y., and C. B. Van Niel. 1962. 'The concept of a bacterium', Arch Mikrobiol, 42: 17-35. 
Starheim, K. K., K. Gevaert, and T. Arnesen. 2012. 'Protein N-terminal acetyltransferases: when 
the start matters', Trends in biochemical sciences, 37: 152-61. 
Stark, H. 2010. 'GraFix: stabilization of fragile macromolecular complexes for single particle 
cryo-EM', Methods in enzymology, 481: 109-26. 
Stein, N. 2008. 'CHAINSAW: a program for mutating pdb files used as templates in molecular 
replacement', Journal of Applied Crystallography, 41: 641-43. 
Støve, Svein I., Robert S. Magin, Håvard Foyn, Bengt E. Haug, Ronen Marmorstein, and Thomas 
Arnesen. 2016. 'Crystal Structure of the Golgi-Associated Human Nα-Acetyltransferase 60 
168 
	
Reveals the Molecular Determinants for Substrate-Specific Acetylation', Structure (London, 
England : 1993), 24: 1044-56. 
Strous, G. J., A. J. Berns, and H. Bloemendal. 1974. 'N-terminal acetylation of the nascent chains 
of alpha-crystallin', Biochemical and biophysical research communications, 58: 876-84. 
Strous, Ger J. A. M., Hanske Westreenen, and Hans Bloemendal. 1973. 'Synthesis of Lens 
Protein in vitro', European Journal of Biochemistry, 38: 79-85. 
Tahirov, T. H., T. Inoue-Bungo, H. Morii, A. Fujikawa, M. Sasaki, K. Kimura, M. Shiina, K. 
Sato, T. Kumasaka, M. Yamamoto, S. Ishii, and K. Ogata. 2001. 'Structural analyses of DNA 
recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta', Cell, 104: 
755-67. 
Tang, G., L. Peng, P. R. Baldwin, D. S. Mann, W. Jiang, I. Rees, and S. J. Ludtke. 2007. 
'EMAN2: an extensible image processing suite for electron microscopy', J Struct Biol, 157: 38-
46. 
Tasaki, T., S. M. Sriram, K. S. Park, and Y. T. Kwon. 2012. 'The N-end rule pathway', Annual 
review of biochemistry, 81: 261-89. 
Teixeira, L. K., and S. I. Reed. 2013. 'Ubiquitin ligases and cell cycle control', Annual review of 
biochemistry, 82: 387-414. 
Thompson, Paul R., Dongxia Wang, Ling Wang, Marcella Fulco, Natalia Pediconi, Dianzheng 
Zhang, Woojin An, Qingyuan Ge, Robert G. Roeder, and Jiemin Wong. 2004. 'Regulation of the 
p300 HAT domain via a novel activation loop', Nature structural & molecular biology, 11: 308-
15. 
Van Damme, P., R. Evjenth, H. Foyn, K. Demeyer, P. J. De Bock, J. R. Lillehaug, J. 
Vandekerckhove, T. Arnesen, and K. Gevaert. 2011. 'Proteome-derived peptide libraries allow 
detailed analysis of the substrate specificities of N(alpha)-acetyltransferases and point to hNaa10p 
as the post-translational actin N(alpha)-acetyltransferase', Molecular & cellular proteomics : 
MCP, 10: M110 004580. 
Van Damme, P., K. Hole, A. Pimenta-Marques, K. Helsens, J. Vandekerckhove, R. G. Martinho, 
K. Gevaert, and T. Arnesen. 2011a. 'NatF contributes to an evolutionary shift in protein N-
terminal acetylation and is important for normal chromosome segregation', PLoS Genet, 7: 
e1002169. 
169 
	
Van Damme, P., M. Lasa, B. Polevoda, C. Gazquez, A. Elosegui-Artola, D. S. Kim, E. De Juan-
Pardo, K. Demeyer, K. Hole, E. Larrea, E. Timmerman, J. Prieto, T. Arnesen, F. Sherman, K. 
Gevaert, and R. Aldabe. 2012. 'N-terminal acetylome analyses and functional insights of the N-
terminal acetyltransferase NatB', Proceedings of the National Academy of Sciences of the United 
States of America, 109: 12449-54. 
Van Damme, Petra, Kristine Hole, Ana Pimenta-Marques, Kenny Helsens, Joël Vandekerckhove, 
Rui G. Martinho, Kris Gevaert, and Thomas Arnesen. 2011b. 'NatF contributes to an evolutionary 
shift in protein N-terminal acetylation and is important for normal chromosome segregation', 
PLoS genetics, 7. 
Verdin, E., and M. Ott. 2015. '50 years of protein acetylation: from gene regulation to 
epigenetics, metabolism and beyond', Nature reviews. Molecular cell biology, 16: 258-64. 
Vetting, M. W., D. C. Bareich, M. Yu, and J. S. Blanchard. 2008. 'Crystal structure of RimI from 
Salmonella typhimurium LT2, the GNAT responsible for N(alpha)-acetylation of ribosomal 
protein S18', Protein Sci, 17: 1781-90. 
Vetting, M. W., S. de Carvalho LP, M. Yu, S. S. Hegde, S. Magnet, S. L. Roderick, and J. S. 
Blanchard. 2005. 'Structure and functions of the GNAT superfamily of acetyltransferases', 
Archives of biochemistry and biophysics, 433: 212-26. 
Wagner, A. 2005. 'Energy constraints on the evolution of gene expression', Mol Biol Evol, 22: 
1365-74. 
Wang, Z., Z. Wang, J. Guo, Y. Li, J. H. Bavarva, C. Qian, M. C. Brahimi-Horn, D. Tan, and W. 
Liu. 2012. 'Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor 
acetylation and prostate tumorigenesis', Proceedings of the National Academy of Sciences of the 
United States of America, 109: 3053-8. 
Wegrzyn, Renee D., Diana Hofmann, Frieder Merz, Rainer Nikolay, Thomas Rauch, Christian 
Graf, and Elke Deuerling. 2006. 'A conserved motif is prerequisite for the interaction of NAC 
with ribosomal protein L23 and nascent chains', The Journal of biological chemistry, 281: 2847-
57. 
Weyer, Felix, Andrea Gumiero, Karine Lapouge, Gert Bange, Jürgen Kopp, and Irmgard Sinning. 
2017. 'Structural basis of HypK regulating N-terminal acetylation by the NatA complex', Nature 
Communications, 8: 15726. 
Wiedmann, B., H. Sakai, T. A. Davis, and M. Wiedmann. 1994. 'A protein complex required for 
signal-sequence-specific sorting and translocation', Nature, 370: 434-40. 
170 
	
Williams, T. A., P. G. Foster, C. J. Cox, and T. M. Embley. 2013. 'An archaeal origin of 
eukaryotes supports only two primary domains of life', Nature, 504: 231-6. 
Wilson, D. N. 2014. 'Ribosome-targeting antibiotics and mechanisms of bacterial resistance', Nat 
Rev Microbiol, 12: 35-48. 
Woese, C. R., and G. E. Fox. 1977. 'Phylogenetic structure of the prokaryotic domain: the 
primary kingdoms', Proceedings of the National Academy of Sciences of the United States of 
America, 74: 5088-90. 
Xu, M., L. Xie, Z. Yu, and J. Xie. 2015. 'Roles of Protein N-Myristoylation and Translational 
Medicine Applications', Crit Rev Eukaryot Gene Expr, 25: 259-68. 
Yan, Y., S. Harper, D. W. Speicher, and R. Marmorstein. 2002. 'The catalytic mechanism of the 
ESA1 histone acetyltransferase involves a self-acetylated intermediate', Nature structural 
biology, 9: 862-9. 
Yang, H., Q. Li, J. Niu, B. Li, D. Jiang, Z. Wan, Q. Yang, F. Jiang, P. Wei, and S. Bai. 2016. 
'microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10', 
Oncotarget, 7: 2709-20. 
Yang, Z., J. Fang, J. Chittuluru, F. J. Asturias, and P. A. Penczek. 2012. 'Iterative stable 
alignment and clustering of 2D transmission electron microscope images', Structure, 20: 237-47. 
Yau, R., and M. Rape. 2016. 'The increasing complexity of the ubiquitin code', Nature cell 
biology, 18: 579-86. 
Yoon, H., H. L. Kim, Y. S. Chun, D. H. Shin, K. H. Lee, C. S. Shin, D. Y. Lee, H. H. Kim, Z. H. 
Lee, H. M. Ryoo, M. N. Lee, G. T. Oh, and J. W. Park. 2014. 'NAA10 controls osteoblast 
differentiation and bone formation as a feedback regulator of Runx2', Nat Commun, 5: 5176. 
Yuan, H., and R. Marmorstein. 2013. 'Histone acetyltransferases: Rising ancient counterparts to 
protein kinases', Biopolymers, 99: 98-111. 
Yuan, H., D. Rossetto, H. Mellert, W. Dang, M. Srinivasan, J. Johnson, S. Hodawadekar, E. C. 
Ding, K. Speicher, N. Abshiru, R. Perry, J. Wu, C. Yang, Y. G. Zheng, D. W. Speicher, P. 
Thibault, A. Verreault, F. B. Johnson, S. L. Berger, R. Sternglanz, S. B. McMahon, J. Cote, and 
R. Marmorstein. 2012. 'MYST protein acetyltransferase activity requires active site lysine 
autoacetylation', The EMBO journal, 31: 58-70. 
171 
	
Yuan, J., P. O'Donoghue, A. Ambrogelly, S. Gundllapalli, R. L. Sherrer, S. Palioura, M. 
Simonovic, and D. Soll. 2010. 'Distinct genetic code expansion strategies for selenocysteine and 
pyrrolysine are reflected in different aminoacyl-tRNA formation systems', FEBS Lett, 584: 342-9. 
Zeng, Y., L. Min, Y. Han, L. Meng, C. Liu, Y. Xie, B. Dong, L. Wang, B. Jiang, H. Xu, Q. 
Zhuang, C. Zhao, L. Qu, and C. Shou. 2014. 'Inhibition of STAT5a by Naa10p contributes to 
decreased breast cancer metastasis', Carcinogenesis, 35: 2244-53. 
Zimorski, V., C. Ku, W. F. Martin, and S. B. Gould. 2014. 'Endosymbiotic theory for organelle 
origins', Curr Opin Microbiol, 22: 38-48. 
 
